Pharmaceutical compositions resistant to abuse

ABSTRACT

The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

This application claims the benefit of priority of U.S. application Ser.No. 12/701,429, filed Feb. 5, 2010, now U.S. Pat. No. 8,603,526, whichclaims the benefit of priority of U.S. Provisional Application No.61/150,620, filed Feb. 6, 2009. This application also claims priority ofDenmark Patent Application No. PA 2009 00192, filed Feb. 6, 2009.

All patent and non-patent references cited in the application are herebyincorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to pharmaceutical compositions. Inparticular embodiments, pharmaceutical compositions in the form of unitdosage forms that are resistant to abuse are provided.

BACKGROUND

In recent years, increased attention has been drawn to the abuse ofprescription drugs. The abuse, or non-medicinal use, of prescriptionmedicines has been reported to be an increasing problem particularly inNorth America. This phenomenon has become an increasing epidemiological,public health and political concern (See, for example, Fischer and Rehm,J. Pain 9:6, 2008 490-493). In 2006, it was reported that 16.2 millionAmericans age 12 and older had taken a prescription pain reliever,tranquilizer, stimulant, or sedative for nonmedical purposes at leastonce in the year prior to being surveyed (National Survey on Drug Useand Health; http://www.samhsa.gov/). In another study, it reported thatapproximately 5.2% of 12^(th) graders abused OxyContin® for nonmedicalpurposes at least once in the year prior to being surveyed (Monitoringthe Future http://www.monitoringthefuture.org/).

Methods for abusing prescription drugs are varied and include, forexample, single or multiple step extraction, physical tampering followedby crushing, extraction, melting, volatilization or directadministration. For purposes of abuse, methods of administering drugsubstances obtained from prescription drug products or of the drugproducts themselves are similarly diverse and include, for example,injection, smoking, swallowing, sublingual or buccal admininstration,chewing, and administration as suppository (See, e.g., NationalInstitute of Drug Abuse, 2008). Prescription drug products thattypically misused primarily fall into three groups: 1) Opioidsprescribed for pain; 2) CNS depressants prescribed for anxiety of sleepproblems; and 3) Stimulants, prescribed, for example, for attentiondeficit hyperactivity, narcolepsy or obesity. In the context ofcontrolled release opioid products, chewing of the drug product to breakup and provide rapid release of a relatively large dose of the opioiddrug substance is one of the most commonly used methods of abuse.

Because the potential for abuse of prescription drug products has becomean important issue for the U.S. Food and Drug Administration (FDA), thepharmaceutical industry is striving to develop abuse resistantformulations in order to reduce the potential for misuse of prescriptiondrugs. Examples of two abuse resistant drug products submitted to theFDA for approval include Remoxy™ and Embeda™. The Remoxy™ product isformulated to be an abuse resistant product for the delivery ofoxycodone, while the Embeda™ product is formulated to be an abuseresistant product for the delivery of morphine. The Embeda™ product wasapproved by the FDA the on the 14 Oct. 2009.

Alcohol-induced dose dumping of drug substance from prescription drugproducts also presents potential abuse and safety problems. For purposesof the present disclosure, “dose dumping” refers to an unintended, rapidrelease of the entire amount or a significant fraction of the drugsubstance contained within a prescription drug product over a short oraccellerated period of time. For purposes of abuse, alcohol-induced dosedumping may facilitate isolation or concentration of drug substancesfrom a prescription drug product. Alternatively, dose dumping in thepresence of alcohol may increase the ease with which a prescription drugproduct simply through the intake of an alcoholic beverageconcommitantly with the prescription drug product. Moreover,alcohol-induced dose dumping may present safety issues outside thecontext of abuse. For example, a patient taking a prescription drugproduct for medicinal purposes may inadvertently cause delivery of adose of drug substance that is too high or absorbed too quickly by selfadministering a drug product shortly before, simultneously with orshortly after intake of an alcoholic beverage or another medicinalprodcut containing alcohol (such as an over the couter cold or flumedicine). It has been reported that some modified-release oral dosageforms contain active drug substances and excipients that exhibit highersolubility in alcoholic solutions compared to water. Such products mayexhibit a more rapid drug dissolution and release rate in the presenceof ethanol.

SUMMARY

Pharmaceutical compositions resistant to abuse and methods of making andusing such compositions are described herein. The pharmaceuticalcompositions described herein include an outer shell and a drugcomposition containing one or more active drug substances. The drugcomposition included in the pharmaceutical compositions described hereinmay be a matrix composition, and the terms “drug composition” and“matrix composition” are used interchangeably herein. Configurations,materials, and methods for producing abuse resistant pharmaceuticalcompositions having an outer shell positioned over a drug compositionare detailed herein. In certain embodiments, the pharmaceuticalcompositions are provided as unit dosage forms suitable for oraladmininstration.

The shell included in the pharmaceutical compositions described hereincan be formulated to resist physical tampering, such as by chewing,crushing, chipping, grinding, or other applications of mechanical forcethat may compromise the physical integrity of the of the composition orresult in particle size reduction. In certain embodiments, the shellincluded in the pharmaceutical compositions described herein isformulated to exhibit a hardness that resists physical tampering. Inother embodiments, the shell is configured to resist physical tampering,such as by inclusion of one or more reinforcement elements. In stillother embodiments, the shell is formulated and/or configured to maintainadherence between the shell and the drug composition, such thatdeformation and separation of the drug composition from the shell ismade more difficult. Of course, it will be understood that the shellincluded in the pharmaceutical compositions described herein mayincorporate each of the features of the embodiments described herein.The shell included in the pharmaceutical compositions described herein,therefore, can be formulated and configured to resist chewing, crushing,chipping, grinding and other methods that may otherwise result inparticle size reduction of the pharmaceutical composition and, thereby,provides a pharmaceutical composition that is resistant to abuse.

The drug composition included in the pharmaceutical compositionsdescribed herein may be formulated to resist abuse. For example, thedrug composition may be formulated in such a way that the compositionmaintains a desired release profile of drug substance even if thepharmaceutical composition is subjected to physical tampering. In someembodiments, the drug composition may incorporate a gelling agent, whichcan render the pharmaceutical composition unfit for injection ifattempts are made to introduce the composition into a liquid solution.In addition, or alternatively, the drug composition included in thepharmaceutical compositions described herein may include an antagonistto the drug substance to be delivered by the pharmaceutical composition.In such an embodiment, the drug composition is formulated such that theantagonist is only released when the pharmaceutical composition issubjected to physical and/or chemical tampering.

An exemplary mastication test and an exemplary particle size reductiontest are disclosed herein. Such tests may be used to evaluate a givenpharmaceutical composition's resistance to physical tampering.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1 (A, B, and C) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 2 (A, B, and C) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 3 (A, B, and C) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 4 (A, B, and C) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 5 (A, B, and C) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 6 (A, B, and C) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 7 (A, B, and C) schematically illustrates an exemplary shellaccording to the present invention.

FIG. 8 illustrates perspective views of the shells of FIGS. 1, and 3-6.

FIGS. 9 (A, B, C and D) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 10 (A, B, C and D) schematically illustrates an exemplary shellaccording to the present invention.

FIGS. 11-13 illustrate examples of pharmaceutical compositions.

FIG. 14 illustrates a flow chart of tampering methods.

FIG. 15 illustrates a freezing test program for a pharmaceuticalcomposition.

FIG. 16 illustrates a heating test program (e.g. microwave, burning andmelting) for a pharmaceutical composition.

FIG. 17 illustrates a mastication and buccal test program for apharmaceutical composition.

FIG. 18 illustrates a particle size reduction test program for apharmaceutical composition.

FIG. 19 illustrates an extraction test program for a pharmaceuticalcomposition.

FIG. 20 illustrates an injection test program for a pharmaceuticalcomposition.

FIG. 21-26 show dissolution profiles of pharmaceutical compositions.

DETAILED DESCRIPTION

The pharmaceutical compositions described herein include a shell and adrug composition. Exemplary materials, configurations and methods forproviding pharmaceutical compositions that are resistant to abuse areprovided herein. In the following description the pharmaceuticalcompostions are described in relation to a conventional threedimensional Cartesian coordinate system with first axis X, second axis Yand third axis Z.

Shell Construction

As it appears from the examples and figures herein, the pharmaceuticalcompositions described herein include a shell that exhibit a structuralstrength that results in a composition, such as a unit dosage formsuitable for oral administration, that is resistant to physicaltampering, such as by chewing, crushing, chipping, grinding, or otherapplications of mechanical force that may compromise the physicalintegrity of the of the composition or result in particle sizereduction. The shell included in the pharmaceutical compositionsdescribed herein forms an outer shell wall (or “shell wall”) thatincludes inner and outer surfaces and defines a cavity generally definedby the inner surface of the shell wall. In particular embodiments, theshell included in the pharmaceutical compositions described hereinexhibits a thickness that provides a shell resistant to physicaltampering. In certain such embodiments, the shell is configured toinclude one or more reinforcement elements, such as one or more ribs,enforcement walls, protrusions or the like, extending into or within thecavity defined by the shell wall.

The drug composition included in the pharmaceutical compositionsdescribed herein is disposed within the cavity formed by the shell walland the inner surface of the shell wall is in contact with at least aportion of the drug composition. In specific embodiments, the outershell wall of the shell extends from a first end to a second end along afirst axis. In one such embodiment, one or more openings may be providedin the shell wall at each end or at one end of the shell enablingcontrolled release of a matrix composition accommodated within in theshell.

Typically, the shell wall will have a thickness in a range of from 1 mmto about 10 mm. In specific embodiments, the shell wall may have amaximum thickness selected from at least 1.0 mm, at least 1.3 mm, and atleast 3.0 mm. In other embodiments, the shell wall has a maximumthickness selected from a range of from 1.0 mm to about 10 mm, and arange of from 1.0 mm to about 7 mm. In yet further embodiments, theshell wall has a maximum thickness selected from about 1.3 mm, 2.0 mm,3.0 mm, 4.0 mm, 5.0 mm, and 6.0 mm, including or any ranges of thicknesstherebetween.

Whenever an amount is recited herein, it is understood that the amountmay also be recited with terms of approximation such as “about” or“approximately.” For example, a disclosure regarding a definitenumerical amount such as “an amount of 1 unit” can also be substitutedby an approximate amount such as “about 1 unit.” As another example, adisclosure regarding a numerical range that is recited with definiteendpoints such as “an amount ranging from 1 unit to 2 units” can also besubstituted by a range with approximate endpoints such as “an amountranging from about 1 unit to about 2 units.” It is also understood thatthe use of the term “about” may be used to account for variations due toexperimental errors.

In still another embodiment, the outer shell wall may have a maximumthickness of at least 1.7 mm, such as at least 2 mm. In certain suchembodiments, the outer shell wall has a maximum thickness in the rangefrom 2.0 mm to about 4 mm, such as thickness of about 2.4 mm.

The thickness of the outer shell wall may be substantially uniformacross the length of the wall, or, alternatively, in specificembodiments, the thickness of the shell wall may vary. In particular,where outer shell wall of the shell is configured to extend from a firstend to a second end along a first axis, the thickness of the outer shellwall may vary along the first axis. Moreover, in particular embodiments,the outer surface of the shell may curve along the first axis, providingan outer surface of the shell wall that is a double curved surface.

In specific embodiments where outer shell wall of the shell isconfigured to extend from a first end to a second end along a firstaxis, the height of the shell varies along the first axis. The height ofthe shell may vary between a minimum height and a maximum height. Theminimum height of the shell may range from, for example, about 2.0 mm toabout 20 mm, and in one particular embodiment, the minimum height may beabout 4 mm. The maximum height of the shell may range from about 3 mm toabout 30 mm, such as in the range from about 4 mm to about 20 mm, suchas about 6 mm, about 8 mm, about 10 mm, about 12 mm, about 14 mm orabout 16 mm.

In specific embodiments where outer shell wall of the shell isconfigured to extend from a first end to a second end along a firstaxis, the width of the shell varies along the first axis. The width ofthe shell may vary between a minimum width and a maximum width.

The minimum width of the shell may range, for example, from about 2.0 mmto about 20 mm, and in one particular embodiment, the minimum height maybe about 4 mm. The maximum width of the shell may range from about 3 mmto about 30 mm, such as in the range from about 4 mm to about 20 mm,such as about 6 mm, about 8 mm, about 10 mm, about 12 mm, about 14 mm orabout 16 mm.

In specific embodiments where the shell wall is configured to extendfrom a first end to a second end along a first axis, the thickness ofthe outer shell wall varies along the first axis, e.g. from about 1.1 mmto about 2.4 mm. In one or more embodiments, e.g. shells having acircular cylindrical cavity and an elliptical outer surface crosssection perpendicular to the first axis, the thickness of the outershell wall varies about the first axis.

The thickness of the outer shell wall may vary along the first axis,e.g. from 0.7 mm to 1.9 mm. The outer shell wall may have a minimumthickness of at least 0.3 mm, such as at least 0.5 mm. The outer shellwall may have a minimum thickness of at least 0.7 mm, such as in therange from 1.0 mm to 3.0 mm.

In specific embodiments where the shell wall is configured to extendfrom a first end to a second end along a first axis, the outer surfaceof the outer shell wall may define a double curved surface, resulting ina curve in a plane perpendicular to the first axis and curve in a planeparallel to the first axis.

In specific embodiments where the shell wall is configured to extendfrom a first end to a second end along a first axis, the outer surfaceof the outer shell wall may be configured to have a cross-sectionperpendicular to the first axis that is selected from one of variousdifferent suitable forms. For example, the cross-section of the shellwall may be configured to exhibit a cross-section perpendicular to thefirst axis, wherein the cross section is selected from a circular,elliptic, oval, or polygonal shape. Moreover, such a cross sectionalshape may be configured to optionally include rounded corners orsections or to exhibit a super-elliptic configuration. In particularembodiments, the shell wall may be configured such that cross-sectionsof the shell wall taken perpendicular to the first axis vary in sizeand/or shape along the first axis, as such a configuration can tofacilitate oral administration as well as production by an injectionmolding.

In one or more embodiments where the shell wall is configured to extendfrom a first end to a second end along a first axis, a cross-section ofthe outer shell surface parallel to the first axis is a curve. In suchembodiments, the outer surface of the shell forms may form an arc, suchas a circular arc, an elliptical arc, a super-elliptical arc, etc.

In one or more embodiments where the shell wall is configured to extendfrom a first end to a second end along a first axis X, a cross-sectionof the outer surface of the shell taken perpendicular to the second axisY may be a curve. In such embodiments, the outer surface of the shellforms may form an arc, such as a circular arc, an elliptical arc, asuper-elliptical arc, etc.

In one or more embodiments where the shell wall is configured to extendfrom a first end to a second end along a first axis, a cross-section ofthe outer shell surface perpendicular to the third axis may be a curve.In such embodiments, the outer surface of the shell forms, may form anarc, such as a circular arc, an elliptical arc, a super-elliptical arc,etc.

A circular arc is defined as a part of the circumference of a circlehaving radius r. The radius r may be given as r=α times d₁, where d₁ isthe length of the shell and α is in the range from 0.5 to about 6, suchas in the range from about 0.7 to about 3, such as in the range fromabout 0.8 to about 2. In one or more embodiments, the shell isconfigured to exhibit an α=1.

As described herein, the inner surface of the shell wall defines acavity. In specific embodiments, the cavity defined by the shell wall isa cylindrical cavity, extending from a first end of the shell to asecond end of the shell. In some embodiments, the shell may define aplurality of cavities extending from a first end to a second end of theshell. In one or more embodiments where outer shell wall is configuredto extend from a first end to a second end along a first axis, thecylindrical cavity or cavities described herein may be configured tohave a cross-section perpendicular to the first axis selected from, forexample, circular, oval, elliptic, super-elliptic, or polygonalcross-sections. Accordingly, a pharmaceutical composition according tothe present description may include a shell that defines one or morecylindrical cavities configured as an elliptic cylinder, a paraboliccylinder, a hyperbolic cylinder or a prism. A prism within the presentcontext refers to a cylinder having a polygonal cross-section.

In one or more embodiments where the shell wall is configured to extendfrom a first end to a second end along a first axis, the inner surfaceof the shell may define a cylindrical cavity having an ellipticalcross-section perpendicular to the first axis. In such embodiments, theellipse formed by the inner shell surface may have semimajor axis a_(in)parallel to the third axis and semiminor axis b_(in) parallel to thesecond axis. The semimajor axis a_(in) of an elliptical cross-section ofa cylindrical cavity of a shell (to be filled with matrix composition)may range from about 0.5 mm to about 10 mm, such as in the range from0.7 mm to about 9 mm, such as in the range from about 2.0 mm to about 8mm. The semiminor axis b_(in) of an elliptical cross-section of acylindrical cavity of a shell (to be filled with matrix composition) mayrange from about 0.5 mm to about 10 mm, such as in the range from 0.7 mmto about 9 mm, or in the range from about 1.0 mm to about 8 mm. Incertain embodiments, a semiminor axis b_(in) in the range from about 1.0mm to about 2.5 mm is provided.

In one or more embodiments, where the shell wall is configured to extendfrom a first end to a second end along a first axis, the inner surfaceof the outer shell wall may define a cylindrical cavity having acircular cross-section perpendicular to the first axis. In such anembodiment, the diameter of a circular cross-section of a cylindricalcavity of a shell (to be filled with matrix composition) may range fromabout 0.5 mm to about 20 mm, such as in the range from 1 mm to about 16mm.

The shell has an outer surface that may be formed to facilitate oraladministration, such as by swallowing of a pharmaceutical composition.The shell provided in the pharmaceutical compositions described herein,therefore, can be configured to have outer dimensions suitable for oraladministration. The shell may have a length (maximum extension along thefirst axis) in the range from about 2 mm to about 30 mm, such as in therange from about 4 mm to about 20 mm, such as about 6 mm, about 7.5 mm,and about 9 mm, about 12 mm. The shell may have a height (maximumextension along the second axis) in the range from about 3 mm to about30 mm, such as in the range from about 4 mm to about 20 mm, such asabout 6 mm, about 8 mm, about 10 mm, about 12 mm, about 14 mm or about16 mm. The shell may have a width (maximum extension along the thirdaxis) in the range from about 3 mm to about 30 mm, such as in the rangefrom about 4 mm to about 20 mm, such as about 6 mm, about 8 mm, about 10mm, about 12 mm, about 14 mm or about 16 mm. The outer surface of theshell may have a double curved surface to facilitate oral administrationof a pharmaceutical composition.

The shell included in the pharmaceutical compositions according to thepresent description may include one or more reinforcement elementsextending from the inner surface of the outer shell wall. Areinforcement element may extend fully or partly from a first end to asecond end or between a first end and a second end. The use of one ormore reinforcement elements enables a production of a pharmaceuticalcomposition having a relatively thinner outer shell wall, while stillmaintaining desired hardness or structural integrity performance suchthat abuse by physical tampering may be deterred. Where thepharmaceutical composition described herein includes one or morereinforcement elements, the one or more reinforcement elements maycomprise one or more protrusions extending from the inner surface of theouter shell wall into the cavity formed by the inner surface. Beyondenhancing the structural integrity of the pharmaceutical compositiondescribed herein, reinforcement elements that extend from the innersurface of the outer shell wall into the cavity from by the innersurface may provide surfaces that facilitate mechanical fastening of thedrug composition, such as a matrix composition, within the shell. Thus,wherein the pharmaceutical compositions described herein include one ormore reinforcement elements, such reinforcement elements may also serveas anchoring elements for the drug composition. In certain embodiments,the one or more reinforcement elements included in a pharmaceuticalcomposition according to the present description may comprise one ormore rods, with each rod extending between two points on the innersurface of the shell. In another embodiment, the one or morereinforcement elements may comprise one or more reinforcement wallsextending from the inner surface of the outer shell wall into the cavityformed by the inner surface of the shell wall. Where the reinforcementelements are provided as one or more reinforcement walls, thepharmaceutical composition may include a first reinforcement wall and/ora second reinforcement wall. Depending on the orientation and shape of areinforcement wall, a reinforcement wall may assist or providemechanical fastening of a matrix composition in the shell. Thus, areinforcement wall may serve as anchoring element for the drugcomposition reinforcement. Where a reinforcement element is configuredas a reinforcement wall, such a reinforcement wall may exhibit asubstantially planar configuration. In an embodiment where the shellwall is configured to extend from a first end to a second end along afirst axis, a first reinforcement wall and/or, if present, a secondreinforcement wall may be configured to be positioned perpendicular tothe first axis and partly or fully covering the cross sectional area ofthe cavity. In such an embodiment, the first reinforcement wall and/or,if present, the second reinforcement wall may be centered between thefirst end and the second end or displaced along the first axis.

In other embodiments where the shell wall is configured to extend from afirst end to a second end along a first axis, a first reinforcementand/or, if present, a second reinforcement wall may be configured to bepositioned parallel to the first axis. In such embodiments, the firstreinforcement wall may be parallel to the second reinforcement wall, andthe first reinforcement wall and the second reinforcement wall mayextend in the same plane. Additionally, the first reinforcement walland/or the second reinforcement wall may extend in a plane comprising acenter axis parallel to the first axis or displaced along the secondaxis and/or the third axis.

In some embodiments, the pharmaceutical compostions described herein mayinclude a first reinforcement wall intersects the second reinforcementwall forming an angle between the first reinforcement wall and thesecond reinforcement wall. The angle between the first reinforcementwall and the second reinforcement wall may be a right angle; however anangle in the range from 0° to 90°, e.g. 15°, 30°, 45°, 60° or 75° may beapplied. An angle between walls is the smallest angle formed between thewalls.

An reinforcement wall, e.g. the first reinforcement wall and/or thesecond reinforcement wall, may have a suitable thickness, such as in therange from about 0.2 mm to about 2 mm, such as in the range from about0.4 mm to about 1.5 mm, such as 0.5 mm, 0.8 mm, 1.0 mm or 1.3 mm.

A reinforcement wall, e.g. the first reinforcement wall and/or thesecond reinforcement wall, may have one or more openings, e.g. forfacilitating fixation of a matrix composition in the shell. One or moreopenings in a reinforcement wall may also facilitate filling of theshell with matrix composition. Reinforcement wall(s) may divide thecavity defined by the inner surface of the outer shell wall in a numberof cavity parts. Cavity parts may be connected via opening(s) inreinforcement wall(s) or via passage(s) between reinforcement wall(s)and the inner surface of the outer shell wall. An opening included in areinforcement wall may have any suitable shape, such as circular, oval,rectangular, triangular, angular, polygonal or star shaped. An openingmay have any suitable size, such as an area in the range from about 1mm² to about 100 mm², such as, in the range from about 3 mm² to about 20mm², such as 5 mm², 10 mm², or 15 mm².

In an embodiment of the present invention, reinforcement element(s) areomitted, and the outer shell wall has suitable dimensions and materialproperties to provide a pharmaceutical composition exhibiting astructural integrity that reduce the susceptibility of thepharmaceutical composition to physical tampering.

In specific embodiments, the shell included in the pharmaceuticalcomposition may constitute at least 40% w/w of the pharmaceuticalcomposition. In certain such embodiments, the shell constitutes at least45% w/w of the pharmaceutical composition, such as at least 50% w/w ofthe pharmaceutical composition. In one particular embodiment, the shellmay constitute 68% w/w of the pharmaceutical composition.

In one or more embodiments, a pharmaceutical composition as describedherein is resistant to abuse by chewing or other physical tampering(e.g. as can be measured by the particle size reduction test describedherein), by including a shell which is extremely hard and unbreakablebut otherwise inert. In one or more embodiments, a pharmaceuticalcomposition as described herein is resistant to abuse by freezing,microwaving, burning, melting, mastication (i.e. chewing), reduction ofthe particle size, extraction, injection, snorting, by including a shellwhich is extremely hard and unbreakable but otherwise inert and/orincluding a gelling agent or an opioid antagonist in the matrixcomposition.

Beyond abuse resistance, pharmaceutical compositions as describedherein, which are resistant to physical tampering, may also decreaseincidents of legitimate, but non-compliant, use of pharmaceuticalproducts, where the patient accidentally chews or crushes thepharmaceutical composition prior to or during administration, whichmight result in a partial or complete instant release of the active drugsubstance. Such incidents are potentially hazardous to the patient,particularly where the pharmaceutical composition is formulated fordelivery of highly potent drug substances.

Shell Composition

The material used to form the shell included in the pharmaceuticalcompositions described herein is selected to provide a shell andpharmaceutical composition that is resistant to physical tampering. Forexample, one or more polymers and, optionally, one or more plasticizersmay be selected to provide a shell having the desired physicalproperties. For purposes of the pharmaceutical compositions describedherein, the materials used to form the shell are selected to beinsoluble in and impermeable to water in order to ensure that therelease of the active drug substance from the matrix composition isgoverned by the surface area of the drug composition that is leftexposed by the shell

In some embodiments, the shell is formed from a material thatbiodegrades, disintegrates, crumbles or dissolves after erosion of thematrix composition and/or during the release of the active drugsubstance in the matrix composition.

In specific embodiments, polymers are used to form the shell, and thepolymers are are thermoplastic polymers. As used herein, “thermoplasticpolymers” refers to polymers that are an elastic and flexible liquidwhen heated, but freeze to a solid state when cooled. In certain suchembodiments, the thermoplastic polymers used to form the shell areselected to exhibit a solid state at 20° C. or to ambient temperature.

The shell included in the pharmaceutical compositions described hereinmay be made of a material comprising one or more of the polymersdescribed herein. For example, the shell may be formed of a materialcomprising one or more starch based polymers, one or more cellulosebased polymers, one or more synthetic polymers, one or morebiodegradable polymers, or a combination thereof, such as mixtures ofstarch and synthetic polymers or mixtures of starch and biodegradablepolymers.

In one or more embodiments, the shell may be made of a materialcomprising one or more polymers selected from Ethyl cellulose grade 20and 100, Polylactic acid (PLA), Cornpack 200, polycaprolactone, PEO7000000, and polyhydroxybuturate.

When the shell comprises biodegradable polymers (such as polylacticacid), the shell may comprise at least 50% w/w biodegradable polymers,such as at least 60% w/w, at least 70% w/w, at least 80% w/w, such as atleast 85% w/w, for example 86% w/w biodegradable polymers (such aspolylactic acid).

In one or more embodiments, the shell material comprises one or moreplasticizers. For example, in certain embodiments, the shell includes atthe most 20% w/w plasticizer, such as at the most 17% w/w, such as atthe most 15% w/w, for example 14% w/w, plasticizer. The plasticizer maybe polyethylene oxides having a molecular weight of at least 200,000daltons.

The shell may be made of a material comprising polylactic acid (PLA).Where the shell includes PLA, the shell may comprise at least 50% w/wPLA, such as at least 60% w/w, at least 70% w/w, at least 80% w/w, suchas at least 85% w/w, for example 86% w/w, PLA.

Starch Based Polymers

The shell material may comprise one or more starch based polymers. Thestarch based polymer may be starch, as such, or a polymer having astarch content of more than 70% w/w, such as more than 80% w/w, forexample, more than 90% w/w. Starch is a linear polysaccaride made up ofrepeating glucose groups with glyco-sidic linkages in the 1-4 carbonpositions with chain lengths of 500 to 2,000 glucose units. Starchcomprises two major polymer molecules—amylose and amylopectin.

The starch based polymers to be employed for a shell and pharmaceuticalcomposition according to the present invention may be thermoplasticstarch biodegradable plastics (TPS). TPS have starch (amylose) contentlarger than 70% w/w and are based on gelatinised vegetable starch. Thevegetable starch may, for example, be selected from potato starch, ricestarch, maize starch, tapioca starch, wheat starch, dextrin,carrageenan, chitosan. The vegetable starch may provide suitablepolymers used in the shell composition. The group of starch basedpolymers, in general, does not have a specified melting point, buttypically changes phase within a temperature range of 90° C. to 260° C.,depending upon the chain length of the starch based polymer, watercontent, branching and added side-groups included in the polymer, andthe degree of crystallinity of the starch. Long chained-starches areusually completely amorphous, while shorter length starches may besemi-crystalline (20-80% crystalline). In particular embodiments,materials exhibiting long polymer chains are used in the formation ofthe shell included in the pharmaceutical compositions described herein.Long polymer chains typically contribute to a material's hardness, whilenot being too brittle.

Starch-based polymers are in general fully biodegradable as they areproducts of plant materials. The degradation rate varies and can befurther induced by addition of other biodegradable polymers, as listedherein.

An example of a suitable starch based polymer, which may be utilized informing the shell material according to the present description is maizestarch. Cornpack is the maize starch used in the examples describedherein.

Starch is widely used in food and pharmaceutical industry as binder anddiluent. It is edible and essentially nontoxic. Starch is, in general,inexpensive and attains a good hardness when molded and thermoformed.Starch materials may also be reheated several times without losing theirthermodynamic properties. Accordingly, in some embodiments, the shellincluded in the pharmaceutical compositions described herein comprisesat least one starch based polymer. In certain such embodiments, theshell included in the pharmaceutical compositions described hereincomprises at least one starch. Starch materials can be selected tofacilitate manufacture of the shell material such as by injectionmolding or co-extrusion production processes.

Starch based polymers are decomposable, and usually have a fastdisintegration rate, especially in mixture with biodegradable polymers.These polymers are in generally recognized as stabile and inert in solidpharmaceutical composition.

Cellulose Based Polymers

The shell material may comprise one or more cellulose based polymers. Inspecific embodiments of the invention, the shell may even consist of oneor more cellulose based polymers (such as ethyl cellulose) andplasticizers (such as any of the plasticizers described herein) and UVstabilisers (such as any of the UV stabilisers described herein).

Cellulose based polymers are suited for use in formation of the shellcomposition because cellulose based polymers, such as, for example,ethylcellulose (particularly grade 100-300), often have increasedhardness and high ductility.

Therefore, in particular embodiments, the shell may include a cellulosebased polymer. Where a cellulose based polymer is used in the shell, thecellulose polymer may be selected to be substantially insoluble orinsoluble in an aqueous medium, Suitable cellulose based polymersinclude, for example, cellulose polymers, wherein one or more of thefree —OH groups have been substituted with an R-group to form a —O—Rgroup. In this context, R may be, for example, a linear or branchedlower alkyl, linear or branched lower alkyl-OH, linear or branched loweralkyl-COOH, —CO-(linear or branched lower alkyl), nitrate, aromaticrings or combinations of the aforementioned. Lower alkyl is preferably aC₁₋₁₀ alkyl, more preferably C₁₋₆ alkyl.

Accordingly, where a cellulose based polymer is used to formulate ashell as described herein, the cellulose based polymer may, for example,be one or more selected from ethylcellulose, cellulose acetate,cellulose propionate, cellulose nitrate, methylcellulose,carboxymethylcellulose and salts thereof, cellulose acetate phthalate,ethylhydroxyethylcellulose, ethylmethylcellulose,hydroxymethylcellulose, hydroxyethylmethylcellulose,hydroxypropylcellulose, hydroxypropylmethylcellulose,hydroxymethylcellulose and hydroxymethylpropylcellulose and celluloseacetate.

The shell may also comprise one or more cellulose based polymersselected from cellulose acetate, cellulose propionate,silicifiedmicrocrystalline cellulose, cellulose nitrate,methylcellulose, carboxymethylcellulose and salts thereof, celluloseacetate phthalate, microcrystalline cellulose,ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose,hydroxyethylmethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose, hydroxymethylcellulose phthalate,hydroxymethylcellulose and hydroxymethylpropylcellulose, celluloseacetate, ceratonia (high molecular-weight 310 000),

Cellulose based polymers are, in general, fully biodegradable, as theyare typically products of plant materials. The degradation rate ofcellulose based polymers is generally slower than that of starch basedpolymers. The degradation rate of cellulose based polymers, however, canbe increased by addition of other biodegradable polymers as listedherein. Such additional polymers may be polymers susceptible todegradation by one or more microorganisms, which can result in quickerdegradation of the shell composition into smaller pieces, giving rise toan increased surface area subject to degradation and, thereby, resultingin faster degradation.

In one or more preferred embodiments, the shell comprises ethylcellulose C₁₂H₂₃O₆(C₁₂H₂₂P₅)_(n)C₁₂H₂₃O₅ wherein n can vary to provide awide variety of molecular weights. Ethylcellulose, an ethyl ether ofcellulose, is a long-chain polymer of β-anhydroglucose units joinedtogether by acetal linkages Ethyl cellulose comes in different gradeswhich varies in molecular weight and number of ethoxy groups. Gradesfrom 20-300 are suitable for use in the present context and are alsoreadily commercially available. Grades with high molecular weights tendto be preferred because they are optimal to give a hard shell. The shellmay comprise one or more ethyl celluloses with different grades, forexample one ethyl cellulose with a grade of in the range of 20 to 300,such as in the range of 50 to 200, in the range of 80 to 120, such as100. Ethyl cellulose generally has a glass transition temperature within129-133° C. These polymers are widely used in food and pharmaceuticalindustry as coater, stabilizer, matrix former and taste masking and areregarded as non toxic substances.

Cellulose based polymers are in general derived from plant material andmay subsequently be modified. Many cellulose based polymers areinexpensive and provide a suitable hardness when moulded andthermoformed. As derivatives of plants, cellulose based polymers are, ingeneral, easily decomposable when disposed. These polymers are stabileand inert in solid state.

Synthetic Polymers

The shell according to the invention may also comprise one or moresynthetic polymers. Suitable synthetic polymers for use in the shellcomposition include, for example, one or more polymer selected frompolyamide, polyethylene, polyethylene terephthalate, polypropylene,polyurethane, polyvinyl acetate, polyvinyl alcohol, polyvinyl butural,polyvinyl chloride, silicone rubber, latex, teflon, copolymers such asethylene vinyl acetate (EVA), styrene-butadienestyrene (SBS) andstyrene-isoprene-styrene (SIS), Polyethylene glycols,polyvinylpyrrolidone, polyethylene oxide (ranging in molecular weights100,000 to 8,000,000), Eudragit L methyl ester, Eudragit RL, andEudragit E, carboxymethylene (Carbomer) and sugars thereof (e.g.allylsucrose), and co-block polymers of ethylene and propylene oxide(Poloxamer).

Biodegradable Polymers

Biodegradation is the process by which microorganisms (microbes such asbacteria, fungi or algae) convert materials into biomass, carbon dioxideand water. Biomass is a general term used to refer to the cells of themicroorganisms that are using the material as a carbon source to growon.

The shell included in the pharmaceutical compositions described hereinmay alternatively or additionally comprise one or more biodegradablepolymers. The biodegradable polymer(s) may be one or more selected fromthe starch based polymers, as described herein, and the cellulose basedpolymers, as described herein. However, the biodegradable polymer(s) mayalso be one or more selected from Polyhydroxybutyrate (PHB),polyhydroxyvalerate (PHV), polyhydroxyvalerate-co-hydroxyvalerate(PHVNH), Polyhydroxyalkanoates (PHA), poly-3-hydroxy-5-phenylvalerate(PHPV), Aliphatic polyesters, Polycaprolactone (PCL), polylactic acid(PLA), polyglycolic acid (PGA), co-polymers or co-block polymers ofPolycaprolactone (PCL), Poly-propylene carbonate (PPC), polyester amide(PEA), polybutylene succinate adipate (PBSA), polybutylene adipateco-terephtalate (PBAT) and polybutylene succinate-adipate (PESA).

The shell may be formed using copolymers or co-block copolymers ofpolycaprolactone (PCL), polylactic acid (PLA) and/or polyglycolic acid(PGA). For example, a copolymer or co-block copolymer may be selectedfrom poly(lactic-co-glycolic acid) (PLGA), polylactic acid andepsilon-caprolactone copolymer (PLA/CL) and polylactic acid/glycolicacid polymers) (PLA/GA), which are all commercially available.

In some embodiments, the shell comprises one or more biodegradablepolymers selected from polylactic acid (PLA), polycaprolactone (PCL) andpolyhydroxybutyrate (PHB). In one such embodiment, the shell comprisesboth polylactic acid (PLA), polycaprolactone (PCL) andpolyhydroxybutyrate (PHB).

The use of polycaprolactone and other polymers in this group has beenincreased over the last decade, while the demand for environmentalfriendly plastics has grown. These polymers are regarded as nontoxic andare already used in parenteral pharmaceutical compositions. Theadvantages of these polymers are their ability to make a more flexibleshell when moulded in mixture with starch derived polymers. Suchpolymers can be used to improve the somewhat rigid structure of purethermoplastic starch. Furthermore, these polymers are decomposable andbiodegradable.

Polylactic Acid

Polylactic acid or polylactide (PLA) is a biodegradable, thermoplastic,aliphatic polyester derived from renewable resources, such as cornstarch. PLA belongs to the chemical family of polyesters, such as, forexample, ε-caprolactone, PLA-caprolactone in different ratios 15% PLA to100% (25, 35, 50, 75, 85%), polyglycolides, polyglycolic acids (PGA),poly (lactide-co-glycolide) in different ratios 15 to 100% PLA (25, 35,50, 75, 85%), and poly (lactide-co-glycolide)-OH in different ratios 15%PLA to 100% (25, 35, 50, 75, 85%). Each of these polymers exists in L orD-form (making them optically active). When such polymers are providedin equal amounts (1:1) of L- and D-forms, the polymer material is anamorphous mixture, while the L- or D-forms, when provided alone possessa certain degree of crystallinity. The degree of crystallinity is highlyrelated to the mechanical properties, such as processability andphysico-chemical properties, particularly stability, of the polymer. Ahigh degree of crystallinity provides hardness, and possibly, morebrittleness. This may affect processability. Additionally, highlycrystalline materials have a high melting temperature, hence processtemperature, while amorphous esters have a lower melting temperature andthus a lower process temperature. Moreover, an increased degree ofcrystallinity implies that the material is more thermodynamicallystable, which can lead to a longer shelf-life. A lower degree ofcrystallinity or completely amorphous materials are usually softer witha lower process temperature. A potential draw back of amorphousmaterials or materials with a lower degree of crystallinity is thattheir physical-chemical stability is lower due to their relativelythermodynamically unstable state.

Where PLA is used in forming the shell of the pharmaceuticalcompositions described herein, it is desirable to find the optimaldegree of crystallinity. Each degree of crystallinity has differentmechanical properties, thus adhesion between PLA and the matrixcomposition will vary depending on the degree of crystallinity of thegiven material (PLA).

The skeletal structure of PLA is shown below.

Due to the chiral nature of lactic acid, several distinct forms ofpolylactide exist. Poly-L-lactide (PLA in its L-form), which is referredto as PLLA, results from polymerization of L,L-lactide (also known asL-lactide), and poly-D-lactide (PLA in its D-form), which is referred toas PDLA, results from polymerization of L,L-lactide (also known asL-lactide). Furthermore, PLLA and PDLA may be mixed with various ratiosof the two stereo forms. As the L-form has stronger mechanicalproperties than the D-form and the L-form has been used inpharmaceutical compositions, it is attempted to optimize the blend byadding the D-form to the L-form, such as, for example in amounts of 5,10, 20, 30, 40% w/w up to a ratio of 1:1, consequently making thematerial completely amorphous. However, it may also form a highlyregular stereo complex with increased crystallinity. Addition of PDLAincreases the molecular energy of the mixture by forming a concentrationgradient, and depending on the extent/magnitude of the temperaturegradient, addition of PDLA may induce slow nucleation and, hence,crystallization. However, addition of PDLA may also induce a nucleationat an uncontrollable nucleation rate, which leads to an amorphous state.

PLA in its L-form has a crystallinity of around 35-45%, a glasstransition temperature between 35-80° C., and a melting temperaturebetween 173-178° C.

Due to the structure of PLA, PLA may be exposed to hydrolysis during itspath through the gastro-intestinal tract, but PLA is impermeable andinsoluble in aqueous media. In applying PLA as shell material, it hasbeen demonstrated that the shell remains intact at leastmacroscopically, within the first 48 hours of exposure. Furthermore, thepossible degradation product of PLA is merely lactic acid.

Polyglycols

The shell may comprise any of the below-mentioned polyglycols in a formthat erodes at a substantially slower rate than the matrix composition.The shell may, therefore, be one which is eroded in an aqueous medium ata substantially slower rate than the matrix composition comprising theactive drug substance, whereby, the area of the matrix compositioncomprising the active drug substance that is exposed during erosionand/or release of the matrix composition is substantially controlledand, whereby, the shell is substantially eroded upon erosion and/orrelease of the matrix composition comprising the active drug substance.Such a shell can be designed so that its longitudinal erosion rate issubstantially the same as the longitudinal erosion and/or release rateof the matrix, whereby the matrix and the shell will erodelongitudinally towards the centre of the pharmaceutical composition atsubstantially the same rate. Thus, when the matrix composition has beencompletely eroded and/or released by the aqueous medium, the shell willalso be substantially completely eroded. A matrix composition havingsuch a shell has the obvious advantage of being completely biodegradedupon release of the active drug substance.

A polyglycol suitable for use within the shell is high molecular weightPEO, such as, for example, PEO with an average molecular weight which issignificantly higher that the average molecular weight of any of thePEOs contained in the matrix composition. Thus, where the shellcomposition includes a PEO, the PEO contained in the shell can beselected to have a significantly higher average molecular weight thanany PEO contained in the drug composition. Examples of PEO materialssuited to use in the shell include, for example, one or more PEO with anaverage molecular weight selected from at least 900,000, at least2,000,000, at least 4,000,000, at least 6,000,000, and at least7,000,000.

Mixtures of Polymers

As noted herein, the shell may comprise one or more different polymersand, in particular, one or more different polymers selected from starchbased polymers, cellulose based polymers, synthetic polymers andbiodegradable polymers, in particular from any of the starch basedpolymers, cellulose based polymers, synthetic polymers and biodegradablepolymers described herein.

In one or more embodiments of the invention, the shell comprisespolymers selected from starch based polymers and biodegradable polymers,such as from any of the starch based polymers and biodegradable polymersdescribed herein. In particular, biodegradable polymers such aspolycaprolactone, polyhydroxybuturate, polyhydroxyvalerate, polylacticacid, polyhydroxyalkanoates and polypropylenecarbonate can be blendedwith various starches (such as any of the starches described herein) indifferent ratios. Suitable mixtures for use in the shell compositionare, for example, polycaprolactone and sago and cassava starch,polycaprolactone or polyhydroxybuturate and pre-dried, thermoplasticstarch, polycaprolactone and gelatinized starch or thermoplastic starch.Other suitable mixtures are starch-based blends with biodegradablethermoplastic components, like polyester amide,polyhydroxybuturate-co-valerate or polybutylene succinate-adipate.Polymers starches can be cross-linked with Maleic anhydride (MA) anddicumyl peroxide (DCP) to provide harder materials when molded andthermoformed.

In one or more embodiments, the shell comprises polymers selected fromstarch based polymers and synthetic polymers as described herein. Inparticular, suitable mixtures for use in the shell composition include,for example, native granular starch, modified starch, plasticized starchblended or grafted with one or more synthetic polymers such aspolyethylene, polystyrene, Purified Terephthalic acid (PTA), optionallyin mixture with aliphatic polyesters or polyvinyl alcohols in differentratios. Polybutylene succinate (PBS), polybutylene succinate adipate inblend with various starches in different ratios are also suitable foruse in formulating the shell. For example, Polybutylene succinate inmixture with thermoplastic starch, or alkylene oxide modified starchesin combination with hydrolyzed polyvinyl alcohol may be used toformulate the shell.

In one or more embodiments, the shell comprises polymers selected fromthe cellulose based polymers and biodegradable polymers describedherein. Thus, the shell may, for example, comprise a mixture of PLA andethylcellulose. In one or more embodiments, the shell consists of PLA,ethyl cellulose, one or more plasticizers (such as any of theplasticizers described herein below), and one or more UV stabilisers(such as any of the UV stabilisers described herein).

The shell may be made of a material comprising a single polymer, whereinthe concentration of the polymer included in the shell is from 5 to 100%w/w.

The shell may be made of a material comprising a mixture of polymers,wherein the total concentration of polymers included in the shell isfrom 70 to 100% w/w.

UV Stabiliser

Radiation from sunlight can accelerate the degradation of plastics, suchas the shell according to the invention, and packaging material thatprotects the pharmaceutical compositions from direct sunlight mayprovide sufficient protection against UV degradation. In particular,where the shell included in the pharmaceutical compositions describedherein includes a high concentration of biodegradable polymers,incorporating one or more UV-stabilizers in the shell composition canwork to stabilize the polymers (particularly the unsaturated functionalgroups that may be included in such polymers). UV-stabilizers suitablefor use in the shell of the pharmaceutical composition include, forexample, titanium dioxide, metal complexes with sulfur containinggroups, hindered amine light stabilisers (HALS), benzophenones, andbenzotriazoles. Titanium dioxide is already widely used inpharmaceutical preparations as pigment and is considered non toxic.

Plasticizer

In addition to above mentioned polymers, the shell may comprise one ormore additional components. Thus, the shell may comprise at least oneselected from

-   -   i) polymers which are soluble or dispersible in water,    -   ii) plasticizers, and    -   iii) fillers/UV stabiliser.

By way of example, the shell material may include one or moreplasticizer selected from Cetostearyl alcohol, castor oil, dibutylsebacate, polyethylene oxides, and/or Poloxamer. However otherplasticizers may also be used to provide desired material properties.

Other suitable plasticizers may be selected from, for example, mono- anddi-acetylated monoglycerides, diacetylated monoglycerides, acetylatedhydrogenated cottonseed glyceride, glyceryl cocoate, Polyethyleneglycols or polyethylene oxides (e.g. with a molecular weight of1,000-500,000 daltons), dipropylene glycol salicylate glycerin, fattyacids and esters, phthalate esters, phosphate esters, amides, diocylphthalate, phthalyl glycolate, mineral oils, hydrogenated vegetableoils, vegetable oils, acetylated hydrogenated soybean oil glycerides,Castor oil, acetyl tributyl citrate, acetyl triethyl citrate, methylabietate, nitrobenzene, carbon disulfide, β-naphtyl salicylate,sorbitol, sorbitol glyceryl tricitrate, fatty alcohols, cetostearylalcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, myristylalcohol, sucrose octaacetate, alfa-tocopheryl polyethylene glycolsuccinate (TPGS), tocopheryl derivative, diacetylated monoglycerides,diethylene glycol monostearate, ethylene glycol monostearate, glycerylmonooleate, glyceryl monostearate, propylene glycol monostearate,macrogol esters, macrogol stearate 400, macrogol stearate 2000,polyoxyethylene 50 stearate, macrogol ethers, cetomacrogol 1000,lauromacrogols, nonoxinols, octocinols, tyloxapol, poloxamers, polyvinylalcohols, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate65, polysorbate 80, polysorbate 85, sorbitan monolaurate, sorbitanmonooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitansesquioleate, sorbitan trioleate, sorbitan tristearate and sucroseesters, amyl oleate, butyl oleate, butyl stearate, diethylene glycolmonolaurate, glycerol tributyrate, Flexol B-400, monomeric polyethyleneester, Piccolastic A-5, Piccalastic A-25, Clorafin 40, acetyl tributylcitrate, acetyl triethyl citrate, benzyl benzoate, butoxyethyl stearate,butyl and glycol esters of fatty acids, butyl diglycol carbonate, butylricinoleate, butyl phthalyl butyl glycolate, camphor, dibutyl sebacate,dibutyl tartrate, diphenyl oxide, glycerine, HB-40, hydrogenated methylester of rosin, methoxyethyl oleate, monoamylphthalate, Nevillac 10,Paracril 26, technical hydroabietyl alcohol, triethylene glycoldipelargonate, solid aliphatic alcohols and mixtures thereof.

In certain embodiments, the shell includes plasticizer at aconcentration of from 0 to 30% w/w.

The shell materials may further incorporate reinforcing fibers made of amaterial selected from, for example naturally derived fibers, such asplant derived fibers, synthetic materials, metal wires or steel bars,which increase the rigidity and/or integrity of the shell, therebyproviding additional protection against physical tampering.

Shell Construction and Shell Composition

The physical characteristics of the shell included in the pharmaceuticalcompositions disclosed herein can be adjusted by selection of shellgeometry and shell material properties. As will be appreciated uponreview of the configurations and materials described herein, variouscombinations of shell geometry and composition can be utilized toprovide a pharmaceutical composition having abuse resistant properties.In certain embodiments, the shell material substantially free ofplasticizer is formed using a polycaprolactone polymer.

Shape of Matrix Compositions

The geometric form of the matrix composition can be adjusted to achievea desired release rate of drug substance included within the matrixcomposition. For example, the matrix composition may be shaped toprovide zero order release of a drug substance from the pharmaceuticalcompositions described herein. In particular, the shell of thepharmaceutical composition is configured in a manner that leaves aportion of the matrix composition exposed such that, uponadministration, drug substance can be released from the exposed portionof the matrix composition.

In certain embodiments, the pharmaceutical composition described hereinis configured such that the exposed releasing area of the matrixcomposition is constant and, thereby, provides for a zero order releaseof the drug substance included withing the matrix composition. The areaof the matrix composition exposed for deliver of drug substance can beadjusted simply by adjusting the configuration of the shell within whichthe matrix composition is disposed. In particular embodiments, thepharmaceutical composition includes shell including two ends and acylindrical matrix composition disposed within the shell. One or both ofthe ends of the shell can include openings configured in manner thatmaintains surface area of the matrix composition exposed substantiallyconstant. In such an embodiment, because the releasing area remainsconstant over the course of delivering the drug substance, the releaseprofile of the drug substance will be zero order (or substantially zeroorder), provided that the release takes place via erosion of an exposedsurface.

In one or more embodiments, the inner surface of the shell may define acavity having a non-cylindrical shape. Such a configuration may be usedto achieve a non-zero-order release profile of the drug substancecontained within the matrix composition. For example, where the shellwall is configured to extend from a first end to a second end along afirst axis, the cross sectional area perpendicular to the first axis mayvary along the first axis. In such an embodiment, the cross sectionalarea may increase from the first end to the second end. Alternatively,the cross sectional area may increase from the first end to the centerand decrease from the center to the second end. In yet anotheralternative embodiment, the cross sectional area may decrease from thefirst end to the center and increase from the center to the second end(hourglass figure). The change in cross sectional area along the firstaxis may be stepwise. As will be appreciated, upon administration ofsuch a dosage form, as the matrix composition erodes, the surface areaof the matrix composition available for delivery of the drug substancesincluded within the matrix composition changes and, thereby, alters therelease rate of drug substance.

The term “cylindrical shape” as used herein refers to any geometricalshape having the same cross section area throughout the length of thegeometrical shape (along an axis, e.g. the first axis). The cylindricalshape may be combined with reinforcement element(s) such as a walland/or mesh or other reinforcement element. The cross section of acylindrical cavity may have any two dimensional shape. For example, thecross section may be circular, oval, rectangular, triangular, angular,polygonal, or star shaped. The pharmaceutical compositions according tothe invention may have a generally cylindrical shape, wherein the outershell wall may be rounded at the first end and the second end.Additionally, where the shell wall is configured to extend from a firstend to a second end along a first axis, the outer shell wall may taperalong the first axis, i.e. the area of the outer shell surface crosssection perpendicular to the first axis may vary, for example, decreaseand/or increase along the first axis. Accordingly, in certainembodiments, the outer shell surface may be a double curved surface.

Optionally, the pharmaceutical compositions of the invention may becylindrical pharmaceutical compositions having rounded and/or taperedend(s). The matrix composition may be of a cylindrical shape (optionallywith tapered end(s)), which preferably is surrounded by a shell havingat least one opening, with each opening exposing a surface of a matrixcomposition contained within the shell.

A cylindrical shape may be any geometrical shape having the same crosssection area throughout the length of the geometrical shape. Within thepresent context, unless otherwise stated, cross sections areperpendicular to the longitudinal axis of the cylinder (first axis). Byway of example, if the cylindrical shape is elongated then the crosssections are perpendicular to the first axis. Preferably, thecylindrical shape is elongated. The cross section of a cylinder withinthe meaning of the present invention may have any two dimensional shape,for example the cross section may be circular, oval, parabola,hyperbola, rectangular, triangular, polygonal, star shaped or anirregular shape. The pharmaceutical compositions according to theinvention may have a generally cylindrical outer surface, wherein theend(s) may be tapered.

Accordingly, the cylindrical shape may, for example, be an ellipticcylinder, a parabolic cylinder, a hyperbolic cylinder, or a prism. Aprism within the present context is a cylinder having a polygonalcross-section.

The pharmaceutical composition, as well as the matrix composition, asdescribed herein may be a cylindrical shape with one tapered end or twotapered ends.

In an embodiment, the matrix composition is substantially surrounded bya shell having at least one opening. In one such embodiment, the shellincludes a single opening exposing a surface of the matrix composition.In another such embodiment, the shell includes two opening exposing asurface of the matrix composition. The one or more openings included theshell of such embodiments may be positioned at one or both ends formedby the cylindrical shape of the matrix composition.

As described herein, the pharmaceutical compositions employed areprovided with a shell. The shell is in general applied with a matrixcomposition in such a way that a surface or part of a surface of thematrix composition is exposed through one or more openings in the shell.Accordingly, during release of the active drug substance or erosion ofthe matrix composition, the release surface has a controlled surfacearea. In some embodiments, the surface area may be controlled such thatit remains substantially constant, which would lead to a zero orderrelease profile for the drug substance. In other embodiments, thesurface area may be controlled such that it varies as the matrixcomposition erodes, which would lead to a non-zero order release profileand the matrix composition erodes. In the present context, controlledsurface area relates to a predetermined surface area typically predictedfrom the shape of the shell of the pharmaceutical compositions describedherein. It may have a simple uniform cylindrical shape or, in someembodiments, the cylindrical form can have one or more tapered ends inorder to decrease (or increase) the initial release period.

FIGS. 1 (A, B and C) shows different views of an embodiment of the shellaccording to the present invention. In FIG. 1, an end view of the shell2 having an outer shell wall 4 with a first end 6 and a second end 8 isshown. The outer shell wall 4 has an inner surface 10 defining acylindrical cavity having an elliptical cross-section perpendicular tothe first axis X. A first opening and a second opening is formed in theshell at the first end 6 and second end 8, respectively. FIG. 1B shows across section taken along line AA in FIG. 1A. FIG. 1C shows a crosssection taken along line BB in FIG. 1A. The outer surface 12 of theouter shell wall 4 tapers slightly in order to facilitate injectionmoulding. Thus, the thickness of the outer shell wall 4 varies along thefirst axis X from 1.4 mm at the second end to 1.8 mm towards the firstend, thus the maximum outer shell wall thickness is 1.8 mm. The lengthd₁ of the shell (extension along the first axis) is 7.5 mm. The heightd₂ of the shell (extension along the second axis Y) is 9 mm. The widthd₃ of the shell (extension along the third axis Z) is 13.5 mm. The innersurface of the outer shell wall defines a cylindrical cavity having anelliptic cross section (a_(in)=5 mm, b_(in)=2.6 mm) perpendicular to thefirst axis X. A matrix composition may be filled into the cavity, thusproviding a pharmaceutical composition as described herein in the formof a unit dosage form.

FIGS. 2 (A, B and C) shows different views of an embodiment of the shellaccording to the present invention. In FIG. 2A, an end view of the shell102 is shown. The outer shell wall 4 has an inner surface 10 defining acylindrical cavity having a circular cross-section perpendicular to thefirst axis X. FIG. 2B shows a cross section taken along line AA in FIG.2A. FIG. 2C shows a cross section taken along line BB in FIG. 2A. Theouter surface 12 of the outer shell wall 4 is rounded in order tofacilitate injection moulding and oral administration. Thus, thethickness of the outer shell wall 4 varies along the first axis X. Themaximum outer shell wall thickness is 4.5 mm. The length d₁ of the shell(extension along the first axis) is 7.5 mm. The height d₂ of the shell(extension along the second axis Y) is 12 mm. The width d₃ of the shell(extension along the third axis Z) is 16 mm. The inner surface of theouter shell wall defines a cylindrical cavity having a circular crosssection perpendicular to the first axis X. The circular cross sectionhas a diameter of 7 mm. A matrix composition may be filled into thecavity, thus providing a pharmaceutical composition as described hereinin the form of a unit dosage form.

FIGS. 3 (A, B and C) shows different views of an embodiment of the shellaccording to the present invention. In FIG. 3A, an end view of the shell202 is shown. The outer shell wall 4 has an inner surface 10 defining acylindrical cavity having an elliptical cross-section perpendicular tothe first axis X. FIG. 3B shows a cross section taken along line AA inFIG. 3A. FIG. 3C shows a cross section taken along line BB in FIG. 3A.The shell 202 comprises a first reinforcement wall 20 and a secondreinforcement wall 22. The first reinforcement wall 20 and the secondreinforcement wall 22 are plane and extend parallel to the first axis X.The first reinforcement wall 20 intersects the second reinforcement wall22 forming a right angle between the first reinforcement wall 20 and thesecond reinforcement wall 22. The first reinforcement wall 20 and thesecond reinforcement wall 22 divide the cavity defined by the innersurface 10 of the outer shell wall 4 in four cavity parts. The firstreinforcement wall 20 and the second reinforcement wall 22 extend fromthe first end 6 towards the second end 8, leaving a passage open at thesecond end 8 as seen in FIGS. 3B and 3C allowing matrix composition tobe injected into all four cavity parts. The first reinforcement wall 20and the second reinforcement wall 22 have a thickness of 0.5 mm. The useof reinforcement elements allows a thinner outer shell wall 4. Thethickness of the outer shell wall 4 varies along the first axis X from1.0 mm at the second end to 1.2 mm towards the first end. The maximumouter shell wall thickness is 1.2 mm. The length d₁ of the shell(extension along the first axis) is 7.5 mm. The height d₂ of the shell(extension along the second axis Y) is 7.5 mm. The width d₃ of the shell(extension along the third axis Z) is 11.5 mm. A matrix composition maybe filled into the cavity, thus providing a pharmaceutical compositionas described herein in the form of a unit dosage form.

FIGS. 4 (A, B and C) shows different views of an embodiment of the shellaccording to the present invention. The shell 302 is similar to theshell 202 of FIG. 3 but does not include the second reinforcement wall.

FIGS. 5 (A, B and C) shows different views of an embodiment of the shellaccording to the present invention. In FIG. 5A, an end view of the shell402 is shown. The outer shell wall 4 has an inner surface 10 defining acylindrical cavity having an elliptical cross-section perpendicular tothe first axis X. FIG. 5B shows a cross section taken along line AA inFIG. 5A. FIG. 5C shows a cross section taken along line BB in FIG. 5A.The shell 402 comprises a plane first reinforcement wall 20 extendingperpendicular to the first axis X and centered between the first end 6and the second end 8. The first reinforcement wall 20 comprises acircular opening 24 with diameter 2.5 mm forming a connection betweenthe two cavity parts. The first reinforcement wall 20 has a thickness of0.5 mm. The thickness of the outer shell wall 4 varies along the firstaxis X from 1.0 mm at the second end to 1.2 mm towards the first end.The maximum outer shell wall thickness is 1.2 mm. The length d₁ of theshell (extension along the first axis) is 7.5 mm. The height d₂ of theshell (extension along the second axis Y) is 7.5 mm. The width d₃ of theshell (extension along the third axis Z) is 11.5 mm. A matrixcomposition may be filled into the cavity, thus providing apharmaceutical composition as described herein in the form of a unitdosage form.

FIGS. 6 (A, B and C) show different views of an embodiment of the shellaccording to the present invention. In FIG. 6A, an end view of the shell502 is shown. The outer shell wall 4 has an inner surface 10 defining acylindrical cavity having an elliptical cross-section perpendicular tothe first axis X. FIG. 6B shows a cross section taken along line AA inFIG. 6A. FIG. 6C shows a cross section taken along line BB in FIG. 6A.The shell 502 comprises a plane first reinforcement wall 20 and a planesecond reinforcement wall 22 extending perpendicular to the first axis Xin the same plane and centered between the first end 6 and the secondend 8. The first reinforcement wall 20 and the second reinforcement wall22 have a thickness of 0.5 mm. The thickness of the outer shell wall 4varies along the first axis X from 1.0 mm at the second end to 1.2 mmtowards the first end. The maximum outer shell wall thickness is 1.2 mm.The length d₁ of the shell (extension along the first axis) is 7.5 mm.The height d₂ of the shell (extension along the second axis Y) is 7.5mm. The width d₃ of the shell (extension along the third axis Z) is 11.5mm. The first reinforcement wall 20 and the second reinforcement wall 22form an opening 24 forming a connection between the two cavity parts. Amatrix composition may be filled into the cavity, thus providing apharmaceutical composition as described herein in the form of a unitdosage form.

FIGS. 7 (A, B and C) show different views of an embodiment of the shellaccording to the present invention. The shell 602 corresponds to theshell 102 illustrated in FIGS. 2 (A, B and C) and additionally comprisesa plane first reinforcement wall 20 extending perpendicular to the firstaxis X and centered between the first end 6 and the second end 8 of theshell 602. The first reinforcement wall 20 comprises a circular opening24 with diameter 2 mm forming a connection between the two cavity parts.The first reinforcement wall 20 has a thickness of 1 mm.

FIG. 8 shows perspective views of shells illustrated in FIG. 1, andFIGS. 3-6.

FIGS. 9 (A, B, C and D) shows different views of an exemplary shellaccording to the present invention. FIG. 9A-B shows an end view of theshell 702 having an outer shell wall 4 with a first end 6 and a secondend 8. The outer shell wall 4 has an inner surface 10 defining acylindrical cavity having an elliptical cross-section perpendicular tothe first axis X. The ellipse formed by the inner shell surface 10 hassemimajor axis a_(in)=4.8 mm parallel to the third axis and semiminoraxis b_(in)=1.9 mm parallel to the second axis. A first opening and asecond opening is formed in the shell at the first end 6 and second end8, respectively. FIG. 9B shows a cross section taken along line AA inFIG. 9A. FIG. 9C shows a cross section taken along line BB in FIG. 9A.FIG. 9D shows a perspective view of the shell 702. The cylindricalcavity may take any suitable shape as described above. The outer surface12 of the outer shell wall 4 has elliptical cross sections along thefirst axis X. The elliptical cross sections vary in size and area alongthe first axis, i.e. the outer surface 12 is a double-curved surface.The outer surface cross sections along the first axis have semimajoraxes a_(out) in the range from about 5.5 mm to about 6.7 mm andsemiminor axes b_(out) in the range from about 2.2 mm to about 4.5 mm.The thickness of the outer shell wall 4 varies along the first axis Xfrom about 0.7 mm at the first and second ends increasing to about 1.9mm in the center between the two ends. Accordingly, the maximum outershell wall thickness is about 1.9 mm. The length d₁ of the shell 702(extension along the first axis) is about 7.5 mm. The height d₂ of theshell 702 (extension along the second axis Y) is about 7.6 mm. The widthd₃ of the shell 702 (extension along the third axis Z) is about 13.4 mm.A matrix composition may be filled into the cavity, thus providing apharmaceutical composition as described herein in the form of a unitdosage form.

Examples of shell dimensions are disclosed in the table below, wherea_(out) is the range for the outer surface semimajor axis ofcross-sections along the first axis, b_(out) is the range for the outersurface semiminor axis of cross sections along the first axis, a_(in) isthe inner surface semimajor axis, and b_(in) is the inner surfacesemimajor axis.

a_(out) (a_(out, min)-a_(out, max))/ b_(out)(b_(out, min)-b_(out, max))/ Shell mm mm a_(in)/mm b_(in)/mm d₁/mmExample 1 3.4-4.8 2.2-3.6 2.4 1.2 7.5 Example 2 4.1-5.7 2.7-4.2 3.3 1.77.5 Example 3 5.9-7.5 3.0-4.3 4.8 1.9 7.5 Example 4 10.1-11.4 2.7-4.59.0 2.0 7.5 Example 5 2.5-4.0 2.1-3.5 0.9 0.9 7.5 Example 6 2.3-4.02.1-3.5 1.6 1.0 7.5 Example 7 4.0-5.4 2.4-3.6 2.9 1.2 7.5 Example 85.1-6.4 2.8-4.1 4.0 1.7 7.5 Example 9  9.0-10.3 2.8-4.1 7.8 1.7 7.5Example 10 2.0-4.0 1.8-3.5 0.9 0.9 7.5 Example 11 2.6-4.0 2.0-3.5 1.61.1 7.5 Example 12 4.0-5.4 2.4-3.6 2.9 1.2 7.5 Example 13 5.1-6.42.8-4.1 4.0 1.7 7.5 Example 14  9.0-10.3 2.8-4.1 7.8 1.7 7.5 Example 154.0-5.2 2.5-4.8 2.8 1.4 7.5 Example 16 4.5-5.7 2.6-4.0 3.3 1.6 7.5Example 17 5.6-7.0 2.8-4.2 4.5 1.8 7.5 Example 18 6.7-7.9 2.9-4.3 5.51.9 7.5

The minimum semimajor axis of the elliptic outer shell surface crosssections may be given by: a_(out,min)=a_(in)+β₁, where β₁ is at least0.5 mm, such as at least 0.7 mm, e.g. in the range from about 1.0 mm toabout 2.5 mm. In one or more embodiments of the shell, β₁=1.1 mm inorder to provide desired strength and at the same time enable apharmaceutical composition that is easy to swallow.

The minimum semiminor axis of the elliptic outer shell surface crosssections may be given by: b_(out,min)=b_(in)+β₂, where β₂ is at least0.5 mm, such as at least 0.7 mm, e.g. in the range from about 1.0 mm toabout 2.5 mm. In one or more embodiments of the shell, β₁=1.1 mm inorder to provide desired strength and at the same time enable apharmaceutical composition that is easy to swallow.

The outer shell surface 12 of the shell 702 in a cross sectionperpendicular to the second axis (see FIG. 9C) forms a circular arc withr=d₁, i.e. α=1. Further, the outer shell surface 12 of the shell 702 ina cross section perpendicular to the third axis (see FIG. 9B) forms acircular arc with r=d₁, i.e. α=1.

FIGS. 10 (A, B, C and D) illustrates an exemplary shell for apharmaceutical composition. FIG. 10A is an end view of the shell 802.FIG. 10B shows a cross section taken along line AA in FIG. 10A. FIG. 10Cshows a cross section taken along line BB in FIG. 10A. FIG. 10D shows aperspective view of the shell 802. The shell 802 extends from a firstend 6 to a second end 8 along a first axis. The shell 802 defines anumber of cavities 804 extending from the first end 6 to the second end8. The shell 802 defines ten cavities 804; however any suitable numberof cavities, such as two, three, four, five, six, seven, eight, nine,ten, or more may be employed. The cavities 804 are circular cylindricalcavities with a suitable radius, e.g. in the range from about 0.5 mm toabout 4.0 mm. In the shell 802, the cavity radii are about 0.96 mm.Different radii for different cavities may be employed. The ten cavities804 are arranged in a 2×5 matrix configuration. It is to be noted thatany suitable configuration of cavities may be employed. For example, thenumber and cross sectional size and shape of the cavities may beadjusted as desired. Optionally, each cavity 804 comprises areinforcement element 806 extending from the inner shell surface intothe cavity. The reinforcement elements 806 extend from the inner surfaceas annular protrusions perpendicular to the first axis X. Thereinforcement elements 806 may also be referred to as reinforcementwalls comprising a circular opening 808. In addition to improving thestrength of the shell 802, the reinforcement elements 806 also functionas anchoring elements for matrix compositions accommodated in thecavities 804. Thereby, the reinforcement elements 806 ensure that matrixcomposition cannot be removed from the cavities 804 without breaking orcrushing the matrix composition, increasing the resistance to abuseachieved by the pharmaceutical composition. The length d₁ of the shell802 (maximum extension along the first axis) is about 7.5 mm. The heightd₂ of the shell 802 (maximum extension along the second axis Y) is about7.0 mm. The width d₃ of the shell 802 (maximum extension along the thirdaxis Z) is about 16.5 mm. A matrix composition may be filled into thecavities 804, thus forming a pharmaceutical composition.

The outer shell surface 12 of the shell 802 forms a double curvedsurface. The height d₂ of the shell varies along the first axis fromabout 4.8 mm at the first and second ends to about 7 mm at the centrebetween the two ends. The width d₃ varies along the first axis fromabout 13.5 mm at the first and second ends to about 16 mm at the centrebetween the two ends.

Drug Composition

The pharmaceutical compositions described herein comprise a drugcomposition, also referred to herein as a “matrix composition.” Thematrix composition may comprise one or more polymers. A generaldescription of materials and methods that may be utilized in theformulation of the matrix compositions in the pharmaceuticalcompositions described herein may be found in in WO 89/09066, WO91/004015, WO 95/22962, WO 99/51208, WO 03/024429, WO 03/024426, WO03/024430, WO 2004/041252, WO 2004/084869, WO 2004/084868, WO2006/128471, WO 2008/086804, and WO 2008/148798, each of which is hereinincorporated by reference.

Suitable polymers for the matrix composition typically comprise apolyglycol. Polyglycols suitable for use in the matrix composition maybe provided in the form of a homopolymer and/or a copolymer. In certainembodiments, the polymer is substantially water soluble, thermoplastic,crystalline, semi-crystalline or amorphous or a mixture of substantiallywater soluble, crystalline, semi-crystalline or amorphous polymers.Suitable polymers for use in a matrix composition are polyethyleneglycols, including derivatives such as mono and dimethoxypolyethyleneglycols (mPEGs), polyethylene oxides and/or block copolymers of ethyleneoxide and propylene oxide.

Polyethylene glycols (PEGs) are linear polydisperse polymers composed ofrepeating units of ethylene glycol. Their chemical formula isHOCH₂[CH₂OCH₂]_(m)CH₂OH, where m represents the average number ofrepeating units. Alternatively, the general formula H[OCH₂CH₂]_(n)OH maybe used to represent polyethylene glycol, where n is the number m+1 inthe previous chemical formula. See the structural presentations ofpolyethylene glycol below. n is the average number of oxyethylenegroups. n equals m+1.

Polyethylene oxides (PEOs) are linear polydisperse nonionic polymerscomposed of repeating units of ethylene oxide. Their chemical formula isHO[CH₂CH₂O]_(n)H, where n represents the average number of oxyethylenegroups. See the structural presentation of polyethylene oxide below. nis the average number of oxyethylene groups. Depending on the appliedpreparation method high molecular weight of PEO may have one terminalmethyl group.

Polyethylene glycols are mixtures of addition of ethylene glycol. Ingeneral PEG refers to polymers chains with molecular weights below20,000, while PEO refers to higher molecular weights polymers. However,because of the similarities between PEO and PEG, the terms are oftenused interchangeably for the same compound.

Polyethylene glycols and/or polyethylene oxides suitable for use in thematrix composition include those having a molecular weights of at leastabout 20,000 daltons, such as, for example, from 20,000 to 700,000daltons, from 20,000 to 600,000 daltons, from 35,000 to 700,000 daltons,from 35,000 to 500,000 daltons, from 35,000 to 400,000 daltons, from35,000 to 300,000 daltons, from 50,000 to 300,000 daltons, such as, forexample at least 35,000 daltons, at least 50,000 daltons, at least75,000 daltons, at least 100,000 daltons, at least 150,000 daltons, atleast 200,000 daltons, at least 250,000 daltons, at least 300,000daltons or at least 400,000 daltons.

In particular embodiments, the polymer is a polyethylene oxide or apolyethylene glycol that has a molecular weight selected from at least20,000 daltons, at least 35,000 daltons, at least 50,000 daltons, atleast 100,000 daltons, at least 200,000 daltons, at least 300,000daltons and at least 400,000 daltons. PEG is commercially available withaverage molecular weights up to 35 000. PEO is commercially availablewith average molecular weights up to 8,000,000. In specific embodiments,the polymer is a PEO having a molecular weight of at least 100,000 suchas, for example, from 100,000 to 8,000,000, from 100,000 to 7,000,000,from 100,000 to 5,000,000, from 100,000 to 4,000,000, from 100,000 to2,000,000, from 100,000 to 1,000,000, form 100,000 to 900,000. When PEOis employed with a molecular weight in the lower end, the PEO typicallyhas a molecular weight as mentioned in the preceding paragraph.Commercially available PEOs with a molecular weight in the higher endhave typically the following molecular weights: 900,000, 1,000,000,2,000,000, 4,000,000, 5,000,000, 7,000,000, 8,000,000.

Poloxamers are copolymers or block copolymers and are a range ofnon-ionic surfactants of polyethylene glycol (PEG) and polypropyleneglycol (PPG).

In chemical abstracts, Diol EO/PO block copolymers are described underthe scientific name-hydroxy-hydroxypoly(oxyethylene)poly(oxypropylene)-poly(oxyethylene)-blockcopolymer in combination with the CAS register number.

In specific embodiments, a suitable poloxamer for use in a matrixcomposition has a HLB value of at least 18 such as, for example, atleast 20. The mean molecular weight of a suitable poloxamer is typicallyat least 2,000.

Typical block copolymers of ethylene oxide and propylene oxide have amolecular weight of from 2,000 daltons, typically 3,000 to 30,000daltons such as, for example from 4,000 to 15,000 daltons. Poloxamer maybe the sole thermoplastic polymer in the matrix composition.

Mixtures of PEO with different average molecular weights can be used inorder to obtain a PEO with a desirable average molecular weight. Thesame applies to PEG.

The polymer has a melting point higher than the body temperature of thehuman in which the pharmaceutical composition is to be used. Thus, thepolymer(s) employed in the matrix composition can be selected frompolymers have a melting point of 20-120° C. such as, for example from 30to 100° C. or from 40 to 80° C.

In one or more preferred embodiments of the invention, the matrixcomposition comprises at least one polyethylene oxide and at least onecopolymer.

In addition, or as an alternative, to a polymer of a polyglycol type,the matrix composition may comprise polymer(s) selected from: modifiedor unmodified water soluble natural polymers, such as glucomannan,galactan, glucan, polygalacturonic acid, polyxylane, polygalactomannans,rhanogalacturonan, polyxyloglycan, arabinogalactan, and starch,cellulose and derivatives thereof, chitosan, alginate, fibrin, collagen,gelatin, hyaluronic acid, amylopectin, pectin including low methylatedor methoxylated pectins, dextran and fatty acids and alcohols; syntheticpolymers such as polyvinylpyrrolidone (PVP), polyvinyl acetate (PVA),polyvinylbutyral (PVB), Eudragit L methyl ester, Eudragit L, EudragitRL, Eudragit E, Eudragit S, PHPV, PHA, Polycaprolactone (PCL),poly(lactic-co-glycolic acid) (PLGA) and polylactic acid (PLA); andhydrogels made from the polymers or combined polymers mentioned aboveand or from polymers originated from, for example, 2-HydroxyethylMethacrylate (HEMA), Ethyleneglycol dimethacrylate (EDGMA),N-Vinyl-2-Pyrrolidone (NVP), acrylamide, hydroxypropyl methacrylate(HPMA), polyethylene glycol acrylate (PEGA), Polyethylene glycolmethacrylate (PEGMA), Poly(ethylene glycol)dimethacrylates (PEGDMA),Polyethylene glycol diacrylate (PEGDA), and Poly(ethyleneglycol)dimethacrylates (PEGDMA).

One or more polymers are typically present in a matrix composition in aconcentration amount of from 5 to 99.9% w/w, such as from 10 to 95% w/wsuch as from 15 to 90% w/w, such as from 20 to 85% w/w, such as from 30to 85% w/w calculated as w/w % of the matrix composition.

In one or more embodiments of the invention, the total concentration ofpolymers in the matrix composition is in the range of from 5 to 95% w/w,such as from 5 to 80% w/w, such as from 10 to 80% w/w, such as from 20to 80% w/w, such as from 30 to 80% w/w, such as from 40 to 80% w/w, forexample, from 45 to 80% w/w.

In one or more embodiments, then the concentration of the homopolymersin the matrix composition is in the range of 5 to 90% w/w, such as inthe range of 20 to 85% w/w, for example, in the range of 20 to 75% w/w,such as in the range of 20 to 70% w/w,

In some embodiments, the concentration of the polyglycol copolymer inthe matrix composition, if present in combination with a polyglycolhomopolymer, is in the range of 0 to 60% w/w, such as for example 0 to30% w/w. If the copolymer is the sole thermoplastic polymer in thematrix composition the concentration may be from about 5 to about 99.5%w/w such as those ranges described above and described for thehomopolymer.

In those cases, where mixture of polymers are present in the matrixcomposition, the concentration of an individual polymer in the matrixcomposition may typically be from 0 to 95% w/w such as, for example,from 5 to 90% w/w, from 10 to 90% w/w, from 10 to 80% w/w, from 10 to70% w/w, from 10 to 60% w/w, from 10 to 50% w/w, from 15 to 50% w/w,from 15 to 45% w/w, from 15 to 40% w/w, from 20 to 40% w/w, from 20 to35% w/w or from 20 to 30% w/w. The concentration is from 0 to 75% w/w,from 10 to 75% w/w, from 20 to 50% w/w, from 20 to 55% w/w. Polymers mayalso be present in low concentrations such as, for example, from 0 to20% w/w.

The total concentration of the polymers (notably the sum of homo- andcopolymers of the polyglycol type) in the matrix composition can be from5 to 99.9% w/w, such as from 10 to 95% w/w, from 15 to 90% w/w, such asfrom 20 to 85%, such as from 30 to 85%, from 30 to 99% w/w, such as, forexample, from 35 to 95% w/w, from 35 to 90% w/w, from 35 to 85% w/w,from 35 to 80% w/w, from 40 to 75% w/w, from 45 to 70% w/w, from 45 to65% w/w, from 55 to 85% w/w, or from 60 to 85% w/w. More specifically,the concentration can be selected from 5 to 85% w/w, from 20 to 85% w/w,from 30 to 85% w/w, and from 40 to 85% w/w.

The concentration of the polyglycol homopolymer can be from 5 to 99.9%w/w, such as from 20 to 90% w/w or from 30 to 90% w/w, and, in thosecases where the homopolymer is the only thermoplastic polymer present inthe matrix composition, then the concentration can be from 50 to 95%w/w, such as, for example, from 55 to 90% w/w, from 60 to 90% w/w, from65 to 90% w/w, from 70 to 90% w/w or from 70 to 85% w/w. Theconcentration can be selected from 10 to 75% w/w, from 20 to 75% w/w,from 25 to 75% w/w, and from 30 to 75% w/w.

The concentration of the polyglycol copolymer, if present in combinationwith a polyglycol homopolymer, can be from 1 to 60% w/w, such as, forexample, from 2.5 to 50% w/w, or from 5 to 45% w/w. If the copolymer isthe sole thermoplastic polymer in the matrix composition, theconcentration may be from 5 to 99.5% w/w, such as those ranges describedabove and described for the homopolymer. Alternatively, theconcentration of polyglycol copolymer with a polyglycol homopolymer maybe from 0 to 25% w/w.

Active Drug Substances

A matrix composition comprises one or more active drug substances. Theamount of substance is determined by the therapeutic index of theindication for which the active drug substance is intended. Typically,the amount of the active drug substance corresponds to a daily or partof a daily therapeutic dose.

Active drug substances that are water soluble, as well those that areslightly soluble or insoluble in water, may be suitable active drugsubstances for inclusion in the drug composition included in thepharmaceutical compositions described herein.

Thus, a matrix composition may comprise one or more active drugsubstances substances that are therapeutically, prophylactically,diagnostically and/or biologically active drug substances. The term“active drug substance” as used herein broadly includes any compound, ormixture thereof, that can be delivered from the matrix composition toproduce a beneficial result.

Examples of specific active drug substances suitable for use in a matrixcomposition of the invention are:

Antiinflammatory and antirheumatic active drug substances:Butylpyrazolidines, Phenylbutazone, Mofebutazone, Oxyphenbutazone,Clofezone, Kebuzone, Acetic acid derivatives and related substances,Indometacin, Sulindac, Tolmetin, Zomepirac, Diclofenac, Alclofenac,Bumadizone, Etodolac, Lonazolac, Fentiazac, Acemetacin, Difenpiramide,Oxametacin, Proglumetacin, Ketorolac, Aceclofenac, Bufexamac, Oxicams,Piroxicam, Tenoxicam, Droxicam, Lornoxicam, Meloxicam, Propionic acidderivatives, Ibuprofen, Naproxen, Ketoprofen, Fenoprofen, Fenbufen,Benoxaprofen, Suprofen, Pirprofen, Flurbiprofen, Indoprofen, Tiaprofenicacid, Oxaprozin, Ibuproxam, Dexibuprofen, Flunoxaprofen, Alminoprofen,Dexketoprofen, Fenamates, Mefenamic acid, Tolfenamic acid, Flufenamicacid, Meclofenamic acid, Coxibs, Celecoxib, Rofecoxib, Valdecoxib,Parecoxib, Etoricoxib, Lumiracoxib, Nabumetone, Niflumic acid,Azapropazone, Glucosamine, Benzydamine, Glucosaminoglycan polysulfate,Proquazone, Orgotein, Nimesulide, Feprazone, Diacerein, Morniflumate,Tenidap, Oxaceprol, Chondroitin sulfate, Feprazone, Dipyrocetyl,Acetylsalicylic acid, Quinolines, Oxycinchophen, Gold preparations,Sodium aurothiomalate, Sodium aurotiosulfate, Auranofin,Aurothioglucose, Aurotioprol, Penicillamine and similar agents,Bucillamine;

Analgesics: Opioids, Natural opium alkaloids, semi-synthetic opiumalkaloids, Morphine, Opium, Hydromorphone, Nicomorphine, Oxycodone,Dihydrocodeine, Diamorphine, Papaveretum, Codeine, Phenylpiperidinederivatives, Ketobemidone, Pethidine, Fentanyl, Diphenylpropylaminederivatives, Dextromoramide, Piritramide, Dextropropoxyphene,Bezitramide, Methadone, Benzomorphan derivatives, Pentazocine,Phenazocine, Oripavine derivatives, Buprenorphine, Morphinanderivatives, Butorphanol, Nalbuphine, Tilidine, Tramadol, Dezocine,Salicylic acid and derivatives, Acetylsalicylic acid, Aloxiprin, Cholinesalicylate, Sodium salicylate, Salicylamide, Salsalate, Ethenzamide,Morpholine salicylate, Dipyrocetyl, Benorilate, Diflunisal, Potassiumsalicylate, Guacetisal, Carbasalate calcium, Imidazole salicylate,Pyrazolones, Phenazone, Metamizole sodium, Aminophenazone,Propyphenazone, Nifenazone, Anilides, Paracetamol, Phenacetin, Bucetin,Propacetamol, Other analgesics and antipyretics, Rimazolium, Glafenine,Floctafenine, Viminol, Nefopam, Flupirtine, Ziconotide.

Anaesthetics: Ethers, Diethyl ether, Vinyl ether, Halogenatedhydrocarbons, Halothane, Chloroform, Methoxyflurane, Enflurane,Trichloroethylene, Isoflurane, Desflurane, Sevoflurane, Barbiturates,Methohexital, Hexobarbital, Thiopental, Narcobarbital, Opioidanaesthetics, Fentanyl, Alfentanil, Sufentanil, Phenoperidine,Anileridine, Remifentanil, Other general anaesthetics, Droperidol,Ketamine, Propanidid, Alfaxalone, Etomidate, Propofol, Hydroxybutyricacid, Nitrous oxide, Esketamine, Xenon, Esters of aminobenzoic acid,Metabutethamine, Procaine, Tetracaine, Chloroprocaine, Benzocaine,Amides, Bupivacaine, Lidocaine, Mepivacaine, Prilocalne, Butanilicaine,Cinchocaine, Etidocaine, Articaine, Ropivacaine, Levobupivacaine, Estersof benzoic acid, Cocaine, Other local anaesthetics, Ethyl chloride,Dyclonine, Phenol, Capsaicin;

Antimigraine active drug substances: Ergot alkaloids, Dihydroergotamine,Ergotamine, Methysergide, Lisuride, Corticosteroid derivatives,Flumedroxone, Selective serotonin (5HT1) agonists, Sumatriptan,Naratriptan, Zolmitriptan, Rizatriptan, Almotriptan, Eletriptan,Frovatriptan, Other antimigraine preparations, Pizotifen, Clonidine,Iprazochrome, Dimetotiazine, Oxetorone;

Antiepileptic active drug substances: Barbiturates and derivatives,Methylphenobarbital, Phenobarbital, Primidone, Barbexaclone,Metharbital, Hydantoin derivatives, Ethotoin, Phenyloin,Amino(diphenylhydantoin) valeric acid, Mephenyloin, Fosphenyloin,Oxazolidine derivatives, Paramethadione, Trimethadione, Ethadione,Succinimide derivatives, Ethosuximide, Phensuximide, Mesuximide,Benzodiazepine derivatives, Clonazepam, Carboxamide derivatives,Carbamazepine, Oxcarbazepine, Rufinamide, Fatty acid derivatives,Valproic acid, Valpromide, Aminobutyric acid, Vigabatrin, Progabide,Tiagabine, Other antiepileptics, Sultiame, Phenacemide, Lamotrigine,Felbamate, Topiramate, Gabapentin, Pheneturide, Levetiracetam,Zonisamide, Pregabalin, Stiripentol, Lacosamide, Beclamide;

Anticholinergic active drug substances: Tertiary amines,Trihexyphenidyl, Biperiden, Metixene, Procyclidine, Profenamine,Dexetimide, Phenglutarimide, Mazaticol, Bornaprine, Tropatepine, Etherschemically close to antihistamines, Etanautine, Orphenadrine (chloride),Ethers of tropine or tropine derivatives, Benzatropine, Etybenzatropine;

Dopaminergic ative drug substances: Dopa and dopa derivatives, Levodopa,Melevodopa, Etilevodopa, Adamantane derivatives, Amantadine, Dopamineagonists, Bromocriptine, Pergolide, Dihydroergocryptine mesylate,Ropinirole, Pramipexole, Cabergoline, Apomorphine, Piribedil,Rotigotine, Monoamine, oxidase B inhibitors, Selegiline, Rasagiline,Other dopaminergic agents, Tolcapone, Entacapone, Budipine;

Antipsychotic active drug substances: Phenothiazines with aliphaticside-chain, Chlorpromazine, Levomepromazine, Promazine, Acepromazine,Triflupromazine, Cyamemazine, Chlorproethazine, Phenothiazines withpiperazine structure, Dixyrazine, Fluphenazine, Perphenazine,Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine,Thioproperazine, Butaperazine, Perazine, Phenothiazines with piperidinestructure, Periciazine, Thioridazine, Mesoridazine, Pipotiazine,Butyrophenone derivatives, Haloperidol, Trifluperidol, Melperone,Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone,Indole derivatives, Oxypertine, Molindone, Sertindole, Ziprasidone,Thioxanthene derivatives, Flupentixol, Clopenthixol, Chlorprothixene,Tiotixene, Zuclopenthixol, Diphenylbutylpiperidine derivatives,Fluspirilene, Pimozide, Penfluridol, Diazepines, oxazepines andthiazepines, Loxapine, Clozapine, Olanzapine, Quetiapine, Neuroleptics,in tardive dyskinesia, Tetrabenazine, Benzamides, Sulpiride, Sultopride,Tiapride, Remoxipride, Amisulpride, Veralipride, Levosulpiride, Lithium,Other antipsychotics, Prothipendyl, Risperidone, Clotiapine,Mosapramine, Zotepine, Aripiprazole, Paliperidone;

Anxiolytic active drug substances: Benzodiazepine derivatives, Diazepam,Chlordiazepoxide, Medazepam, Oxazepam, Potassium clorazepate, Lorazepam,Adinazolam, Bromazepam, Clobazam, Ketazolam, Prazepam, Alprazolam,Halazepam, Pinazepam, Camazepam, Nordazepam, Fludiazepam, Ethylloflazepate, Etizolam, Clotiazepam, Cloxazolam, Tofisopam,Diphenylmethane derivatives, Hydroxyzine, Captodiame, Carbamates,Meprobamate, Emylcamate, Mebutamate, Dibenzo-bicyclo-octadienederivatives, Benzoctamine, Azaspirodecanedione derivatives, Buspirone,Other anxiolytics, Mephenoxalone, Gedocarnil, Etifoxine;

Hypnotic and sedative active drug substances: Barbiturates,Pentobarbital, Amobarbital, Butobarbital, Barbital, Aprobarbital,Secobarbital, Talbutal, Vinylbital, Vinbarbital, Cyclobarbital,Heptabarbital, Reposal, Methohexital, Hexobarbital, Thiopental,Etallobarbital, Allobarbital, Proxibarbal, Aldehydes and derivatives,Chloral hydrate, Chloralodol, Acetylglycinamide chloral hydrate,Dichloralphenazone, Paraldehyde, Benzodiazepineemepronium derivatives,Flurazepam, Nitrazepam, Flunitrazepam, Estazolam, Triazolam,Lormetazepam, Temazepam, Midazolam, Brotizolam, Quazepam, Loprazolam,Doxefazepam, Cinolazepam, Piperidinedione derivatives, Glutethimide,Methyprylon, Pyrithyldione, Benzodiazepine related active drugsubstances, Zopiclone, Zolpidem, Zaleplon, Ramelteon, Other hypnoticsand sedatives, Methaqualone, Clomethiazole, Bromisoval, Carbromal,Scopolamine, Propiomazine, Triclofos, Ethchlorvynol, Valerian,Hexapropymate, Bromides, Apronal, Valnoctamide, Methylpentynol,Niaprazine, Melatonin, Dexmedetomidine, Dipiperonylaminoethanol;

Antidepressant active drug substances: Non-selective monoamine reuptakeinhibitors, Desipramine, Imipramine, Imipramine oxide, Clomipramine,Opipramol, Trimipramine, Lofepramine, Dibenzepin, Amitriptyline,Nortriptyline, Protriptyline, Doxepin, Iprindole, Melitracen,Butriptyline, Dosulepin, Amoxapine, Dimetacrine, Amineptine,Maprotiline, Quinupramine, Selective serotonin reuptake inhibitors,Zimeldine, Fluoxetine, Citalopram, Paroxetine, Sertraline, Alaproclate,Fluvoxamine, Etoperidone, Escitalopram, Monoamine oxidase inhibitors,non-selective, Isocarboxazid, Nialamide, Phenelzine, Tranylcypromine,Iproniazide, Iproclozide, Monoamine oxidase A inhibitors, Moclobemide,Toloxatone, Other antidepressants, Oxitriptan, Tryptophan, Mianserin,Nomifensine, Trazodone, Nefazodone, Minaprine, Bifemelane, Viloxazine,Oxaflozane, Mirtazapine, Medifoxamine, Tianeptine, Pivagabine,Venlafaxine, Milnacipran, Reboxetine, Gepirone, Duloxetine, Agomelatine,Desvenlafaxine, Centrally acting sympathomimetics, Amfetamine,Dexamfetamine, Metamfetamine, Methylphenidate, Pemoline, Fencamfamin,Modafinil, Fenozolone, Atomoxetine, Fenetylline, Xanthine derivatives,Caffeine, Propentofylline, Other psychostimulants and nootropics,Meclofenoxate, Pyritinol, Piracetam, Deanol, Fipexide, Citicoline,Oxiracetam, Pirisudanol, Linopirdine, Nizofenone, Aniracetam,Acetylcarnitine, Idebenone, Prolintane, Pipradrol, Pramiracetam,Adrafinil, Vinpocetine;

Anti-dementia active subtances: Anticholinesterases, Tacrine, Donepezil,Rivastigmine, Galantamine, Other anti-dementia active drug substances,Memantine, Ginkgo biloba;

Other nervous system active drug substances: Parasympathomimetics,Anticholinesterases, Neostigmine, Pyridostigmine, Distigmine,Ambenonium, Choline esters, Carbachol, Bethanechol, Otherparasympathomimetics, Pilocarpine, Choline alfoscerate;

Active drug substances used in addictive disorders: Nicotine, Bupropion,Varenicline, Disulfuram, Calcium carbimide, Acamprosate, Naltrexone,Buprenorphine, Methadone, Levacetylmethadol, Lofexidine. Antivertigoactive drug subtances; Betahistine, Cinnarizine, Flunarizine,Acetylleucine, Gangliosides and ganglioside derivatives, Tirilazad,Riluzole, Xaliproden, Hydroxybutyric acid, Amifampridine;

Opium alkaloids and derivatives: Ethylmorphine, Hydrocodone, Codeine,Opium alkaloids with morphine, Normethadone, Noscapine, Pholcodine,Dextromethorphan, Thebacon, Dimemorfan, Acetyldihydrocodeine,Benzonatate, Benproperine, Clobutinol, Isoaminile, Pentoxyverine,Oxolamine, Oxeladin, Clofedanol, Pipazetate, Bibenzonium bromide,Butamirate, Fedrilate, Zipeprol, Dibunate, Droxypropine, Prenoxdiazine,Dropropizine, Cloperastine, Meprotixol, Piperidione, Tipepidine,Morclofone, Nepinalone, Levodropropizine, Dimethoxanate and Naltrexone;

The active drug substance may, for example, be an active drug substancewith abuse potential or safety risk suitable. Such active drug substancemay, for example, be selected from:

1-(1-Phenylcyclohexyl)pyrrolidine,1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine,1-[1-(2-Thienyl)-cyclohexyl]piperidine,1-[1-(2-Thienyl)cyclohexyl]pyrrolidine,1-Methyl-4-phenyl-4-propionoxy-piperidine, 1-Phenylcyclohexylamine,1-Piperidinocyclohexane-carbonitrile, 2,5-Dimethoxy-4-ethylamphetamine,2,5-Dimethoxyamphetamine, 2C-B (i.e.4-bromo-2,5-dimethoxypenethylamine), 2C-D (i.e.2,5-dimethoxy-4-methyl-phenethylamine), 2C-I (i.e.4-iodo-2,5-dimethoxy-phenethylamine), 2C-T-2 (i.e.2,5-dimethoxy-4-ethylthiophenethylamine), 2C-T-4 (i.e.2,5-dimethoxy-4-isopropyl thiophenethylamine), 2C-T-7 (i.e.2,5-dimethoxy-4-(n)-propylthiopenethylamine),3,4-Methylene-dioxymethamphetamine, 3,4,5-Trimethoxyamphetamine,3,4-Methylenedioxyamphetamine, 3,4-Methylenedioxy-N-ethylamphetamine,3-Methylfentanyl, 3-Methylthiofentanyl,4-Bromo-2,5-dimethoxyamphetamine, 4-Bromo-2,5-dimethoxy-phenethylamine,4-Methoxyamphetamine, 4-Methyl-2,5-dimethoxyamphetamine,4-Methylaminorex (cis isomer), 5-MeO-DIPT5-Methoxy-N,N-diisopropyltryptamine), 5-MeO-DMT5-Methoxy-N,N-dimethyltryptamine),5-Methoxy-3,4-methylenedioxyamphetamine, Acetorphin, Acetorphine,Acetyl-alpha-methylfentanyl, Acetyldihydrocodeine, Acetylmethadol,Alfentanil, Allobarbital, Allylprodin, Allylprodine, Alphacetylmethadol,levo-alphacetylmethadol, Alpha-ethyltryptamine, Alphameprodine,Alphamethadol, Alpha-Methylfentanyl, Alpha-Methylthiofentanyl,Alphaprodine, Alprazolam, Amfepramon, Amfetaminil, Amineptin, Aminorex,Amobarbital, Amphetamine, Dexamphetamine, Lisdexamphetamine, AmyInitrit(all isomers of the amyl group), Anabolic steroids, Anileridine,Aprobarbital, Barbital, Barbituric acid derivative, BDB (i.e.3,4-methylenedioxyphenyl)-2-butanamine), Benzethidin, Benzethidine,Benzoylecgonine, Benzphetamine, Benzphetamine, Benzylmethylketon,Benzylmorphine, Betacetylmethadol, Beta-Hydroxy-3-methylfentanyl,Beta-Hydroxyfentanyl, Betameprodine, Betameprodine, Betamethadol,Betaprodine, Bezitramide, Bezitramide, Boldenone, Brolamfetamin,Bromazepam, Brotizolam, Bufotenine, Buprenorphine, Butabarbital,Butalbital, Butobarbital, Butorphanol, BZP (A 2) (i.e.1-benzylpiperazin), Camazepam, Cannabis, Carfentanil, Catha edulis,Cathine, Cathinone, Chloral betaine, Chloral hydrate, Chlordiazepoxide,Chlorhexadol, Chlorotestosterone (same as clostebol), Chlorphentermine,Clobazam, Clonazepam, Clonitazene, Clonitazene, Clorazepate,Clortermine, Clostebol, Clotiazepam, Cloxazolam, Coca Leaves, Cocaine,Codeine, Codeine & isoquinoline alkaloid, Codeine methylbromide,Codeine-N-oxide, Codoxim, Cyclobarbital (Hexemal NFN), Cyprenorphine,Dehydrochlormethyltestosterone, Delorazepam, Desomorphine,Dexamphetamine, Dexfenfluramine, Dextromoramide, Dextropropoxyphene,Diacetylmorphine, Diampromide, Diazepam, Dichloralphenazone,Diethylpropion, Diethylthiambutene, Diethyltryptamine, Difenoxin,Dihydrocodeine, Dihydroetorphine, Dihydromorphine, Dihydrotestosterone,Dimenoxadol, Dimepheptanol, Dimethylthiambutene, Dimethyltryptamine,Dioxaphetyl butyrate, Diphenoxylate, Dipipanone, Diprenorphine,Dronabinol, Drostanolone, Drotebanol, Ecgonine, Estazolam,Ethchlorvynol, Ethinamate, Ethyl loflazepate, Ethylestrenol,Ethylmethylthiambutene, Ethylmorphine, Ethylmorphine, Eticyclidin,Etilamphetamine, Etonitazene, Etorphine, Etoxeridine, Etryptamine,Fencamfamin, Fenethylline, Fenetylline, Fenfluramine, Fenproporex,Fentanyl, Fludiazepam, Flunitrazepam, Fluoxymesterone, Flurazepam,Formebolone, Fungi and Spores of the species Psilocybe Semilanceata,Furethidine, Gammahydroxybutanic acid, Glutethimide, Halazepam,Haloxazolam, Heroine, Hydrocodone, Hydrocodone & isoquinoline alkaloid,Hydromorphinol, Hydromorphone, Hydroxypethidine, Ibogaine,Isobutylnitrit, Isomethadone, Ketamine, Ketazolam, Ketobemidone,Levamphetamine, Levo-alphacetylmethadol, Levo-methamphetamine,Levomethorphan, Levomoramide, Levophenacylmorphan, Levorphanol,Loprazolam, Lorazepam, Lormetazepam, Lysergic acid, Lysergic acid amide,Lysergic acid diethylamide, Marijuana, Mazindol, MBDNN-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine), mCPP (i.e.1-(3-chlorophenyl)piperazine), Mebutamate, Mecloqualone, Medazepam,Mefenorex, MeOPP 1-(4-methoxyphenyl)piperazine), Meperidine, Meperidineintermediate, Meprobamate, Mescaline, Mesocarb, Mesterolone,Metamphetamine, Metazocine, Methadone, Methadone intermediate,Methamphetamine, Methandienone, Methandranone, Methandriol,Methandrostenolone, Methaqualone, Methcathinone, Methenolone,Methohexital, Methyldesorphine, Methyldihydromorphine, Methylphenidate,Dexmethylphenidate, Methylphenobarbital (mephobarbital),Methyltestosterone, Methyprylone, Metopone, Mibolerone, Midazolam,Modafinil, Moramide-intermediate, Morpheridine, Morphine, Morphinemethylbromide, Morphine methylsulfonate, Morphine-N-oxide, Myrophine,N,N-Dimethylamphetamine, Nabilone, Nalorphine, Nandrolone,N-Ethyl-1-phenylcyclohexylamine, N-Ethyl-3-piperidyl benzilate,N-Ethylamphetamine, N-Hydroxy-3,4-methylenedioxyamphetamine,Nicocodeine, Nicocodine, Nicodicodine, Nicomorphine, Nimetazepam,Nitrazepam, N-Methyl-3-piperidyl benzilate, Noracymethadol, Norcodeine,Nordiazepam, Norethandrolone, Norlevorphanol, Normethadone, Normorphine,Norpipanone, Norpipanone, Opium, Oxandrolone, Oxazepam, Oxazolam,Oxycodone, Oxymesterone, Oxymetholone, Oxymorphone, Para-Fluorofentanyl,Parahexyl, Paraldehyde, Pemoline, Pentazocine, Pentobarbital,Petrichloral, Peyote, Phenadoxone, Phenampromide, Phenazocine,Phencyclidine, Phendimetrazine, Phenmetrazine, Phenobarbital,Phenomorphan, Phenoperidine, Phentermine, Phenylacetone, Pholcodine,Piminodine, Pinazepam, Pipradrole, Piritramide, PMMA (paramethyxymethylamphetamine), Prazepam, Proheptazine, Properidine, Propiram,Psilocybine, Psilocyn, Pyrovalerone, Quazepam, Racemethorphane,Racemoramide, Racemorphane, Remifentanil, Salvia divinorum, SalvinorinA, Secobarbital, Secobarbital, Sibutramine, SPA, Stanolone, Stanozolol,Sufentanil, Sulfondiethylmethane, Sulfonethylmethane, Sulfonmethane,Talbutal, Temazepam, Tenamfetamin, Testolactone, Testosterone,Tetrahydrocannabinols, Tetrazepam, TFMPP (i.e.1-(3-trifluormethylphenyl)piperazine), Thebacon, Thebaine, Thiamylal,Thiofentanyl, Thiopental, Tiletamine & Zolazepam in Combination,Tilidine, Trenbolone, Triazolam, Trimeperidine, Vinbarbital, Zaleplon,Zipeprol, Zolpidem, and Zopiclon.

Other suitable examples of useful active drug substances for the matrixcomposition include alfentanil, allylprodine, alphaprodine, aniloridine,benzylmorphine, bezitramide, buprenorphine, butophanol, clonitazene,codeine, cyclazocine, desomorphine, dextromoramide, dezocine,diapromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimephetanol,dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine,ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene,fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine,isomethadone, dextropropoxyphene, ketobemidone, levallorphan,levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol,metazocine, methadone, metopon, morphine, morphine 6-glucuronide,morphine 3-glucuronide, myrophine, nalbuphine, narccine, nicomorphine,norlevorphanol, normethadone, nalorphine, normorphine, norpipanone,opium, oxycodone, oxycodeine, oxymorphone, papavereturn, pentazocine,phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine,piritramide, propheptazine, promedol, properidine, propiram,propoxyphene, sufentanil, tilidine, tramadol, thebaine,levo-alphacetylmethadol (LAAM), remifentanil, carfentanyl, ohmefentanyl,MPPP, prodine, PEPAP, levomethorphan, etorphine, lefetamine, loperamide,diphenoxylate, and pethidine.

Other suitable examples also include Anabolic steroids, cannabis,cocaine and diazepam.

In preferred embodiments, the active drug substance is selected from thetherapeutic classes including non-steroids anti-inflammatory andantirheumatic active drug substances.

In certain embodiments, the active drug substance is selected from thetherapeutic classes including analgesics, opioids, antipyretics,anaesthetics, antimigraine agents, antiepileptics, anti-parkinsonagents, dopaminergic agents, antipsychotics, anxiolytics, sedatives,antidepressants, psychostimulants agents, dopamine, noradrenaline,nicotinic, alfa-andrenergic, serotonin, H₃ antagonist used for ADHD, andnootropic agents used in addictive disorders.

In certain embodiments, the active drug substance is selected from thetherapeutic classes including anaesthetics, centrally-acting analgesics,sedative-hypnotics, anxiolytics, appetite suppressants, decongestants,antitussives, antihistamines, antiemetics, antidiarrheals, and activedrug substances used to treat narcolepsy and attention deficithyperactivity disorder.

In some embodiments, the active drug substance is associated with abusesyndromes and the active drug drug substance may thus for example beselected from opioids, CNS depressants, CNS stimulants, cannabinoids,nicotine-like compounds, glutamate antagonists and N-methyl-D-aspartate(NMDA) antagonists.

In some embodiments, the active drug substance is selected frombuprenorphine, codeine, dextromoramide, dihydrocodeine, fentanyl,hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine,oxycodone, oxymorphone and tramadol.

In some embodiments, the active drug substance is selected fromamphetamine, dexamphetamine, lisdexamphetamine, methamphetamine,methylphenidate and dexmethylphenidate.

In some embodiments, the active drug substances have abuse potential orsafety risk. In principle, the use of a pharmaceutical composition toavoid alcohol dose dumping can be of relevance for any active drugsubstance. However, the main interest is with respect to active drugsubstances with abuse potential or safety risk.

The above mentioned active drug substances may also be in the form ofpharmaceutically acceptable salts, uncharged or charged molecules,molecular complexes, solvates or anhydrates thereof, and, if relevant,isomers, enantiomers, racemic mixtures, and mixtures thereof.

Furthermore, the active drug substance may be in any of its crystalline,polymorphous, semi-crystalline, amorphous or polyamorphous forms.

The active drug substance may by modified to change physical-chemicalproperties of the drug substance, which may be by increasing ordecreasing lipophilicity to modify the release characteristics of theactive drug substance.

The term “pharmaceutically acceptable salts” of an active drug substanceincludes alkali metal salts, such as, for example, sodium or potassiumsalts, alkaline earth metal salts, such as, for example, calcium andmagnesium salts, and salts with organic or inorganic acid, such as, forexample, hydrochloric acid, hydrobromic acid, nitric acid, sulfuricacid, phosphoric acid, citric acid, formic acid, maleic acid, succinicacid, tartaric acid, methansulphonic acid, and toluenesuiphonic acid,etc.

The term “solvates” includes hydrates or solvates wherein solvents otherthan water are involved such as, for example, organic solvents likechloroform and the like.

The concentration of the active drug substance in a matrix compositiondepends on the specific active drug substance, the disease to betreated, the condition of the patient, the age and gender of thepatient, etc. The above-mentioned active drug substances are well-knownactive drug substances, and a person skilled in the art will be able tofind information as to the dosage of each active drug substance and,accordingly, he will know how to determine the amount of each activedrug substance in a matrix composition.

The active drug substance may be a new chemical entity for which theamount of information is limited. In such cases, the dosage regimen hasto be evaluated based on available preclinical and/or clinical data.

The active drug substance may be included in the matrix composition at aconcentration amount of from 0.01-99% w/w such as, for example, from0.01 to 90% w/w, from 0.01 to 80% w/w, from 0.01 to 70% w/w, from 0.01to 50% w/w, or from 0.01 to 40% w/w. The specific embodiments the drugsubstance is included in the matrix composition at a concentration offrom 10 to 55% w/w.

In one or more embodiments, the active drug substance is apharmaceutically active powder. Where the drug substance is provided aspowder composition, the powder typically have a particle size of from0.1 μm to 500 μm, typically from 0.5 μm to 300 μm, more typically from 1μm to 200 μm, especially from 5 μm to 100 μm.

In one or more embodiments, the active drug substance is crystalline.Where included as a crystalline material, the drug substance can exhibita particle size of from 0.1 μm to 1000 μm such as, for example, 0.1 μmto 750 μm, 0.1 μm to 500 μm, typically from 0.5 μm to 500 μm, moretypically from 1 μm to 500 μm, especially from 5 μm to 500 μm.

In one or more embodiments, a matrix composition comprises active drugsubstance that at least partially present in amorphous form with a meanparticle size of at least 0.01 μm such as, for example, from 0.01 μm to500 μm, from 0.05 μm to 500 μm, from 0.1 μm to 500 μm, from 0.5 μm to500 μm, 1 μm to 500 μm, typically from 0.5 μm to 300 μm, from 1 μm to200 μm, or from 1 μm to 100 μm.

A pharmaceutical composition with a matrix composition containing anactive drug substance is typically for oral administration. Due to thepossibility of controlling the release rate of the active drugsubstance, the pharmaceutical composition may be adapted for oraladministration 1-6 times a day, such as 1-4 times daily, including 1-3times, 1-2 times or 1 times daily. The technology may also providepharmaceutical compositions for administration only once or twice daily.

Pharmaceutically Acceptable Excipients

The pharmaceutical composition may also contain other excipients aswell, for example in order to improve the technical properties of thepharmaceutical composition so that it may be easier to produce or inorder to improve the properties of the pharmaceutical composition suchas release rate of the active drug substance, stability of the activedrug substance or of the pharmaceutical composition itself.

A suitable pharmaceutically acceptable excipient for use in apharmaceutical compositions described herein may be selected fromfillers, diluents, disintegrants, glidants, pH-adjusting agents,viscosity adjusting agents, solubility increasing or decreasing agents,osmotically active agents and solvents.

Suitable excipients include conventional tablet or capsule excipients.These excipients may be, for example, diluents such as dicalciumphosphate, calcium sulfate, lactose or sucrose or other disaccharides,cellulose, cellulose derivatives, kaolin, mannitol, dry starch, glucoseor other monosaccharides, dextrin or other polysaccharides, sorbitol,inositol or mixtures thereof; binders such as alginic acid, calciumalginate, sodium alginate, starch, gelatin, saccharides (includingglucose, sucrose, dextrose and lactose), molasses, panwar gum, ghat gum,mucilage of isapol husk, carboxymethylcellulose, methylcellulose,veegum, larch arabolactan, polyethylene glycols, ethylcellulose, water,alcohols, waxes, polyvinylpyrrolidone such as, for example, PVP K90 ormixtures thereof; lubricants such as talc, silicium dioxide, magnesiumstearate, calcium stearate, stearic acid, hydrogenated vegetable oils,sodium benzoate, sodium chloride, leucine, carbowax 4000, magnesiumlauryl sulfate, Sodium laurilsulfate, Stearyl alcohol, Polysorbate 20,Polysorbate 60, Polysorbate 80, Macrogol stearate, Macrogol laurylether, Stearoyl macrogolglycerides, Sorbitan stearate, Sorbitan laurate,Macrogol glycerol hydroxystearat, colloidal silicon dioxide and mixturesthereof, disintegrants such as starches, clays, cellulose derivativesincluding microcrystalline cellulose, methycellulose,carboxymethycellulose calcium, carboxymethylcellulose sodium, cellulose,crosscarmellose sodium, gums, aligns, various combinations ofhydrogencarbonates with weak acids (e.g. sodiumhydrogencarbonate/tartaric acid or citric acid) crosprovidone, sodiumstarch glycolate, agar, alginic acid, calcium alginate, sodium alginate,chitosan, colloidal silicon dioxide, docusate sodium, guar gum,low-substituted hydroxypropyl cellulose, hydroxypropyl starch, magnesiumaluminium silicate, polacrilin potassium, povidone, sodium starchglycolate, pregelatinized starch, cation exchange resins, citrus pulp,veegum, glycollate, natural sponge, bentonite, sucralfate, calciumhydroxyl-apatite or mixtures thereof, effervescent agents (carbonaterelease) such as citric acid, anhydrous, citric acid, monohydrate,dextrates, fumaric acid, potassium bicarbonate, sodium bicarbonate,sodium citrate, dehydrate, tartaric acid or mixtures thereof.

The matrix composition may comprise one or more gelling agents. The term“gelling agent” as used herein refers to any substance, which is capableof providing the texture of a gel, when added to a liquid solution.Suitable gelling agents may be selected from, for example: polymersselected from modified or unmodified water soluble natural polymer, suchas glucomannan, galactan, glucan, polygalacturonic acid, polyxylane,polygalactomannans, polyxyloglycan, arabinogalactan, starch, cellulose,chitosan, alginate, fibrin, collagen, gelatin, amylopectin, pectinincluding low methylated or methoxylated pectins, dextran; syntheticpolymers such as PVA and PVB; and hydrogels made from the polymers orcombined polymers mentioned above and or from polymers originatedfromHEMA, HEEMA, MEMA, MEEMA, EDGMA, NVP, VAc, AA, acrylamide, MAA,HPMA, PEGA, PEGMA, PEGDMA, PEGDA, and/or PEGDMA, hydroxypropylmethylcellulose, hydroxypropyl cellulose, methylcellulose, hydroxyethylncellulose, ethylcellulose, hydroxypropyl methylcellulose phthalate,hydroxypropyl methylcellulose Acetate Succinate or other cellulosederivates, carboxymethylcellulose sodium, carboxymethylcellulosecalcium, carrageenans, guar gum, gellan gum, xanthan gum, tragacanth andArabic gum.

Furthermore, the pharmaceutical composition may comprise one or moreagents selected from sweetening agents, flavouring agents and colouringagents, in order to provide an elegant and palatable preparation.Examples of such agents include, for example, maltol, citric acid, watersoluble FD&C dyes and mixtures thereof with corresponding lakes anddirect compression sugars such as Di-Pac from Amstar. In addition,coloured dye migration inhibitors such as tragacanth, acacia orattapulgite talc may be added. Specific examples include Calciumcarbonate, 1,3,5-trihydroxybenzene, Chromium-cobalt-aluminium oxide,ferric ferrocyanide, Ferric oxide, Iron ammonium citrate, Iron (III)oxide hydrated, Iron oxides, Carmine red, Magnesium carbonate andTitanium dioxide.

Plasticizer may be incorporated in the matrix composition and/or in theshell. Suitable plasticizer may be selected from, for example: mono- anddi-acetylated monoglycerides, diacetylated monoglycerides, acetylatedhydrogenated cottonseed glyceride, glyceryl cocoate, Polyethyleneglycols or polyethylene oxides (such as, for example, with a molecularweight of 1,000-500,000 daltons), dipropylene glycol salicylateglycerin, fatty acids and esters, phthalate esters, phosphate esters,amides, diocyl phthalate, phthalyl glycolate, mineral oils, hydrogenatedvegetable oils, vegetable oils, acetylated hydrogenated soybean oilglycerides, dibutyl sebacate, Castor oil, acetyl tributyl citrate,acetyl triethyl citrate, methyl abietate, nitrobenzene, carbondisulfide, β-naphtyl salicylate, sorbitol, sorbitol glyceryl tricitrate,fatty alcohols, cetostearyl alcohol, cetyl alcohol, stearyl alcohol,oleyl alcohol, myristyl alcohol, sucrose octaacetate, alfa-tocopherylpolyethylene glycol succinate (TPGS), tocopheryl derivative,diacetylated monoglycerides, diethylene glycol monostearate, ethyleneglycol monostearate, glyceryl monooleate, glyceryl monostearate,propylene glycol monostearate, macrogol esters, macrogol stearate 400,macrogol stearate 2000, polyoxyethylene 50 stearate, macrogol ethers,cetomacrogol 1000, lauromacrogols, nonoxinols, octocinols, tyloxapol,poloxamers, polyvinyl alcohols, polysorbate 20, polysorbate 40,polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, sorbitanmonolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitanmonostearate, sorbitan sesquioleate, sorbitan trioleate, sorbitantristearate and sucrose esters, amyl oleate, butyl oleate, butylstearate, diethylene glycol monolaurate, glycerol tributyrate, CumarW-1, Cumar MH-1, Cumar V-1, Flexol B-400, monomeric polyethylene ester,Piccolastic A-5, Piccalastic A-25, Beckolin, Clorafin 40, acetyltributyl citrate, acetyl triethyl citrate, benzyl benzoate, butoxyethylstearate, butyl and glycol esters of fatty acids, butyl diglycolcarbonate, butyl ricinoleate, butyl phthalyl butyl glycolate, camphor,dibutyl sebacate, dibutyl tartrate, diphenyl oxide, glycerine, HB-40,hydrogenated methyl ester of rosin, methoxyethyl oleate,monoamylphthalate, Nevillac 10, Paracril 26, technical hydroabietylalcohol, triethylene glycol dipelargonate, solid aliphatic alcohols,nitrobenzene, carbon disulfide, β-naphtyl salicylate, phthalylglycolate, dioctyl phthalate and mixtures thereof.

Chemical stabilizers that maybe included in the matrix compositioninclude TPG, for example, in the form of TPGS, BHA, BHT, t-butylhydroquinone, calcium ascorbate, gallic acid, hydroquinone, maltol,octyl gallate, sodium bisulfite, sodium metabisulfite, tocopherol andderivates thereof, citric acid, tartaric acid, and ascorbic acid. Otherstabilisers include trivalent phosphorous, such as, for example,phosphite, phenolic antioxidants, hydroxylamines, lactones such assubstituted benzofuranones. Hindered phenols, thiosynergists and/orhindered amines, acids (ascorbic acid, erythorbic acid, etidronic acid,hypophosphorous acid, nordihydroguaiaretic acid, propionic acid etc.),phenols, dodecyl gallate, octyl gallate, 1,3,5-trihydroxybenzene,organic and inorganic salts (calcium ascorbate, sodium ascorbate, sodiumbisulphite, sodium metabisulfite, sodium sulfite, potassium bisulphite,potassium metabisulphite), esters (calcium ascorbate, dilaurylthiodipropionate, dimyristyl thiodipropionate, distearylthiodipropionate), pyranon (maltol), and vitamin E (tocopherol,D-α-tocopherol, DL-α-tocopherol, tocopheryl acetate, d-α-tocopherylacetate, dl-α-tocopheryl acetate. However, other anti-oxidative agentsknown in the art may be used according in the matrix compositions. Othersuitable stabilizers may be selected from, for example, sorbitolglyceryl tricitrate and sucrose octaacetate.

A release modifier may be incorporated in the matrix composition. Asuitable release modifier may be selected from, for example, fatty acidsand esters, fatty alcohols, cetyl alcohol, stearyl alcohol, mineraloils, hydrogenated vegetable oils, vegetable oils, acetylatedhydrogenated soybean oil glycerides, Castor oil, phosphate esters,amides, phthalate esters, glyceryl cocoate, oleyl alcohol, myristylalcohol, sucrose octaacetate, diacetylated monoglycerides, diethyleneglycol monostearate, ethylene glycol monostearate, glyceryl monooleate,glyceryl monostearate, propylene glycol monostearate, macrogol esters,macrogol stearate 400, macrogol stearate 2000, polyoxyethylene 50stearate, macrogol ethers, cetomacrogol 1000, lauromacrogols,poloxamers, polyvinyl alcohols, sorbitan monolaurate, sorbitanmonooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitansesquioleate, sorbitan trioleate, sorbitan tristearate, ethylcellulose,cellulose acetate, cellulose propionate, cellulose nitrate, cellulosederivative selected from methylcellulose, carboxymethylcellulose andsalts thereof, cellulose acetate phthalate, microcrystalline cellulose,ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose,hydroxyethylmethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose, hydroxymethylcellulose andhydroxymethylpropylcellulose, cellulose acetate, polylactic acid orpolyglycolic acid and copolymers thereof, methacrylates, a co-polymer ofmethacrylate-galactomannan, Polyvinyl alcohols, glycerinated gelatin andcocoa butter.

Other suitable release modifiers may be selected from inorganic acids,inorganic bases, inorganic salts, organic acids or bases andpharmaceutically acceptable salts thereof, saccharides,oligosaccharides, polysaccharides, polyethylene glycol derivatives andcellulose and cellulose derivatives.

Alternatively or additionally, mono-, di-, oligo, polycarboxylic acid oramino acids may be included as a pharmaceutically acceptable excipientin the matrix compositions described herein. Examples of such excipientsinclude, for example, acetic acid, succinic acid, citric acid, tartaricacid, acrylic acid, benzoic acid, malic acid, maleic acid, sorbic acid,aspartic acid and glutamic acid.

Examples of suitable organic acids that may be used in the matrixcompositions described herein include acetic acid/ethanoic acid, adipicacid, angelic acid, ascorbic acid/vitamin C, carbamic acid, cinnamicacid, citramalic acid, formic acid, fumaric acid, gallic acid, gentisicacid, glutaconic acid, glutaric acid, glyceric acid, glycolic acid,glyoxylic acid, lactic acid, levulinic acid, malonic acid, mandelicacid, oxalic acid, oxamic acid, pimelic acid, and pyruvic acid. Examplesof suitable inorganic acids that may be used in the matrix compositionsdescribed herein include pyrophosphoric, glycerophosphoric, phosphoricsuch as ortho and meta phosphoric, boric acid, hydrochloric acid, andsulfuric acid.

Inorganic compounds may be included in the matrix compositions describedherein. An example of a suitable inorganic compound is aluminium.

Organic bases may be included in the matrix compositions describedherein. Examples of organic bases are p-nitrophenol, succinimide,benzenesulfonamide, 2-hydroxy-2cyclohexenone, imidazole, pyrrole,diethanolamine, ethyleneamine, tris(hydroxymethyl)aminomethane,hydroxylamine, sodium citrate, aniline or hydrazine.

Inorganic bases may be included in the matrix compositions describedherein. Examples of inorganic bases include aluminium oxide, such as,for example, aluminium oxide trihydrate, alumina, sodium hydroxide,potassium hydroxide, calcium carbonate, ammonium carbonate or ammoniumhydroxide.

Salts of an organic acid may be included in the matrix compositionsdescribed herein. Suitable pharmaceutically acceptable salts of anorganic acid include, for example, an alkali metal salt or an alkalineearth metal salt such as, for example sodium phosphate, sodiumdihydrogenphosphate, disodium hydrogenphosphate, potassium phosphate,potassium dihydrogenphosphate, potassium hydrogenphosphate, calciumphosphate, dicalcium phosphate, sodium sulfate, potassium sulfate,calcium sulfate, sodium carbonate, sodium hydrogencarbonate, potassiumcarbonate, potassium hydrogencarbonate, calcium carbonate, magnesiumcarbonate, sodium acetate, potassium acetate, calcium acetate, sodiumsuccinate, potassium succinate, calcium succinate, sodium citrate,potassium citrate, calcium citrate, sodium tartrate, potassium tartrateor calcium tartrate.

Inorganic salts may be included in the matrix compositions describedherein. A suitable inorganic salt for use in a matrix composition may besodium chloride, potassium chloride, calcium chloride or magnesiumchloride.

Saccharides may be included in the matrix compositions described herein.Suitable saccharides may be selected from, for example, glucose, ribose,arabinose, xylose, lyxose, xylol, allose, altrose, inosito, glucose,sorbitol, mannose, gulose, Glycerol, idose, galactose, talose, mannitol,erythritol, ribitol, xylitol, maltitol, isomalt, lactitol, sucrose,fructose, lactose, dextrin, dextran, amylose, xylan.

Polyethylene glycol derivatives may be included in the matrixcompositions described herein. Suitable polyethylene glycol derivativesmay be selected from, for example, polyethylene glycol di(2-ethylhexoate), polyethylene glycols (200-600 daltons) or polyethylene oxides,for example with a molecular weight of 900-300,000 daltons.

Cellulose and cellulose derivatives may be included in the matrixcompositions described herein. Cellulose and cellulose derivativessuitable for use in the matrix composition may be selected frommethylcellulose, carboxymethylcellulose and salts thereof,microcrystalline cellulose, ethylhydroxyethylcellulose, ethylcellulose,cellulose acetate, cellulose proprionate, cellulose nitrate, celluloseacetate phthalate, ethylmethylcellulose, hydroxyethylcellulose,hydroxyethylmethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose, hydroxymethylcellulose andhydroxymethylpropylcellulose.

Preparation of a Pharmaceutical Composition

In some embodiments, the reinforcement elements mentioned above may bemolded or extruded together with the shell wall in one process. In suchan embodiment, the injection mold, or extrusion die is built in theproper shape to assure the desired dimensions of shell wall andreinforcement elements. If the reinforcement element is not the samematerial as the outer shell wall, the pharmaceutical composition may bemanufactured using a multi-part process. For example, such a process mayinclude a 3 component extrusion/injection moulding (1^(st) outer shellwall; 2^(nd) reinforcement element(s); 3^(rd), matrix composition).Where a multi-extrusion process is employed, the order in which thedifferent components are extruded may be arranged as desired to providea finished dosage form.

In specific embodiments, where the shell wall is configured to extendfrom a first end to a second end along a first axis, reinforcement wallsperpendicular to the first axis can beinjection molded. For suchembodiments, the injection mold is built in the proper shape, to assurethe dimensions of the outer shell wall and reinforcement wall. If thereinforcement wall is not the same material as the outer shell wall, thepharmaceutical composition may be manufactured using a multi-stepprocess. For example, such a process may include a 3 component injectionmolding (1^(st) outer shell wall; 2^(nd) reinforcement element(s);3^(rd), matrix composition). Where a multi-part injection moldingprocess is employed, the order in which the different components areextruded may be arranged as desired to provide a finished dosage form.

The matrix composition may also be extruded or molded and subsequentlyput into a weave for wrapping a mesh of fiber thread around the matrixcore. The fiber thread is warmed into the matrix composition by means ofa heating gun, or moulded directly into the matrix, and finally wound-upfor cooling. When the fiber thread has been wrapped around the matrixcomposition, depending on shape, the shell composition may beco-extruded or molded over the matrix composition.

The pharmaceutical composition, as well as the matrix composition andshell composition described herein, may also be produced by variousother methods which are either known in the pharmaceutical industry orwhich, for example, are used in the production of polymer-basedmaterials. The process used to manufacture a pharmaceutical compositionas described herein will depend upon the desired embodiment and thematerials employed in the pharmaceutical composition in question. Anadvantage pharmaceutical compositions described herein is that they maybe produced by methods, which are relatively simple and inexpensive.

Suitable preparation methods for pharmaceutical compositions describedherein include extrusion, injection moulding, tabletting, capsulefilling, thermoforming, melt-processing, spray coating, microencapsulation and other methods of preparing controlled releasepharmaceutical compositions. Also, a combination of one or more of theaforementioned may be employed.

The controlled release pharmaceutical composition may be prepared byseveral different methods. Many systems for controlled release aremarketed and it is currently an aim for the industry to reduce the riskof dose dumping, drug abuse or alcohol induced dose dumping in each ofthe systems.

Pharmaceutical compositions for controlled release according to theinvention may be prepared in numerous ways giving rise to differentrelease mechanisms. Particularly, the pharmaceutical compositionsdescribed herein may be prepared by 1, 2 or multiple component injectionmouldings, by conventional tablet compression, by micro encapsulation,by 1, 2 or multiple component extrusions, by capsule filling, bythermoforming or by melt-processing. In cases where a preparation isneeded in order to make the controlled release properties before/afterthe above mentions preparation steps, the preparation may also compriseseparate steps, such as, for example, wet granulation, dry granulation,melt granulation, pelletizing, spray coating, electrostatic coating orother methods for preparing controlled release dosage forms.

In a particular example, the pharmaceutical composition is prepared bytwo component injection moulding of a matrix composition and a shellsurrounding the matrix and exposing at least one surface of the matrix,preferably the two ends of the matrix composition for erosion governedrelease.

A pharmaceutical composition may also be produced by, for example,injection moulding, co-extrusion of the shell with the matrixcomposition and the active drug substance, extrusion and dip coating,injection moulding and dip coating, or by extrusion or injectionmoulding and solvent coating by spraying or dipping, multiple componentinjection moulding, or a combination of these methods.

Pharmaceutical Compositions

In specific embodiments, the pharmaceutical composition according to thepresent invention comprises: an active drug substance selected frommorphine, oxycodone, hydrocodone, hydromorphone, norhydrocordone,oxymorphone, noroxycodone, morphine-6-glucuronode and pharmaceuticallyacceptable salts thereof, such as morphine sulphate, morphine sulphatepentahydrate, oxycodone hydrochloride, hydromorphone hydrochloride andhydrocodone bitartrate; a matrix comprising at least one of polyglycolselected from polyethyleneglycol and polyethylene oxide and any mixturesthereof, at least one block copolymer which is poloxamer, at least onepharmaceutical excipients selected from mannitol, butylatedhydroxytoluene and Vitamin E Polyethylene Glycol Succinate, Eudragit L,Eudragit RL, Eudragit RS, Eudragit E, Eudragit S, and at least onegelling agent selected from carrageenan andhydroxypropylmethylcellulose; and a shell selected from ethyl cellulose,cetostearyl alcohol and titanium dioxide or polylactic acid andpolyethylene oxide.

In specific embodiments, the pharmaceutical composition according to thepresent invention comprises: an active drug substance selected frommorphine, oxycodone, hydrocodone, hydromorphone, norhydrocordone,oxymorphone, noroxycodone, morphine-6-glucuronode and pharmaceuticallyacceptable salts thereof, such as morphine sulphate, morphine sulphatepentahydrate, oxycodone hydrochloride, hydromorphone hydrochloride andhydrocodone bitartrate; at least one opioid antagonist which isNaltrexone; at least one polyglycol selected from polyethyleneglycol andpolyethylene oxide and any mixtures thereof; at least one blockcopolymer which is poloxamer; at least one pharmaceutical excipientselected from mannitol, butylated hydroxytoluene and Vitamin EPolyethylene Glycol Succinate, Eudragit L, Eudragit RL, Eudragit RS,Eudragit E, Eudragit S; and at least one gelling agent selected fromcarrageenan and hydroxypropylmethylcellulose; and a shell selected fromethyl cellulose, cetostearyl alcohol and titanium dioxide or polylacticacid and polyethylene oxide.

Other Aspects

Dose Dumping

Pharmaceutical compositions described herein are particularly suited forproviding controlled release pharmaceutical compositions containing amatrix composition comprising a) polymer or a mixture of polymers, b) anactive drug substance and optionally c) one or more pharmaceuticallyacceptable excipients; the matrix composition being provided with ashell (coating). In specific embodiments, the matrix compositions andshell included in the pharmaceutical compositions described herein maybe formulated and configured such that the pharmaceutical compositiondoes not exhibit alcohol-induced dose dumping. In such embodiments, thematrix composition exhibits a solubility and/or drug substance releaserate in alcohol containing media (e.g., ethanol containing media) thatis lower than or equal to the solubility and/or release rate in aqueousmedia that does not include alcohol (e.g., water, phosphate buffermedium pH 6.8 or hydrochloride solution pH 1.2). In some suchembodiments, the polymers and excipients chosen for use in the matrixcomposition are selected and provided in relative amounts that result inan unchanged or lower dissolution rate and/or release rate of the drugsubstance in alcohol containing media (e.g., ethanol containing media)as compared to the solubility and/or release rate exhibited in aqueousmedia that does not include alcohol (e.g., water, phosphate buffermedium pH 6.8 or hydrochloride solution pH 1.2). In certain suchembodiments, the dissolution and/or release rate of the drug substancefrom the matrix composition in alcohol containing media (e.g., ethanolcontaining media) is at least 1.25 times lower, such as at least 1.5times lower, at least 2 times lower, such as 5 times, 10 times, 25times, 50 times, or 100 times lower than the dissolution and/or releaserate of the drug substance in aqueous media that does not includealcohol (e.g., water, phosphate buffer medium pH 6.8 or hydrochloridesolution pH 1.2).

More specifically, the invention may provide a matrix composition of i)a polymer and ii) an active drug substance, which pharmaceuticalcomposition mitigates or elminates alcohol-induced dose dumping.Typically, the solubility or release rate of the matrix composition islower or substantially the same in alcohol than that in water. Morespecifically, the solubility or release is equal or at least 1.25 timeslower such as at least 1.5 times lower, at least 2 times lower inalcohol than in water, notably 5 times, 10 times, 25 times, 50 times or100 times lower.

Encapsulation of the Active Drug Substance to Prevent Abuse of aPharmaceutical Composition According to the Invention

Another approach to making pharmaceutical compositions resistant toabuse is to modify the physical-chemical properties of the active drugsubstance in such a way that the bioavailability of the active drugsubstance in the GI tract is determined not only by the controlledrelease mechanism of the pharmaceutical compositions, but also by thesolubility and/or absorption characteristics. This is, in effect, toinclude a second controlled release mechanism in conjunction with thepharmaceutical compositions in such a way that the overall releasepattern in vitro is conserved even after physical tampering.

An abuse resistant pharmaceutical composition has been developed withthe objective of reducing the likelihood of tampering and/or improperadministration of pharmaceutical composition, such as, for example, apharmaceutical composition for the delivery of opioids. A controlledrelease pharmaceutical composition may be provided in the form ofmicrocapsules, wherein release of the active drug substance iscontrolled by the solubility of the active drug substance and/or releasecontrolled by matrix microstructure.

In particular embodiments, the release profile of the drug substance maybe modified by means of encapsulation or microencapsulation of theactive drug substance in a lipophilic environment. In such embodiments,the encapsulated active drug substance is dispersed in a hydrophilicmatrix consisting of polymeric systems, such as, for example, PEG/PEOand poloxamers.

The encapsulated active drug substance may be coated with one or morelayers of coating which is degradable in the GI tract. Theabuse-deterrent features of such a pharmaceutical composition willensure that the physical release characteristics of the active drugsubstance are not compromised even if the matrix is compromised by, forexample, crushing, chewing or grinding. If the pharmaceuticalcomposition is taken as prescribed, the active drug substance willrelease as intended by means of erosion, surfactant action anddegradation in the GI tract.

Encapsulation is a well-known technology, and has been commerciallyapplied in the taste masking of products in, for example, the foodindustry. There are a number of techniques such as fluid bed coating,pan coating, chemical encapsulation and other techniques, which could beused in the encapsulation of a specific active drug substance.

In some embodiments, a pharmaceutical composition as described herienmay include a hydrophilic matrix, which is advantageous in preventingalcohol induced dose dumping, combined with a hydrophobicmicroenvironment around the active drug substance, which is advantageousin preventing abuse of active drug substance by means of manipulatingthe matrix.

Once the active drug substance has been modified by means ofencapsulation, the resulting matrix composition is blended and used inthe conventional manufacturing process for example injection moulding.

Naltrexone and/or Other Opioid Antagonists and/or any Type of AversiveAgents

Naltrexone (see chemical formula below), marketed as naltrexonehydrochloride, is an opioid receptor antagonist (antidote). Naltrexoneis used primarily in the management of alcohol dependence and opioiddependence.

Naltrexone does not posses a biological response itself upon binding toa receptor, but blocks or dampens agonist-mediated responses. It worksby binding to the active site or to allosteric sites on receptors, orthey may interact at unique binding sites not normally involved in thebiological regulation of the receptor's activity. Thereby, Naltrexonewill occupy the active site, which otherwise would have been a vacantreceptor site for the opiod.

Partial agonists may also be applicable for incorporation in thepharmaceutical compositions described herein. Partial agonists (such asbuspirone, aripiprazole, buprenorphine, or norclozapine) bind andactivate a given receptor, but have only partial efficacy at thereceptor relative to a full agonist. They may also be considered ligandswhich display both agonistic and antagonistic effects—when both a fullagonist and partial agonist are present.

Naltrexone and/or other similar antagonists of the opioid receptor canbe used to prevent abuse of opioids. More specifically, when apharmaceutical composition that includes Naltrexone and/or one or moreother, similar antagonists is subjected to physical tampering, theNaltrexone and/or similar antagonists will be released along with theopioid, thereby hindering the opioid effect. In such formulations, theNaltrexone and/or other similar antagonists are incorporated in thepharmaceutical composition in a way that prevents release of theantagonist as long as the pharmaceutical composition remains intact andit is administered as intended. Thus, it will not interfere with theopioid/pain relieving effect expected by the patients when usedaccording to the recommendation.

As an alternative or in addition to one or more antagonists, such anopioid antagonist, an aversive agent can be added to the pharmaceuticalcomposition. These agents are added to provide, for example, an irritantand/or painful stimulus and/or bad taste and/or any other form ofdiscomfort if the dosage form is subjected to physical tampering orother conditions associated with abuse. As is true of antagonists, theaversive agents should only be released if attempts are made to use thepharmaceutical composition in a manner different than intended.

The Naltrexone and/or other similar antagonists and/or any type ofaversive agents in the pharmaceutical composition may be:

-   -   Embedded in a matrix compositionas coated particles or other        physical forms with a water-resistant surface coating.    -   Embedded in a shell composition either internally of externally;        and/or    -   Provided around the shell and/or matrix or otherwise added to        the pharmaceutical composition to prevent effect of tampering        and abuse.

Such a pharmaceutical composition may have an inner core containingantagonist/aversive agent(s), wherein the antagonist/aversive agent(s)is embedded between a first reinforcement wall and a secondreinforcement wall with no openings. In such an embodiment the first andsecond reinforcement walls are impermeable under normal use conditions,ensuring no release of the antagonist/aversive agent from an intactpharmaceutical composition. In such an embodiment the first and secondreinforcement wall can take on any configuration, and the matrixformulation and shell may be configured as desired.

In FIG. 11, a pharmaceutical composition 50 comprises a shell 52 forminga number of cavities for accommodating a matrix composition.Antagonist/aversive agent(s) is embedded between a first reinforcementwall 20 and a second reinforcement wall 22, which has no openings(impermeable) and, thereby, ensures no release of theantagonist/aversive agent release from an intact pharmaceuticalcomposition. The outer shell wall 52, the first reinforcement wall 20,and the second reinforcement wall 22 form a closed cavity enclosing theantagonist/aversive agent. The first reinforcement wall 20 and thesecond reinforcement wall 22 are perpendicular to the first axis X.

FIG. 12 schematically illustrates a a pharmaceutical composition 54comprising a shell 52 with an opening at the first end and the secondend, respectively, where the pharmaceutical composition comprises aninner core 56 enclosing an antagonist/aversive agent. The inner core ispositioned in the cavity formed by the shell 52 and can take any shapeor form, such as, for example, round, cylindrical, oval and triangular.The inner core may be either randomly placed in the cavity or fixed at acertain position. The inner core 56 may have a shell/coating preventingrelease of the antagonist/aversive agent. If the pharmaceuticalcomposition 54 is subject to physical tampering, for example bycrushing, heating, or other means, the shell/coating of the inner core56 breaks and the antagonist/aversive agent is released and mixed withthe active drug substance, thereby mitgating or preventing abuse.

In particular embodiments, the pharmaceutical composition may comprise amatrix composition comprising coated particles containingantagonist/aversive agent(s). As illustrated in FIG. 13A, thepharmaceutical composition 54′ comprises a number of coated particles 58embedded in the matrix composition accommodated in the shell 52. Forexample, a number of coated particles, such as coated particles 58, maybe embedded in a matrix composition such as those as shown in FIG. 8,shell 2, 102, 202, 302, 402, 502, 602; FIG. 9, shell 702; and FIG. 10,shell 802; where the coating on the coated particle 58 ensures that noantagonist/aversive agent is released from an intact pharmaceuticalcomposition. The particles 58 can take any shape or form i.e. round,cylindrical, oval and/or triangular.

In particular embodiments, the pharmaceutical composition may comprise amatrix composition comprising one or more tubes optionally with closedends, with the one or more tubes enclosing an antagonist/aversiveagent(s). As illustrated in FIG. 13B, the pharmaceutical composition 54″comprises a tube 60 embedded in the matrix composition accommodated inthe shell 52, for example shell, 2, 102, 202, 302, 402, 502, 602, 702,802, where the tube 60 ensures that no or limited amount ofantagonist/aversive agent is released from an intact pharmaceuticalcomposition.

The pharmaceutical compositions as described herein may compriseantagonist/aversive agent(s) in shell composition or in chambers in theshell construction which ensures that no antagonist/adversive agent isreleased from an intact pharmaceutical composition. These chambers caneither partly or entirely surround the matrix composition.

The pharmaceutical composition may have antagonist/aversive agent(s)surrounding the matrix composition internally. In such an embodiment,the shell ensures that no antagonist/aversive agent is released from anintact pharmaceutical composition. This antagonist/aversive agentchambers can be either partly or entirely surrounded by the matrixcomposition and can take any form as part of the interior of thepharmaceutical composition.

The pharmaceutical composition may comprise a grid comprisingantagonist/aversive agent(s) as illustrated in FIG. 13C. In such casethe active drug substance may be released through the grid having ahollow grid structure containing antagonist/aversive agent(s), which canonly be released upon tampering with the pharmaceutical composition.Alternatively, the antagonist/aversive agent(s) containing grid caneither fully or partly surround the pharmaceutical composition.

The antagonist/aversive agent(s) may be coated and or imbedded in thepharmaceutical composition in such a way that the antagonist/aversiveagent is not released when the pharmaceutical composition isadministered as intended. The antagonist/aversive agent included in sucha composition should be released when the pharmaceutical composition istampered and is physically changed from its intended form. The amount ofantagonist/aversive agent(s) in the pharmaceutical composition issufficiently high to prevent an abuser in getting a “high” when thepharmaceutical composition is tampered with and the intended releasemechanism is compromised. The antagonist/aversive agent(s) of an intactpharmaceutical composition will pass through the gastrointestinal tractto be excreted in feaces. Alternatively, where the pharmaceuticalcomposition is administered as intended, antagonist/aversive agent(s)contained therein can be otherwise hindered in exerting an effect, suchas by enzymatic interaction.

In the case of opioids, an antagonist may prevent an abuser fromachieving a “high”. The antagonist or aversive agent can be any agentthat negates the effect of the therapeutic agent or produces unpleasantor punishing stimulus or effect, which will deter or cause avoidance oftampering with the pharmaceutical compositions comprising the same.Desirably, the antagonist/aversive agent does not harm the abuser by itsadministration or consumption but has properties that deter itsadministration or consumption if the controlled release mechanism asintended is altered, such as by chewing and swallowing or by crushingand snorting. The antagonist/aversive agent can, for example, have astrong or foul taste or smell, provide a burning or tingling sensation,cause a lachrymation response, nausea, vomiting or any other unpleasantor repugnant sensation or color. The antagonist/aversion agent isselected from antagonists of a therapeutic agent, a bittering agent, adye, a gelling agent and an irritant.

Examples of suitable irritants may be of natural or synthetic origin andinclude, for example, mustard, allyl isothiocyaanate and p-hydroxybenzylisothiocyanate; capsaicinoids, such as, for example, capsaicin,dihydrocapsaicin, nordihydrocapsaiscin, homocapsaicin, andhomodihydrocapsaicin; mint; aspirin; and acids such as, for example,acids with one or more carboxyl moieties, such as, for example, formicacid, acetic acid, propionic acidy, butyric acid, valeric acid, caproicacid, caprillic acid, capric acid, oxalic acid, malonic acid, succicnicacid, glutaric acid, adipic acid, maleic acid, fumaric acid, and citricacid. In one or more embodiments, local irritants for use as aversiveagents are capsaicinoids, such as, for example, capsaicin.

In one or more embodiments, the pharmaceutical composition may includeone or more mucous membrane irritants as aversive agents that causeirritation of mucous membranes located anywhere on or in the body,including membranes of the mouth, eyes, nose and intestinal tract. Suchpharmaceutical compositions can deter abuse via oral, intra-ocular,rectal, or vaginal routes. The above-described irritants can be furtheroptimized as necessary or desired in terms of for example concentrationand irritation severity. In particular embodiments, the surfactant canbe an anionic surfactant. In one such embodiment, an anionic surfactant(for example, docusate) can also function as a potential laxative and/orstool softener at excess doses.

Examples of other aversive agents include derivatives or complexes,pharmaceutically acceptable salts, and combinations of benzoicbenzylamine amide, denatonium benzoat alkaloids, amino acids, trichloroanisole, methyl anthranilate, quinine, denatonium saccharide, denatoniumchloride, sucrose octaacetate, quassinoids, such asquassin or brucine,flavenoids, such as quercetin or naringen, resinferatoxin, piperine,allyl isothiocyanate and/or niacine.

In the instance when the therapeutic agents is an opioid agonist,suitable antagonists include: derivatives or complexes, pharmaceuticallyacceptable salts and/or combinations of naltrexone, methoxy-naltrexone,naloxone, naloxone methiodide, phenylhydrazone derivatives, nalmefene,cyclazine, nalorphine, levallorphan; peptides derived from lactoferrin;selective sub-type opioiod receptor antagonists, such as cyprodime,naltrindole, norbinaltorphamine, D-Pen², D-Pen⁵]enkephalin andderivatives thereof; and/or peptides derived from lactoferrin and orpartial agonist also having opioid antagonist properties exemplified bybuprenorphine. In specific embodiments, the opioid antagonist isnaloxone or naltrexone. “Opioid antagonist” refers to one or more opioidantagonists, either alone or in combination, and further includespartial antagonist, pharmaceutically acceptable salts thereof,stereoisomers thereof, ethers thereof, esters thereof and combinationsthereof. The antagonist or aversive agent may comprise of a single typeof antagonist and/or aversive agent, or a combination of different typesof antagonists and aversion agents.

Protocol on Tampering Methods

A series of methods have been developed to illustrate the pharmaceuticalcomposition extent of being abuse resistant. The methods are based onthe in vitro test shown in the flow chart of FIG. 14.

Two separate paths are shown in the flow chart. The first path 1002entails a buccal & mastication method/test to evaluate abuse potentialwhen intact pharmaceutical compositions are subjected to chewing. Thesecond path 1004 entails a particle size reduction test method toevaluate abuse potential when the pharmaceutical composition issubjected to physical and/or chemical tampering. Both intactpharmaceutical compositions (compositions that have not been subjectedto tampering) and pharmaceutical compositions subjected to tampering,such as by, for example, freezing, microwaving, burning and melting aresubjected to particle size reduction. Provided that the pharmaceuticalcompositions do not change release profile of the active drug substancesubsequent to this test, the test program is successfully completed,indicating a dosage form that is resistant to abuse. Tests onpharmaceutical compositions subjected to tampering or may also result inequipment failure, and in such an instance, the test program isconsidered successfully completed, indicating a dosage form that isresistant to abuse.

If a given pharmaceutical composition is crushed or broken into smallpieces or small particles, an increased exposed surface area is created,which increases release rate of the active drug substance. Such anincrease in release rate may lead to an increased potential for abuse.If a change in the release profile of the active drug substance isnoticed, the pharmaceutical composition is considered to have failed. Atsuch a point, it is the potential for abusing the compromisedpharmaceutical composition, such as by snorting or chemical extraction,is evaluated. If the active drug substance can be extracted from thecompromised pharmaceutical composition, the ease with which suchextracted drug substance can be injected is evaluated.

Tampered by Freezing

The purpose of the freezing test is to evaluate if freezing is asuitable technique for defeating the controlled release mechanism of thepharmaceutical compositions. Furthermore, the purpose is to evaluatewhether freezing results in a brittle pharmaceutical composition and/orshell.

The freezing test program is shown in FIG. 15. The dissolution tests canbe used to evaluate if the controlled released mechanism in the frozenpharmaceutical compositions (i.e., freeze tampered) has been defeated.The freezing test can be conducted by test A, B and C. The dissolutiontests can be performed as described in the section describingdissolution testing.

Test A: Perform a dissolution test on intact pharmaceutical compositionssuch as tablets (e.g., n=3). The results from test A are defined ascontrol data. Test B: Place, for example, 3 pharmaceuticalcompositions/tablets in a freezer (−18° C.) for a predetermined periodof time, such as approximately 24 hours. Perform a dissolution test onthe freeze tampered tablets. Test C: Place, for example, 3 tablets in afreezer (−18° C.) for approximately 24 hours. Place the tablet in aplastic bag and fold the bag around the tablet a least three times toavoid escape of the tablet. Strike the tablet with a hammer until thetablet is broken, if possible. Perform a dissolution test on the freezetampered tablets.

Microwave Tampering

The purpose of the heating test is to evaluate if thermal manipulationby heating in a microwave oven is a suitable technique for defeating thecontrolled release mechanism in the pharmaceutical compositions.

The heating test program is shown in FIG. 16. The microwave effect canbe based on several tests conducted in a microwave oven in order toestablish knowledge on thermal treatment of the pharmaceuticalcomposition for example tablets. It has been shown that heating thetablets two times, each without water for one minute at 800 W issufficient to heat the entire tablet. Prolonging the time to 2 minutesdid not result in increased tablet temperature. After 3 minutes, theover-temperature safeguard in the microwave was activated.

Several tests adding 10 ml up to 100 ml water to pharmaceuticalcomposition (for example, tablets) in different beakers have also beenconducted. Relatively large cone-shape flasks (250 ml) were selected, asit then was possible to boil the tablets without bumping. It was foundthat a 250 ml flask with 30 ml water was most suitable. Small volumes ofwater resulted in the tablets not being entirely covered by the water,and larger volumes resulted in boiling over in the microwave around 1minute after start.

The microwave test can be conducted by test A, B and C illustrated inFIG. 16. The Dissolution tests can be performed as described in thesection describing dissolution testing to evaluate whether thecontrolled release mechanism in the heated pharmaceutical compositionhas been defeated. Test A: Perform dissolution test on intact tablets(e.g. n=3). The results from test A are defined as control data. Test B:Place one tablet in a 250 mL flask. Heat the tablet in a microwave ovenfor 1 minute and inspect the tablet visually. Perform this heatingprocedure 3 times, followed by a dissolution test (e.g., n=3). Test C:Place one tablet in a 250 mL flask and add 30 mL water. Heat the tabletin a microwave oven for 1 minute. Survey the flask and stop themicrowave if the water is boiling over. Pick up the tablet with aforceps and try to remove matrix from the shell with a spatula. Performthe heating and matrix removal procedure for example 3 tablets. Performa dissolution test on the tablets (e.g. n=3).

Tampered by Heating/Melting with for Example Gas Burner

The purpose of the heating test is to evaluate if thermal manipulationby heating or melting of the pharmaceutical composition with a gasburner is a suitable technique for defeating the controlled releasemechanism in the pharmaceutical composition.

The heating test program is shown in FIG. 16. The burning time chosen isbased on preliminary tests with a gas burner, which were conduced inorder to establish suitable conditions for the thermal treatment of thepharmaceutical compositions. The gas burner is adjusted to burn at lowtemperature with blue flame. It was found to be very difficult toheat/melt the tablets without charring the tablets completely. However,it was possible to avoid charring by moving the gas burner slightly backand forth for approximately 5 minutes.

The heating test can be conducted by test A and B, and the Dissolutiontests can be performed as described in the section describingdissolution testing to evaluate whether the controlled release mechanismin the heated pharmaceutical composition for example tablets has beendefeated. Test A: Perform a dissolution test on intact tablets (e.g.n=3). The results from test A are defined as control data. Test B: Placefor example 3 tablets on a large plate. Heat the tablets forapproximately 5 minutes while avoiding charring. If possible, turn thetablets approximately each minute. Visually inspect the tablets duringheating. Perform a dissolution test on the burned/melted tablets (e.g.n=3)

Tampered by Heating/Melting with for Example Heating Plate

The purpose of this heating test is to evaluate whether thermalmanipulation by melting on for example a heating plate is a suitabletechnique for defeating the controlled release mechanism in thepharmaceutical compositions.

The heating test program is shown in FIG. 16. The temperature and timeparameter chosen are based on preliminary tests conducted on a heatingplate in order to establish conditions suitable for the thermaltreatment of the pharmaceutical compositions. It was found that thetemperature should be at least 150° C. before the tablet starts to meltproperly. It was decided to heat the intact tablet for around 8 minutesturning the tablet each minute to avoid browning the tablet. Furtherheating resulted in browning of the surfaces.

The heating test can be conducted by test A and B, and the dissolutiontests can be performed as described in the section describingdissolution testing to evaluate whether the controlled release mechanismin the heated pharmaceutical composition has been defeated. Test A:Perform a dissolution test on intact tablets (e.g. n=3). The resultsfrom test A are defined as control data. Test B: Place for example 3tablets on a large petri dish. Heat the tablets for 8 minutes atapproximately 180° C. Turn the tablets approximately each minute.Visually inspect the tablets during heating. Perform a dissolution teston the heated tablets (e.g. n=3).

Buccal & Mastication

The method aims to evaluate the abuse potential of active drug substancefrom pharmaceutical compositions by chewing.

The mastication and buccal test program is shown in FIG. 17. The chewingtest can be carried out using a chewing apparatus which has beendeveloped to determine the release rate of the active drug substancefrom medicated chewing gum formulations.

A chewing apparatus to perform tests on medicated chewing gumformulation is described in Chewing apparatus, Ph. Eur 2.9.25. The basicprinciple behind the apparatus is a masticatory movement employed tosimulate the chewing action on a material, such as gum, placed in asmall chewing chamber, where the material is chewed by two horizontalpistons representative of teeth. The teeth are working alternately witha third vertical piston (tongue) at a constant speed. The results haveshown that the apparatus can provide strong mechanical forces thatinfluence the release of active drug substance from chewing gum. Theapparatus is found interesting as it has the ability to simulate the“grinding” movement of the bite on the tablet when continuously chewed.The apparatus used was from Weissen Born maskinfabrik, Vejle, Denmark.

In principle, the apparatus gives a simple masticatory movement tosimulate the chewing action on a piece of material placed in a smallchewing chamber containing a known volume of, for example, a buffersolution at 37° C. In this test, the chewing apparatus is a model systemfor human chewing of pharmaceutical compositions. The time point chosenin test B is based on experience with hard model chewing gums.

The mastication and buccal test can be conducted as described in test A,B and C. Test A: Perform a dissolution test as described in the sectiondescribing dissolution testing on pharmaceutical compositions (e.g.n=3). The results from test A are defined as control data. Test B,Mastication: Place one tablet in the chewing chamber. Start the chewingaction and visually inspect the tablet after 1 minute (44 chews), 3minutes (132 chews) and 5 minutes (220 chews). Note the appearance ofthe tablet, especially the integrity of the shell. Assessment criteriaof the chewing test is operated as described or until equipment failure.Test C, Buccal: Place one tablet in a beaker and add 5 ml artificialsaliva. Withdraw 300 μl samples after 10, 30 and 60 minutes.

Transfer the sample to a HPLC vial and add 1 ml phosphate buffer pH 6.8.Analyze the samples as content uniformity (CU). For CU dilute singletablets in 100 ml phosphate buffer 6.8. Dissolve over night. Morphinesulphate as API is determined by reverse phase chromatography, using aLiChroCAR T 250-4 packed with LiChrospher 100 RP-18, 5 μm column and aLiChroCAR T 250-4 packed with LiChroCAR T 4-4 RP-18, 5 μm aspre-collumn. The mobile phase consists of Acetonitrile:Ammonium acetatebuffer (10:90 v/v). The HPLC settings are as follows: Isocratic, columntemperature 30° C. flow 1.0 ml/min, detection HPLC-UV at 285 nm,injection volume 20 μl with a run time if 10 minutes. Compare theextracted amount to the data obtained in test A. The extracted amount(in mg) must be evaluated both absolutely and in comparison to the labelclaim. Furthermore, the amount of active drug substance must beevaluated to determine whether enough was extracted to meet the ultimategoal for the abusers to feel a “high”.

Particle Size Reduction

The method aims at evaluating the efforts required to reduce theparticle size of the pharmaceutical compositions via physical methods,such as, for example, crushing, grinding, cutting and other means ofparticle size reduction.

The particle size reduction test program is shown in FIG. 18. The testcan be carried out using a number of mechanical and electrical toolsfound in common households or commonly available in retail. The types oftools included in this test are given in Table 1.

TABLE 1 Overview of tool types Test no. Tool name and type 1 Mortar andpestle - pestle 5 times 2 Hammer (hammer head 470 g, impact area 5.7cm²) - strike 5 times 3 Grater (at least 4 openings pr. cm²) - grate 5times 4 Food Chopper, Mini Quick 6720 OBH (150 W, 4500-5000 rpm) - 30second (pulsating) 5 Coffee Grinder, Krups GVX242 (200 W) - 30 second(pulsating)

If the pharmaceutical composition is physically disrupted (Test B andC), the resulting tampered tablet can be analyzed and compared to theintact tablets (test A). Compositions, such as tablets, subjected totampering can furthermore be run through a particle size analyzer andthe different fractions collected. Each fraction is weighed anddissolved to assess the contents of active drug substance in thedifferent fractions (test D). The applicability of each tool is testedand recorded and the procedure is to operate each tool to the limit.This means that each tool is operated until pharmaceutical composition(e.g., a tablet) or equipment failure is observed.

The particle size reduction test can be performed as described in test Ato D and repeated for all tests given in Table 1. Test A: Perform adissolution test on intact tablets (e.g., n=3) as described in thesection describing dissolution testing. The results from test A aredefined as control data. Test B: Subject the tablets to tamperingaccording to Table 1 test no. 1, etc., by placing one tablet in a mortarand attempting to crush it with the pestle. Perform a dissolution test(e.g., n=3) to evaluate if the controlled released mechanism in thetablets has been defeated by comparing the results from test B withresults from test A.

Test C1 Freezing: Place for example three tablets in a freezer (−18 forapproximately 24 hours. Perform a hammer test on the tablets subjectedto freeze tampering by placing the tablets on the floor and striking thetablets with a hammer. Conduct a dissolution test on the freeze/hammeredtampered tablets (e.g. n=3). Test C2 Microwave heating: Place, forexample, three tablets in a beaker and heat them in a microwave aspreviously described. Subject the tablets to tampering using the methodfrom test B, where the largest particle size reduction is found. Performa dissolution test on the heated tampered tablets. Test C3: Heating bygas burner: Place, for example, three tablets on a plate. Heat thetablets as previously described. Subject the tablets to tampering usingthe method from test B, where the largest particle size reduction isfound. Perform a dissolution test on the burned/melted tampered tablets(e.g. n=3). Test C4 Melting: Place, for example, three tablets on alarge petri dish. Heat the tablets as previously described. Subject thetablets to tamperng using the method from test B, where the largestparticle size reduction is found. Perform a dissolution test on thetampered and heated tablets.

Test D: Subject the tablet to tampering according to Table 1 test no. 1,etc., by placing one tablet in a mortar and attempting to crush it withthe pestle. Transfer the tablet subjected to tampering to the particlesize analyzer and collect the different fractions. Quantify the amountof active drug substance in each fraction collected as contentuniformity as previously described in section mastication and buccaltest. Report the results in Table 2.

TABLE 2 Result from test no. 1 etc. Test no. 1: Mortar and pestle Activedrug substance Particle size fraction Fraction weight Content (mg - % of(mm) (mg) label claim) Comments X > 5 5 > X > 2.5 2.5 > X > 1.12 1.12 >X > 0.5 0.5 > X > 0.3 0.3 > X > 0.125 0.125 > X > 0.063 0.063 > X

The preferred ways of tampering with pharmaceutical compositions from anabuser's point of view, typically achieve maximal reduction of thepharmaceutical composition in a minimal amount of time, while obtaininga powder or similar product which can be dissolved or administered aseasily as possible. Efforts required to reduce the particle size of thepharmaceutical compositions via physical methods such as for examplecrushing, grinding, cutting and other means of particle size reducingmethods, are evaluated above. The tampering method which results in thelargest reduction of pharmaceutical compositions, such as, for exampletableted compositions, is used as the tampering method in the testdescribed below.

Extraction

The extraction test evaluates the extractability of active drugsubstance from pharmaceutical compositions in different solvents, underdifferent conditions.

The extraction test program is shown in FIG. 19. Extraction tests can beperformed in 5, and 30 ml solvent in order to cover a relevant range.Different sites on the internet describe that 3 ml water often is usedwhen preparing a solution of, for example, MS Contin® for injection.Tests in the laboratory have shown that an extraction volume of 3 ml isinsufficient to get reliable and reproducible results when several timepoints are required. It was found that 5 ml was the smallest practicalextraction volume. The second amount of solvent to be tested is 10 ml,as this amount represents a sip. Furthermore, 10 ml can still be used toprepare an injectable solution after evaporation. The third and largestamount of solvent to be tested is 30 ml. This amount is used in order tobe sure that as much active drug substance as possible has beenextracted. Different ways of handling the solutions have been testedprior to this test. Periodically shaking up to 300 minutes is assessedas the most realistic to be employed by intentional drug abusers. But tobe sure that as much as possible of the active drug substance has beenextracted, continuous shaking has been selected as method.

Several time points have also been tested prior to this test to obtainreliable and reproducible results. The mean T_(max) observed in vivo is240 minutes for Egalet® morphine, therefore this time point is selectedas the latest sampling point. Three time points are taken within thefirst 60 minutes, as this is most relevant for abusers. Time pointstested in this test can be 10, 30, 60, 120, 240 and 1440 minutes.

The solvents have been chosen to cover a broad range of liquids with lowand high pH, with some beingsome polar and some non-polar. The solventscan be grouped into five groups: aqueous buffers; beverages; commonhousehold liquids; exotic organic liquids; and simulated liquids. Priorto the extraction test program, the solubility of the active drugsubstance in the selected solvent is evaluated. If the active drugsubstance does not dissolve in a given solvent, the solvent can beexcluded from the list and the total number of experiments is reduced.

Extraction of active drug substance from pharmaceutical compositions canbe performed by dissolving, for example, tablets in different solventsaccording to, for example, Table 3. The shaking table IKA®-Werke Shakerhorizontal HS501 digital, is applied and the shaking speed is140-160/min.

TABLE 3 List of solvents for extraction of active drug substance fromtablets Type Solvent Aqueous solutions Solution pH 1.2 Buffer pH 6.8Buffer pH 10.0 Water Water + EtOH (40% v/v) Beverages Coca-Cola ®Coca-Cola ® + 40% EtOH Vodka Common household liquids 1% acetic acidEthanol Methylethylketone Acetone

Test A: Place one tablet in a brown 30 ml bottle and add 5 ml of theselected solvents according to Table 3 (one solvent per bottle). Placethe bottle on the table and (non-stirred) and on a shaking table andshake continuously (speed 140-160/min) throughout the whole experimentalperiod. Withdraw 300 μl sample after 10, 30, 60, 120, 240, and 1440minutes, respectively. Transfer the sample to a HPLC vial and add 1 mlphosphate buffer pH 6.8. Analyze the samples as content uniformity (CU)as previously described in sections describing mastication and buccaltesting. Test B: Subject the tablets to tampering as described above,such as by, for example, freezing, microwave heating, direct heating andmelting. Place the tablets subjected to tampering in a brown 30 mlbottle and add 5 ml of the selected solvents according to Table 3 (onesolvent per bottle). Place the bottle on a shaking table and shakecontinuously throughout the whole experimental period. For the rest ofthe procedure follow the description for test A regarding sampling andanalysis.

Test A and test B (for example by freezing, microwave, heating andmelting, respectively) must be repeated with volumes of 10 ml and 30 mlof the selected solvents, respectively (cf Table 3). All extractionexperiments are conducted at room temperature and near-boilingtemperature. All experiments are conducted with, for example, n=5.

Injection

The injection test aims to evaluating both quantitatively (i.e. such asfor example time, yield, and unit operations required) and qualitatively(i.e. such as for example appearance) the abuse potential of active drugsubstance from pharmaceutical compositions.

The injection test program is shown in FIG. 20. The general strategybehind this test is to mimic the actual procedures applied by drugabusers when preparing a pharmaceutical composition for injection andinjecting it. The study design is therefore divided into three parts: A.Preparation, B. Filtration and C. Injection.

Part A, Preparation: The objective of this part is to record the timeand effort required to prepare a solution or dispersion that can be usedfor injection. As pointed out, drug abusers are only prepared to spendlimited time for preparing a pharmaceutical composition for abuse. Thetests performed as part of this test will thus record the time requiredto achieve a relevant solution or dispersion that may be utilized forabuse via injection. All tests can be performed in an aqueous media,which is a commonly applied solvent for injection. Three differentamounts of solvent (3 ml, 5 ml and 10 ml) are used in order to cover arelevant range. At the internet site Bluelight.com, 3 ml is oftenmentioned as the approximate volume when preparing a solution of forexample MS Contin® for injection. Even though it has been shown that 3ml solvent may result in problems with reproducibility, using thisvolume can nevertheless provide useful information. All experiments areconducted at room temperature and near boiling temperature in thedilution step. The effort required to prepare the solution/dispersion isassessed. A measure for this is to assess the number of operationsrequired to achieve the wanted solution/dispersion. Finally, theappearance of the resulting solution/dispersion is assessed in order toevaluate the likelihood that a drug abuser would inject the resultinginjectable mass. Part B, Filtration: The objective of this part is totest the types of filter that can be used in filtration of a preparedsolution/dispersion. For example, three commonly used filters aretested, and the filtration time, yield and appearance of the resultingsolution are recorded. Thereby, an assessment of the time and effortrequired to perform this operation, which is common practice among drugabusers, can be achieved. Part C, Injection: The objective of this partis to record the time, yield and effort required for injection of asolution/dispersion to take place.

In order to assess the abuse potential of the pharmaceuticalcompositions, a number of parameters can be recorded. The followingcriteria can be used to assess the potential for abusing, for example,tableted compositions by injection. A. Time: Drug abusers do not want tospend a significant amount of time trying to prepare a pharmaceuticalcomposition for abuse. Several sources point 0.5-1 hour as the maximumtime a drug abuser would want to expend preparing a pharmaceuticalcomposition for abuse. B. Yield: The yield of drug substance that can beobtained from a given pharmaceutical composition is an important factorin determining the desirability of a particular technique for abuse.Yield can be recorded in “% of dose” or mg. C. Appearance: In order todeter intravenous (IV) abuse, many abuse resistant pharmaceuticalcomposition as described herein may include gelling agents. Appearanceof the resulting solution or dispersion is considered important as itwill deter a number of drug abusers if the injectable mass is not aclear solution, but a viscous and/or unclear, opaque or cloudydispersion. D. Effort: It seems evident that drug abusers are willing tospend a fair amount of time and effort to prepare a pharmaceuticalcomposition for drug abuse. However, there seems to be a connectionbetween the effort the drug abuser is willing to spend and the “qualityof high”, i.e., the yield. Therefore, correlating all three parametersabove with each other is part of the assessment of abuse potential ofthe pharmaceutical composition with respect to injection. This will formthe overall evaluation on the effort the drug abuser needs to put intopreparing the pharmaceutical composition for abuse.

The injection test program is performed on intact compositions andcompositions subjected to tampering as shown in Table 4. As is true ineach for each of the tests described herein, the pharmaceuticalcomposition evaluated may be a tableted composition. Part A(preparation): Test X (intact tablets) to Y (tablets subjected totampering according to the particle size reduction part), see Table 4.Place intact tablets and tablets subject to tampering (e.g. n=3) insmall bottles and add 3 ml of water to each of the bottles. Place thebottles on a shaking table and shake continuously (speed 140-160/min)throughout the whole experimental period. When everything is dissolved,register the time consumption in Table 4. Transfer the solutions into 5ml plastic syringes with 19 G (1.1×40 mm) needles.

TABLE 4 Observation on part A preparation volume 3 ml and roomtemperature Time to Effort Time to tamper (operations Appearancedissolve Appearance Part A (min) required) T = start (min) T = dissolvedX1 X2 X3 Y1* Y2* Y3*

Part B: (filtration): Test X (intact tablets) to Y (tablets subjected totampering according to the particle size reduction part) see Table 5(e.g. n=3). Filter each of the solutions through a separate cigarettefilter. After filtration, transfer the filtered solutions into 10 mlplastic syringes with 19 G (1.1×40 mm) needles and note the remainingvolume. Report the observations in Table 5.

TABLE 5 Observation on part B filtration (e.g. Cigarette filter) Part BFiltration time (min) Appearance after filtration Volume (ml) X1 X2 X3Y1* Y2* Y3*

Part C: (injection): Test X (intact tablets) to Y (tablets subjected totampering according to the particle size reduction part) see Table 6(e.g. n=3). Exchange the 19 G needles with a common insulin syringes (27G×½″) needle. Place the syringes with the needle horizontal and presswith 3 kg on the piston, measure the time for the mass to pass throughthe needle. Withdraw 300 μl of each solution, transfer the samples tovials and dilute with phosphate buffer pH 6.8. Analyze the samples ascontent uniformity (CU) as previously described in sections describingmastication and buccal testing. Report the observations in Table 6.

TABLE 6 Observation on part C injection Part C Time (sec) Yield (%)Remarks X1 X2 X3 Y1* Y2* Y3*

Repeat the procedure with all filters (for example cigarette filter,cotton pad, tea filter) and volumes stated in Part A (preparation).Furthermore, repeat the procedure performing the dissolution nearboiling point.

Snorting

The snorting test aimed to at evaluate the abuse potential of activedrug substance from pharmaceutical compositions via snorting. Thesnorting test program is shown in FIG. 18 (Test D) on pharmaceuticalcompositions that have been subjected to tampering. In order to assessthe potential for abuse of pharmaceutical compositions by snorting, theprimary parameter in this test is to assess the physical disruption ofthe pharmaceutical compositions. The different fractions of tabletssubjected to tampering are collected from the particle size analyzer(Test D). The amount of active drug substance in each fraction isdetermined by content uniformity, as described previously in thesections describing mastication and buccal testing. Report the resultsin Table 7. Make a qualitative evaluation of the possibility to snortingthe different fractions from the particle size analyser.

TABLE 7 Observation from snorting test Qualitative Fraction Active drugsubstance evaluation Particle size weight Content (mg - % of of thepossible to fraction (mm) (mg) label claim) snorting (Yes/No) X > 5 5 >X > 2.5 2.5 > X > 1.12 1.12 > X > 0.5 0.5 > X > 0.3 0.3 > X > 0.1250.125 > X > 0.063 0.063 > XAbuse-Resistance of a Pharmaceutical Composition

A pharmaceutical composition may be evaluated by three parameters,dissolution rate, particle size distribution, and content uniformity.

If the pharmaceutical composition is classified as an immediated releasecomposition, the pharmaceutical composition is not abuse-resistant, i.e.fail the dissolution test. The term “immediated release composition”denotes a pharmaceutical composition where at least 75% of active drugsubstance is released from the pharmaceutical composition within 60minutes when subjected to a dissolution test as described herein.

The pharmaceutical composition fails to be abuse-resistant if thecontain of active drug substance is found to be more than 20 mg testedby Content Uniformity in the pharmaceutical composition having aparticle size at or less than 0.5 mm upon mechanical treatment by testequipment (physical tampering).

The pharmaceutical composition fails to be abuse-resistant if more than20 mg of active substance is dissolved in 5 ml solvent after 60 minutesas tested by Content Uniformity.

DEFINITIONS

In the present context, the term “resistant to abuse by alcohol” isintended to mean that the in vitro dissolution behaviour of apharmaceutical composition of the invention is the same or shows adecreased release rate when the pharmaceutical composition is tested ina dissolution medium containing alcohol compared to a medium withoutalcohol. The ratio (R₅₀) between t_(50% (v/v)) (40% (v/v) ethanol inmedium 1) and t_(50% (v/v)) (medium 1) is 1 or more. t_(50% (v/v))(medium 1) denotes the time it takes to release 50% (v/v) of the activedrug substance from the pharmaceutical composition in an in vitrodissolution test according to USP 32, NF 27, (711), Apparatus 2, paddleemploying buffer or solution at specified pH as dissolution medium(medium 1), and t_(50% (v/v)) (40% (v/v) ethanol in medium 1) denotesthe time it takes to release 50% (v/v) of the active drug substance fromthe pharmaceutical composition in an in vitro dissolution test accordingto USP 32, NF 27, (711), Apparatus 2, paddle employing 40% (v/v) ethanolin medium 1 as dissolution medium.

The same may also apply for ratios determined for example for the timewhen 25%, 30%, 40%, 60%, 70%, 80%, 90% and/or 95% w/w has been released,the conditions being as described above.

In specific embodiments of the pharmaceutical compositions describedherein, the ratio R₅₀ is at the most 5, such as at the most 4, at themost 3, or at the most 2. In particular such embodiments, the ratio R₅₀is selected from a range of 1 to 1.5, 1 to 1.4, 1 to 1.3, 1 to 1.2, 1 to1.1, and 1 to 1.05. In another such embodiment the ratio R₅₀ is or 1.

In the present context, the term “abuse” is intended to denote the useof a drug in order to induce euphoria or another excitement effect, i.e.the use is not intended to cure a disease or alleviate disease symptoms,but rather for obtaining intoxication.

Solubility definitions; Parts of solvent needed to dissolve 1 part ofsolute—Very soluble<1; Freely soluble 1-10, Soluble 10-30; Sparinglysoluble 30-100; Slightly soluble 100-1000; Very slightly soluble1000-10,000, Insoluble>10,000 at ambient temperatures.

EXPERIMENTAL

General Aspects of Analytical Methods

Evaluation of candidate, most optimal regarding abuse resistance, reliesupon two critical parameters: A shell-construction, which exhibitsincreased resistance towards physical tampering, in general, and ashell-composition exhibiting an increased hardness or, morespecifically, toughness and low ductility, which results in apharmaceutical composition that is difficult to crush/chew. This meansthat optimal combination between a shell-composition and ashell-construction provides a virtually non-chewable pharmaceuticalcomposition or a pharmaceutical composition that is extremely difficultto chew. As a perfect shell composition may reduce the importance of theconstruction (or vice versa) still making the pharmaceutical compositiondifficult to chew, it is decided not to set an objective of a hardnessbut do an objective/analytical and subjective comparison between thecandidates. All of the candidates (shell-constructions as well as shellcomposition) may be suitable but it is only the candidates rating thebest that go through an extensive evaluation. Different types ofanalytical/objective methods are used, since they provide limitedinformation regarding chewability when assessed individually. Whenevaluated/compared to each other they give a good measure of howdifficult it is to chew a pharmaceutical composition for example tabletaccording to the invention.

Micro Hardness

The microhardness of polymeric material is related to mechanicalproperties such as modulus, strength, elasticity and plasticity. There atendency for high modulus and strength values to correlate with higherdegrees of microhardness. Furthermore, mechanical performance factorssuch as creep resistance, fatigue life, toughness and the stability ofproperties with time, stress and temperature have become subjects wheremicrohardness emerges as a property which is sensitive to structuralchanges.

Chewing on very hard material will introduce pain in the teeth or jaw.As the hardness of the surface of a material increases, the materialbecomes more resistant to chewing I composition. Additionally, in thecontext of the pharmaceutical compositions described herein, it ispresently thought that if the shell composition is so hard thatdeformation of the composition by chewing is impossible, then the matrixcomposition should not separate from the shell as a result of chewingalone. Measurements of the microhardness of different shell and matrixcompositions could provide information on the resistance to chewing.

A Vickers hardness tester, which measure the surface material resistanceto indentation was used. The Vickers hardness test method consists ofindenting the test material with a diamond indenter, in the form of aright pyramid with a square base. The two diagonals of the indentationleft in the surface of the material after removal of the load aremeasured using a microscope and their average calculated. The area ofthe sloping surface of the indentation is calculated.

One tablet was placed at the test plat and the diameter indenter isplaced just at the surface. The full load was set to 5 N and the timefor indenting was set to 30 s.

The Vickers hardness in this case is given by dividing the load in Pa bythe square mm area of indentation.

Measuring of the microhardness makes it possible to rate different shellcompositions in relation to chewability. As described herein, the methodis an objective measurement of hardness.

Tablet Breaking Force

The tablet breaking force is described in USP general chapters <1217>and in Ph. Eur 2.9.8 as resistance to crushing of tablets. The test isintended to determine, under well-defined conditions, the resistance tocrushing of tablets measured by the force needed to disrupt them bycrushing. The results are normally forces expressed in newtons.

The normal breaking force apparatus described in USP chapter <1217> hasflat surfaced platens moving toward each other. The flat surface of theplatens does not simulate a bite on a tablet. To gain information aboutchewability it is important to simulate the bite in the mouth. Thereforean apparatus with two molar teeth was constructed. The apparatus is anolder model of a normal tablet breaking force apparatus. Two molar teethwere obtained from the School of Dentistry, University of Copenhagen,Denmark. The molar teeth were glued on the flat surfaced platens.

The pressure applied was initially given at kg/molar. An estimate wasmade of the surface of the molar that touches the tablet. A molar toothis usually around 1 cm². The tablet only received a downward pressurefrom one third of the teeth as only one third of the tooth was incontact with the tablet. Therefore the surface is estimated to 0.3 cm².One tablet was placed between the teeth and weights of respectively 4.7and 10 kg were placed on the apparatus. It was noted at which weight thetablet disintegrates or the tablet was visual inspected for marks.

The apparatus was only capable of deliver a pressure of 10 kg pr molarfor example 10 kg pr 0.3 cm² teeth. The tests performed with thisapparatus made it possible to illustrate a poor resistance to chewing ofconventional tablets, cf. the examples below. However, this method isnot capable of providing a pressure that will damage a tablet formulatedaccording to the description provided herein. Tablet breaking strength

In general, testing of pharmaceutical compositions with a TextureAnalyser can be used to quantify quality parameters such as compression,puncture/penetration, tension, fracture/bending, extrusion,cutting/shearing. The measurements are used to give information oftablet strength, swelling and disintegration of tablets, tablet coatingadhesion and breaking strength of hard capsules etc.

In particular with respect to evaluation of the chewability of apharmaceutical composition, the quality parameters compression andpuncture/penetration are of relevance. These measurements are performedusing a texture analyser (TA.XTplus, Stable Micro Systems Ltd., Surrey,UK). Both techniques, compression and penetration, are used to evaluatethe power of resistance, for example, the breaking strength, ofdifferent shell and matrix compositions according to the invention andOxyContin®. The values obtained by compression and penetration cannot becompared directly as the result depends on given test conditions.

Different special attachments to the texture analyzer are availabledependent on the specific technique employed. One technique is theuniaxial compression test, where the samples are deformed using a simplecylindrical probe or a flat plate as described under the breaking force.Another technique is a penetration or puncture test, where a probe ismade to penetrate into the test sample and the force necessary toachieve a certain penetration depth or the depth of penetration in aspecified time, under defined conditions, is measured and used as anindex of hardness.

In the examples, the following techniques were applied using the TextureAnalyser: compression technique and penetration technique.

Parameters for Compression Technique

One tablet at a time was placed at the test surface, and a plate with adiameter of 45 mm was pressed into the tablet with a test speed of 0.5mm/s. The load needed to compress the tablet 3 mm was measured.

Parameters for Penetration Technique

One tablet at a time was placed at the test surface, and a needle with adiameter of 2 mm was pressed into tablets with a test speed of 0.5 mm/s.The load needed to penetrate the needle 4 mm down was measured.

The texture tests made it possible to illustrate that the tabletsaccording to the invention have a very high index of hardness comparedto that of a conventional tablet. Given that an increased hardnessindicates a better resistance against chewability, these methods can bea part of several methods used to evaluate the chewability.

Chewing Apparatus

The chewing apparatus is as described in the section directed tomastication and buccal testing. One tablet from each of examples 1-4 wasplaced in the chewing chamber without any kind of solution (drychewing). At each test initial position (matrix side horizontal orvertical) was noted. When each piston touched the tablet it was twistedsimulating a chew with a frequency of approx. 55 chews per minute. Thetemperature of the chewing chamber was set to 37° C. to simulate thetemperature of a human mouth. The chew counter was set to 15 chews and,afterwards, the tablets were visually inspected and the condition ofeach tablet was noted. Hereafter, the chew counter was set to 60 chews,followed by visual inspection and the condition of each tablet wasnoted. This procedure was followed until the shell was damaged to anextent where the shell and matrix could be separated.

This analytical method can to a certain extent simulate the masticationprocess in the mouth, but the influence of saliva on the mastication ofthe pharmaceutical composition is not investigated by this method. Themethod can be used to evaluate different pharmaceutical compositionsaccording to the invention in relation to chewability. Together withinformation of the material hardness (measured by the microhardness ofthe material), and hardness of the pharmaceutical composition (measuredby the tablet breaking force and tablet breaking strength), the resultscan be helpful to select the best materials to fulfill the aim ofdeveloping a pharmaceutical composition that is extremely difficult tochew/break.

Methods

Moulding of Shells in Laboratory

An accurate amount of polymer and, if present, plasticizer are weightedand blended with simple volumetric mixing. Liquid plasticizers are addeddrop for drop. The mixture is hereafter placed in the heater cylinder ofan injection moulding machine (Haake MiniJet II, Thermo Electron,Karlsruhe, Germany). Temperature in the cylinder was usually set within120-190° C. Moulding pressure was 500-900 bar (50-90 MPa) and time wasset to 15-30 seconds. Approximately 8 minutes were used for the shellcompositions to melt, then the shell was moulded and removed from themould shortly after.

Filling with Placebo Matrix

The below mentioned matrix composition was filled into the heatercylinder of an injection moulding machine (Haake MiniJet II, ThermoElectron, Karlsruhe, Germany) and the temperature in cylinder is set to90-120° C., 500-800 bar (80 MPa) in 15-30 seconds. The shell was theninserted and filled with matrix.

Matrix composition (placebo) PEO 300,000 74.3% (w/w) PoloXamer 188 19.2%(w/w) Mannitol  6.4% (w/w) BHT  0.1% (w/w)Preparation of the (Shell) Composition and Preparation of PharmaceuticalCompositions in Large Scale

The shell material/composition was prepared by adding the polymer andplasticizer to a MTI-Mixer at a temperature about 19-21° C. After mixingat around 1000 rpm, the mixer was stopped when the temperature reached40-50° C. and material adhered to the MTI-Mixer, if any, was manuallyincorporated into the mixture. The mixture was left to cool for about 10minutes. The mixing was then finalized with a short high-speed mix inorder to minimize lump formation. The matrix material/composition wasprepared as described above.

The shell and matrix were moulded in one process, where the shell wasmoulded in a first step and the matrix was moulded directly into theshell in a second step (co-moulding or 2 component moulding). Theinjection moulding machine used is Arburg Allrounder 420 V 800-60/35.

Dissolution Test

Dissolution tests were performed in accordance with USP 32, NF 27,(711), Apparatus 2 (paddle method). The dissolution medium consisted ofphosphate buffer solution pH 6.8 and ethanol in concentrations from0-40% v/v or HCl solution pH 1.2 and ethanol in concentrations from0-40% v/v. The volume of the dissolution medium was 900 ml and therotation speed of the paddles was 50 rpm throughout the dissolution run.The temperature was 37° C. Samples were withdrawn at suitable timeintervals and analysed for content of active drug substance (morphine)by HPLC UV-detector at 281 nm and by UV-online at 285 nm.

Analytical and Rating System for Chewability

The rating system was divided into two parts; one that provided anobjective/analytical description of chewability and another thatprovided a subjective description.

The analytical part entailed: measurements of micro hardness, tabletbreaking force, texture analysis and chewing test.

Subjective Analysis (i.e. Tested in Man)

The subjective part entailed: hardness of shell, discomfort whenchewing, extent of deformation, adherence between shell and matrix; allthe previous mentioned parameters reveal how difficult it is to separateshell from matrix (how much time does it take to separate shell frommatrix)—hence chewability. In those situations where the matrix isseparated from the shell, it is important to ensure that the matrix isunpleasant to chew. If this is the case, it is inconvenient and,accordingly, the person would have less motivation to chew the matrix.Moreover, if the matrix is very hard, it becomes more difficult todeform the tablet and accordingly, and it becomes more difficult to chewthe tablet.

Shell Constructions and their Properties

In order to make the shell more abuse resistant some efforts concerningthe construction of the shell was made. The main purpose was to gain ahard shell without changing the dissolution rate of the pharmaceuticalcomposition. Constructions that were thought to contribute to physicaladhesion within shell and matrix was tried. Different shellconstructions are described and discussed below:

Shell construction (Corresponding to shell of FIGS. 1A, 1B and 1C—shell2), however with a wall thickness of approx. 0.6 mm. Matrix volume 300mm³. Concerning the controlled release feature in the system of thetecnology, this construction has no influence on the usualdissolution-profile (it provides the usual zero-order release). Comparedwith the other constructions (see below), this construction showed nextto no resistance to chewing. The shell broke easily and matrix fell out.This construction would score lower in the rating system compared toother candidates, although it is relatively resistant towardschewability.

Shell construction (see FIGS. 1A, 1B and 1C—shell 2)). Wall thickness1.4-1.8 mm. Matrix volume 300 mm³. This construction is the most simpleway of achieving an increased hardness and discomfort when attempted tochew—thus less appealing to chew seen from the point of view of apotential abuser (discomfort is a subjective measure and can only berated by testing in man). The matrix construction is similar to matrixconstruction in shell construction (FIGS. 1A, 1B and 1C—shell 2, with athickness of approximately 0.6 mm), hence it resulted in the samedissolution rate. The hardness and discomfort are increased for thepharmaceutical compositin using shell construction (FIGS. 1A, 1B and1C—shell 2, with a thickness of 1.4-1.8 mm). The construction does notgive increased adhesion between shell and matrix. Any deformation of theshell caused the matrix to fall out; therefore the choice of shellmaterial was critical for this construction. This construction wouldscore lower in the rating system compared to other candidates, althoughit is relatively resistant towards chewability, however if the optimalshell composition was used for the shell construction, preventing thedeformability of the construction, then this construction would be OK.The choice to pursue a construction relies on two parameters: shellconstruction and shell composition. One parameter could have such aneffect that it compensates the weaknesses of the other parameter.

Shell construction (see FIGS. 3A, 3B and 3C—shell 202). Outer shell wallthickness approx. 1.0 mm, reinforcement wall thickness approx. 0.5 mm.Matrix volume approx. 244 mm³. The crossed reinforcement walls insidethis pharmaceutical composition increased the resistance regardingchewability without increasing the size. These evaluations weresubjective evaluations based on chewing. The construction showed goodhardness and highly increased discomfort (better than the construction(FIGS. 1A, 1B and 1C—shell 2, with a thickness of 1.4-1.8 mm)). Due tothe crossed reinforcement walls the physical adhesion between matrix andshell are slightly increased. The drawback for this construction is thechange of dissolution rate in vitro as well as in vivo.

Shell construction (see FIGS. 4A, 4B and 4C—shell 302). As construction(FIGS. 3A, 3B and 3C—shell 202), but only one reinforcement wall. Outershell wall thickness approx 1.0 mm, reinforcement wall thickness 0.5 mm.Matrix volume approx. 281 mm³. Same pros and cons as construction (FIGS.3A, 3B and 3C—shell 202).

Shell construction (see FIGS. 5A, 5B and 5C—shell 402). Outer shell wallthickness approx. 1.25 mm, reinforcement wall thickness about 1.0 mm.Matrix volume approx. 305 mm³. In order to be able to fill matrix fromone end, an opening in the reinforcement wall was needed. Theconstruction showed good hardness and increased discomfort (same asconstruction (FIGS. 1A, 1B and 1C—shell 2, with a thickness of 1.4-1.8mm)). The physical adhesion between shell and matrix was highlyincreased due to the opening in the reinforcement wall (better thanconstruction (FIGS. 3A, 3B and 3C—shell 202) and construction (FIGS. 4A,4B and 4C—shell 302)). A pharmaceutical composition with a highhardness, for example shell composition (V), showed very good propertiesregarding discomfort.

Shell construction (See FIGS. 6A, 6B and 6C—shell 502). As construction(FIGS. 5A, 5B and 5C—shell 402) with two reinforcement walls. Matrixvolume approx. 311 mm³. This construction had the same adhesive, anddiscomforting properties as construction (FIG. 5A, 5B and 5C—shell 402),the passage between the reinforcement elements was changed to avoidseparation of matrix composition in half.

Shell construction (see FIGS. 7A, 7B and 7C—shell 602). Elliptical shape12×16×8.5 mm. Wall inside as construction (FIGS. 5A, 5B and 5C—shell402). The outer wall had a minimum thickness of approx. 2.4 mm. Matrixvolume approx. 305 mm³. This construction was an attempt to increase theshell thickness as much as possible, and keeping the pharmaceuticalcomposition swallowable. Because of the good physical adhesion achievedin construction (FIGS. 5A, 5B and 5C—shell 402) and construction (FIGS.6A, 6B and 6C—shell 502) a similar reinforcement wall is provided. Theconstruction shows highly increased hardness and discomfort. Thereinforcement wall has been removed from the construction and evenwithout the reinforcement wall (see FIG. 2) this construction showedhighly increased discomfort.

Shell construction (see FIGS. 10A, 10B, 10C and 10D—shell 802). Tenmatrixes placed in ten cavities of the shell. The volume of each matrixcomposition is approximately 217 mm³/10×21.7 mm³. This constructionforms a number of reinforcement walls between the cavities/lumens, whichradically increases the strength of the pharmaceutical composition. Theouter shell wall has a thickness between 0.2 and 1.4 mm. Because of thegood physical adhesion achieved in construction (FIGS. 5A, 5B and5C—shell 402) and construction (FIGS. 6A, 6B and 6C—shell 502) a similarreinforcement wall was provided in each lumen. To facilitate productionof this shell in large scale machinery, a channel 0.35 mm deep and 0.7mm wide was placed at the first end between the cavities. This channelensured a consistent filling of matrix composition into all cavities.

Shell construction (see FIGS. 9A, 9B, 9C and 9D—shell 702). Oval shapedpharmaceutical composition. Elliptic cylinder shaped matrix. Matrixvolume approximately 217 mm³, leading to active drug substance of 100mg. The outer wall had a thickness between 0.7 and 1.9 mm. Theconstruction was based on the construction (FIGS. 1A, 1B and 1C—shell 2,with a thickness of 1.4-1.8 mm). To facilitate oral administration(swallowing), the shape was more rounded. To facilitate production ofthis construction in large scale machinery, the shell was not equippedwith the reinforcement wall, described in construction (FIGS. 5A, 5B and5C—shell 402) and construction (FIGS. 6A, 6B and 6C—shell 502).Therefore it was crucial to the tamper resistance that a certainadherence between shell and matrix was achieved.

Example 1 Different Shell Constructions were Tested with ShellComposition I

Shell composition I Ethyl Cellulose “20” 88.0% (w/w) Cetostearyl alcohol12.0% (w/w)

Ethyl Cellulose is a starch derived polymer and is widely used in oralpharmaceutical compositons.

The shell composition was moulded in laboratory scale as well as inlarge scale production described above. Shells made from the shellcompositions above and having construction shell 2 (wall thickness1.4-1.8 mm), shell 402 and shell 602 were tested in man. The followingresults were obtained:

Shell construction Shell 2, wall thickness Composition I 1.4-1.8 mmShell 402 Shell 602 Duration 7 sec 15 sec 30 sec

The constructions shell 2 (wall thickness 1.4-1.8 mm) and shell 602 werealso tested in the chewing apparatus. The shell with shell construction2 (wall thickness 1.4-1.8 mm) had signs after 15 chews and after 75chews, the shell crushed. The shell construction 602 exhibited goodduration, which can be ascribed to the shell construction itself and thehardness that can be obtained from ethyl cellulose if the thickness ofshell is sufficient.

In the following examples 2-5, a number of pharmaceutical compositionscomprising different shell composition and constructions with theplacebo matrix composition, as described above, are tested.

Example 2 Shell Compositions with Different Grades of Ethyl Celluloseand Castor Oil as Plasticizer to Achieve Hard Shell with BetterAdherence to Matrix than Shell Composition I

Shell composition II Ethyl Cellulose “20” 88.0% (w/w) Castor Oil 12.0%(w/w)

Ethyl Cellulose provided a hard shell, but had the tendency to shrink,which complicated the removal of the shell from the mould and filling ofthe matrix in the laboratory procedure. This will not become a problemin larger scale production, where matrix and shell are preparedsimultaneously and cooled together. Castor oil did not weaken thepolymer and made the material soft enough to be able to mould shellconstructions 2 (wall thickness 1.4-1.8 mm) and 402 in the laboratory.

Shell construction Shell composition II Shell 2, wall thickness 1.4-1.8mm Shell 402 Duration 30 sec 30 sec Micro hardness 11 kPa/mm² 11 kPa/mm²

The chewability test showed that shell composition II could be describedas good in accordance with the criteria described above in shellconstruction 2 (wall thickness 1.4-1.8 mm) and 402 due to adherence tomatrix and a good hardness of the shell.

The micro hardness was measured as described above and this shellcomposition had a hardness of 11 kPa/mm², which is quite a lot comparedto the other shell compositions that will be described. Accordingly, theshell composition tested has improved properties compared with shellcomposition I. Thus, choice of plasticizer seems to have impact on thechewability of the shell.

Shell composition III Ethyl Cellulose “100” 88% (w/w) Castor Oil 12%(w/w)

A similar shell composition was prepared with Ethyl Cellulose “100”,which has longer polymer chains that could lead to a harder shell.

Shell construction Shell 2 (wall Shell composition III thickness 1.4-1.8mm) Shell 402 Duration 30 sec 15 sec

This construction had teeth marks after 15 chew in the chewing apparatusand it crushed after 90 chew.

Accordingly, substituting ethyl cellulose “20” with ethyl cellulose“100” seems to improve the hardness of the shell and the resistanceagainst chewing.

In the chewing apparatus shell composition III showed higher resistancethan shell composition I.

This example shows that shell compositions with Ethyl Cellulose 100 forma hard shell.

Example 3 Shell Compositions with Polycaprolactone (IV)

Shell Composition IV

The shells were made of 100% polycaprolactone.

The Polycaprolactone used here has a molecular weight of 80,000, whichhas a higher tensile strength (measured by texture-analysis), whichmakes it more resistant towards chewing. It has a melting point around60° C. No plasticizer was employed.

The shell composition is easy to mould and possess the necessaryducility (i.e. the extent to which materials can be deformed plasticallywithout fracture, such that it will deform and not fracture upon chewingattempts). This polymer demonstrated good adherence to matrix as well,as removal of shell during the subjective tests was difficult comparedto other shell compositions. Moreover, the low melting point was foundto be an advantage in large scale production.

Shell construction Shell Shell 2 (wall composition IV thickness 1.4-1.8mm) Shell 402 Shell 602 Duration 20 sec 20 sec 30 sec Micro hardness  2kPa/mm²  2 kPa/mm²  2 kPa/mm²

The penetration technique was carried out as described above on shellconstruction 2 (wall thickness 1.4-1.8 mm) with matrix composition, butthe needle bent before a given pressure could be established. Thisindicated that the shell polymer forms a shell with high density leadingto a hard surface. Moreover, this polymer had a good adherence to thematrix composition.

The low melting point and, low ductility, adherence to matrixcomposition and density was an advantage with this polymer. It alsoperformed well in chewability test. This polymer may be promising due toits low ductility, which alone gives a hard shell and that lacks offlexibility and adherence.

Example 4 Shell composition V with Cornpack 200

Shell Composition V

The shells were made of 100% Cornpack 200.

Cornpack 200 is a starch derived polymer, and can consist of a highnumber of glucose molecules and can have a number of side chains. It hasa high melting point, and when moulded it gives a very hard shell.Saliva in the oral cavity contains amylase, an enzyme, which degradesstarch to di and tri saccharides and into the final degradation step tomaltose and glucose molecules. Corn starch will not degradeconsiderably, despite the presence of amylase due to the side chains ofthe polymer when moulded to a hard shell. No plasticizer was employed.

Shell construction Shell 2 (wall Shell composition V thickness 1.4-1.8mm) Shell 402 Shell 602 Duration >2 min >2 min >2 min Micro hardness 11kPa/mm² 11 kPa/mm² 11 kPa/mm²

The micro hardness of 11 kPa/mm² also indicated a pharmaceuticalcomposition with a hard shell.

This polymer showed much promise because it was almost impossible tochew, and measurements indicated a good hardness.

Example 5 Breaking Force and Texture Analyses—A Comparison of a TabletMade from Shell Construction 2 (Wall Thickness 1.4-1.8 Mm) and ShellComposition IV Versus OxyContin® Tablet

A pharmaceutical composition made from shell composition IV andcontained in shell construction 2 (wall thickness 1.4-1.8 mm), was usedto compare OxyContin® tablet.

The compression technique was used and following results was established

Applied Load Remarks Tablet with shell Overload at 50 kg (It was not Nosign of construction 2 (wall possible to destroy the tablet) compressionthickness 1.4-1.8 mm) & shell composition IV OxyContin ® tablet NA(disintegrated) Disintegration

In the test with compression, the shell also showed a high resistance tothe applied pressure, while the conventional, compressed tablet wasdisintegrated. Further, the shell composition IV showed no sign ofcompression, possibly due to its low ductility.

Example 6 Resistant to Abuse by Alcohol in a Pharmaceutical CompositionContaining Morphine Sulphate with Different Shell Compositions andConstructions

A matrix composition (batch no. 066-0169-08-009B) was prepared from thefollowing ingredients:

Matrix % (w/w) Morphine sulphate pentahydrate 51.5 PEO 300.000 32 BHT0.1 Mannitol 3PoloXamer 188 13.4

Two different shell compositions were prepared from the followingingredients

Shell composition V % (w/w) Cornpack 200 100

Shell composition III Ethyl Cellulose (grade 100) 88 Castor Oil 12

In addition, two different shell constructions 2 (wall thickness 1.4-1.8mm) and 602 were prepared using the two different shell compositions, asshown in the table.

Batch No. Shell composition Shell construction 08-0226-058 III 2 (wallthickness 1.4-1.8 mm) 08-0228-085 III 602 08-0230-058 V 2 (wallthickness 1.4-1.8 mm) 08-0232-058 V 602

The four batches were tested using the dissolution tests described insection Methods. Batch No. 08-0226-058 and 08-0228-058 were tested inphosphate buffer pH 6.8 and phosphate buffer pH 6.8 containing ethanolin ratio 60:40 (% v/v). Batch No. 08-0230-058 and 08-0232-058 weretested in phosphate buffer pH 6.8, phosphate buffer pH 6.8 containingethanol in ratio 60:40 (% v/v) as well as in HCl solution pH 1.2 and HClsolution pH 1.2 containing ethanol in ratio 60:40 (% v/v).

All dissolution profiles showed that the release corresponds to a zeroorder release. In the table below is shown values for the time to where50% of the drug is released. For both shell compositions and shellconstructions are shown that the R₍₅₀₎ are higher than 1.2, whichclarify that the dissolution profiles are much slower in alcoholcontaining media compared to the same media without alcohol. Theseresults show that it is only the composition of matrix, which affect therelease behaviour in the alcohol versus non-alcohol media.

t_(50% (v/v)) Batch no. Media (min) R₍₅₀₎ 08-0226-058 buffer pH 6.8 4241.4 buffer pH 6.8:EtOH 60:40 (w/w %) 610 08-0230-058 buffer pH 6.8 4651.2 buffer pH 6.8:EtOH 60:40 (w/w %) 548 08-0228-058 buffer pH 6.8 4931.6 buffer pH 6.8:EtOH 60:40 (w/w %) 770 HCl solution pH 1.2 477 2.3 HClsolution pH 1.2:EtOH 60:40 (w/w %) 1102 08-0232-058 buffer pH 6.8 4341.6 buffer pH 6.8:EtOH 60:40 (w/w %) 678 HCl solution pH 1.2 418 1.7 HClsolution pH 1.2:EtOH 60:40 (w/w %) 709

CONCLUSION

In conclusion, neither the shell compositions nor the shellconstructions affected the dissolution results in relation to abuseresistance related to alcohol.

Example 7 Resistant to Abuse by Alcohol in a Composition ContainingMorphine Sulphate with Different Shell Constructions

A pharmaceutical composition (batch no. 066-203-09-005B) was preparedfrom the following ingredients:

Matrix % (w/w) Morphine sulphate pentahydrate 36.0 PEO 200.000 22.7 PEO300.000 16.0 HPMC 100.000 5.0 Carrageenan 379 5.0 BHT 0.1 Mannitol 3.0PoloXamer 188 12.2

The shell composition (batch no. 058-063-000B) was prepared from thefollowing ingredients:

Shell composition V % (w/w) PLA 86.0 PEO 200.000 14.0

Two shell constructions 702 and 802, respectively, were tested using thedissolution tests described above. Batch No. 1044-059 and 1044-056 weretested in phosphate buffer pH 6.8, phosphate buffer pH 6.8 containingethanol in ratio 60:40 (% v/v) and Batch No. 1044-056 was additionallytested in HCl solution pH 1.2 and HCl solution pH 1.2 containing ethanolin ratio 60:40 (% v/v). Typical release behaviour (drug release (%)versus time (minutes)) is shown in FIG. 21, when applying shellconstruction in FIG. 9.

All dissolution profiles showed that the release corresponds to a zeroorder release. In the table below is shown values for the time to where50% of the active drug substance is released. Both shell constructionsshown that the R₍₅₀₎ are higher than 1.2, which clarify that thedissolution profiles are much slower in alcohol containing mediacompared to the same media without alcohol. These results show that itis only the composition of matrix, which affect the release behaviour inthe alcohol versus non-alcohol media and the shell constructions do notaffected the dissolution results.

t_(50% (v/v)) Batch no. Media (min) R₍₅₀₎ 1044-059 (Shell buffer pH 6.8605 1.3 construction 802) buffer pH 6.8:EtOH 60:40 (% v/v) 780 1044-056(Shell buffer pH 6.8 255 1.2 construction 702) buffer pH 6.8:EtOH 60:40(% v/v) 300 HCl solution pH 1.2 240 1.4 HCl solution pH 1.2:EtOH 60:40345 (% v/v)

Example 8 Tampered Tablets Subjected to Freezing, Microwaving, Burningand Melting Followed by Particle Size Reduction

A matrix composition (batch no. 10-0001-066) was prepared from thefollowing ingredients:

Matrix % (w/w) Morphine sulphate pentahydrate 36.0 PEO 300.000 16.0 PEO200.000 22.7 Butylhydroxytoluene (BHT) 0.1 Carrageenan 379 5.0 Mannitol3.0 PoloXamer 188 12.2 HPMC 100.000 5.0

Shell composition % (w/w) Polylactic acid 86 PEO 200.000 14

The shell construction of shell 702 is applied.

Dissolution profiles conducted on tampered tablets were compared todissolution profiles of intact tablets (c.f. protocol on tamperingmethods).

Tablets Exposed to Freezing

The procedure is described in the protocol as freezing, procedure Athrough C (A: Intact tablets, B: Intact tablets placed in a freezer at−12° C. for 24 hours, C: Intact tablets placed in a freezer at −12° C.for 24 hours and then subjected to a hammer test). Subsequently alltablets were tested by dissolution described above in buffer pH 6.8. Thedissolution profiles (drug release (%) versus time (minutes)) are shownin FIG. 22. As seen in the figure, freezing for 24 hours affect thecontrolled release mechanism, given that the dissolution profile isslower after freezing. The controlled release mechanism on the frozentablet knocked with a hammer was affected, given that the dissolutionprofile is faster than the baseline profile. Conclusively, even thoughthe release rate increases when the tablet has been subjected tofreezing and then a hammer, it is not a significant change (such as aninstant release behaviour).

Tablets Exposed to Microwaving

The procedure is described in the protocol as microwaving, procedure Aand B (A: Intact tablets, B: Intact tablets placed microwaved 3 times, 1min. each time, at 800 W). Subsequently all tablets were tested bydissolution described above in buffer pH 6.8. The dissolution profilesare shown in FIG. 23 showing dissolution profile (drug release (%)versus time (minutes)) for baseline (not tampered tablets n=3) andtablets warmed in a microwave for 3 time 1 min (n=3). As seen in thefigure, warming tablets for three times 1 min in a microwave oven doesnot affect the controlled release mechanism, given that the dissolutionprofile for the tampered tablets is similar to the intact not tamperedtablets (named baseline).

Tablets Exposed to Heating by a Gas Burner

The procedure is described in the protocol as heating by a gas burner,procedure A and B (A: Intact tablets, B: Intact tablets melted with agas burner for 5 min.). Subsequently all tablets were tested bydissolution described above in buffer pH 6.8. The dissolution profilesare shown in FIG. 24 showing dissolution profile (drug release (%)versus time (minutes)) for baseline (not tampered tablets n=3) andtablets warmed/melted by a gas burner (n=3). As seen in the figure,warming/melting the tablets with a gas burner will only affect thecontrolled release mechanism by making the release rate slightly lowercompared to the intact not tampered tablets (named baseline).

Tablets Exposed to Melting

The procedure is described in the protocol as melting, procedure A and B(A: Intact tablets, B: Intact tablets melted on a heating plate for 20min. at 180° C.). Subsequently all tablets were tested by dissolutiondescribed above in buffer pH 6.8.

The dissolution profiles are shown in FIG. 25 showing dissolutionprofile (drug release (%) versus time (minutes)) for baseline (nottampered tablets n=3) and tablets warmed/melted on a heating plate(n=3). As seen in the figure, warming/melting the tablets on a heatingplate do not affect the controlled release mechanism, given that thedissolution profile for the tampered tablets is similar to the intactnot tampered tablets (named baseline).

Tablets Exposed to Particle Size Reduction

The procedure is described in the protocol as particle size reduction,procedure A through D (A: Intact tablets, B: Intact tablets subjected tophysical tampering by use of mechanical or electrical tools, C: Intacttablets placed in a freezer, subjected to microwaving, burning ormelting and then subjected to physical tampering by use of mechanical orelectrical tools, D: Intact tablets subjected to physical tampering byuse of mechanical or electrical tools, followed by particle sizeanalysis). The applied mechanical and electrical tools are listed belowwith results from the particle size reduction tests. All tests werecarried out in triplicate.

Test Tool name no. and type Results 1 Mortar and Not possible to disruptthe tablets with the pestle pestle* 2 Hammer Possible to disrupt thetablets to some extent. The shell stick to the matrix. 3 Grater* Notpossible to disrupt the tablets with the grater 4 Food Chopper, Notpossible to disrupt the tablets before Mini Quick equipment failure. Theshell got some marks, but 6720 OBH the matrix was not affected 5 CoffeeGrinder, Not possible to disrupt the tablets before Krups GVX242equipment failure. The shell got some marks, but the matrix was notaffected *no further tests were performed with these tampering methodsas the tablet was considered as a no tampered intact tablet.

Subsequently all tablets were tested by dissolution described above inbuffer pH 6.8. The dissolution profiles from test 2, test 4 and test 5are shown in FIG. 26 showing dissolution profiles (drug release (%)versus time (minutes)) for baseline (not tampered tablets n=3), hammertest (n=3), milled tablet with Krups coffee mill (n=3) and chopped withOBH chopper (n=3). As seen in the figure, the hammer test affect thecontrolled release mechanism, by making the release profiles slightlyfaster than the no tampered tablets (named baseline). Milling the tabletin the coffee grinder or chopping the tablet in the chopper does notaffect the controlled release mechanism as the dissolution profile forthe tampered tablets is almost similar to the intact not tamperedtablets (named baseline).

As it was more or less not possible to reduce the particle size ofintact tablets subjected to physical tampering it was decided not tomade the extraction, injection and snorting test described in theprotocol on tampering methods.

Example 9 Intact Tablets Subjected to Mastication and Physical Tamperingby Use of Electrical Tool

For the mastication test, the chewing apparatus as described in protocolon tampering methods has been applied on intact tablets and intacttablets has been subjected to physical tampering by use of electronicaltool. The abuse deterrence of the tablets is evaluated as a combinationof the applied shell construction and shell composition. The measuredchew was defined as “dry chewing” as no saliva was present. The chewingmachine was calibrated so 44 chews would correspond to 1 minute ofchewing. Two identical tablets, from each construction, were tested(duplicates).

The pharmaceutical composition below was applied

Matrix % (w/w) Morphine sulphate pentahydrate 36.0 PEO 300.000 16.0 PEO200.000 22.7 Butylhydroxytoluene (BHT) 0.1 Carrageenan 379 5.0 Mannitol3.0 PoloXamer 188 12.2 HPMC 100.000 5.0

Shell composition V % (w/w) Polylactic acid 86 PEO 200,000 14

The shell construction of shell 2 having an outer wall thickness of 0.6mm is applied). The results are shown below.

Batch. Tablet No. of chew: No. of chew: no. no. No. of chew: 44 (1 min.)132 (3 min.) 220 (5 min) 1563-062 1 Some marks from the piston of theThe shell broke The tablet machine were left on the tablet at the end ofbecame flat and the shell was still intact. the tablet 2(*) (*)As thistablet was considered a reference before optimizations only one tabletwas tested.

The shell construction of shell 2 having an outer wall thickness of1.4-1.8 mm is applied. The results are shown below.

Batch. Tablet no. no. No. of chew: 44 (1 min.) No. of chew: 132 (3 min.)No. of chew: 220 (5 min) 1044- 1 No signs of marks A few marks from theA few marks from the 057 from the piston of piston of the machine pistonof the machine the machine were were left on the tablet were left on thetablet left on the tablet and the shell was still and the shell wasstill intact. intact. 2 No signs of marks A few marks from the Somemarks from the from the piston of piston of the machine piston of themachine the machine were were left on the tablet were left on the tabletleft on the tablet and the shell was still and the shell was stillintact. intact.

The shell construction of shell 402 is applied. The results are shownbelow.

Batch. Tablet no. no. No. of chew: 44 (1 min.) No. of chew: 132 (3 min.)No. of chew: 220 (5 min) 1563- 1 No signs of marks Some marks from theSome marks from the 062 from the piston of the piston of the machinepiston of the machine machine were left on were left on the tablet wereleft on the tablet the tablet and the shell was still and the shell wasstill intact. intact. 2 Subsequent to 17 NA NA chew, the chewing machinefailed to proceeding chews

The shell construction of shell 502 is applied. The results are shownbelow.

Batch. Tablet no. no. No. of chew: 44 (1 min.) No. of chew: 132 (3 min.)No. of chew: 220 (5 min) 1563- 1 No signs of marks Some marks from theSome marks from the 062 from the piston of piston of the machine pistonof the machine the machine were were left on the tablet were left on thetablet left on the tablet and the shell was still and the shell wasstill intact. intact. 2 No signs of marks Some marks from the Some marksfrom the from the piston of piston of the machine piston of the machinethe machine were were left on the tablet were left on the tablet left onthe tablet and the shell was still and the shell was still intact.intact.

The shell construction of shell 702 is applied. The results are shownbelow.

Batch. Tablet no. no. No. of chew: 44 (1 min.) No. of chew: 132 (3 min.)No. of chew: 220 (5 min) 1044- 1 A few signs of marks A few signs of Afew signs of 056 from the piston of the marks from the marks from themachine were left on piston of the piston of the the tablet machine wereleft machine were left on the tablet on the tablet 2 Subsequent to 6chew, NA NA the chewing machine failed to proceeding chews

The shell construction of shell 102 is applied. The results are shownbelow.

Batch. Tablet no. no. No. of chew: 44 (1 min.) No. of chew: 132 (3 min.)No. of chew: 220 (5 min) 1044- 1 No signs of marks A few marks from theSubsequent to 1 058 from the piston of the piston of the machine chew,the chewing machine were left on were left on the tablet machine failedto the tablet and the shell was still proceeding chews intact. 2Subsequent to 1 NA NA chew, the chewing machine failed to proceedingchews

The shell construction of shell 802 is applied. The results are shownbelow.

Batch. No. of chew: No. of chew: no. Tablet no. No. of chew: 44 (1 min.)132 (3 min.) 220 (5 min) 1044-059 1 Subsequent to 3 chew, the chewing NANA machine failed to proceeding chews 2 Subsequent to 2 chew, thechewing NA NA machine failed to proceeding chews

Besides the tests mentioned above the intact tablets were subjected tophysical tampering by use of electronical tool (coffee grinder, KrupsGVX242).

The construction applied is shown below with the results.

Batch. Tablet no. Construction (ref. to shell) no. Results 1563- Shell402 1 Only few marks on the shell and 062 equipment failure 2 Only fewmarks on the shell and equipment failure 3 Only few marks on the shelland equipment failure Shell 502 1 Only few marks on the shell andequipment failure 2 Only few marks on the shell, and matrix pops out.Equipment failure 3 Only few marks on the shell and equipment failure1044- Shell 2 (wall thickness 1 Only few marks on the shell and 0571.4-1.8 mm) equipment failure 2 Only few marks on the shell andequipment failure 3 Only few marks on the shell and equipment failure1044- Shell 102 1 Only few marks on the shell and 058 equipment failure2 Only few marks on the shell and equipment failure 3 Only few marks onthe shell and equipment failure 1044- Shell 802 1 One small piece ischopped off, no other 059 marks on the shell and equipment failure 2Only few marks on the shell and equipment failure 3 Only few marks onthe shell and equipment failure

Example 10 Gelling Agents to Prevent Injectability of PharmaceuticalComposition (e.g. Tablets) when Melted or Dissolved

The purpose of adding gelling agents to the pharmaceutical compositionis to make it more physical deterrent, so that it is impossible toinject melted or dissolved tablets (c.f. protocol on tampering methods).

It was chosen to use Acetaminophen as a model drug substance and add 10%(w/w) of the chosen gelling agent in the pharmaceutical composition,which was prepared as described in Methods above.

To attain a measure of how easy it is to inject the melted or dissolvedpharmaceutical composition dependent on which gelling agent that hasbeen chosen. The pharmaceutical composition for example tablet, in whichthe gelling agent has been incorporated, is melted under a candle.Subsequently 1 mL of the liquid is extracted by a syringe with adiameter of ca. 0.5 mm, after which the liquid pressed out with apressure/weight of the syringe of approximately 3 kg. The time requiredto press out the liquid is measured illustrating how difficult it is toinject the pharmaceutical composition.

Composition % w/w Acetaminophen 9.0 PoloXamer 188 4.5 PEO 200.000 76.5Gelling agent (c.f. the list below) 10

Gelling agent Time for required to inject the solution (s) EudragitL100-55 7.3 Guar Gum 400 7.6 HPMC 100 000 13.7 Carboxy MethylCellulose-Na 13.5 Gelcarin 379 25.4 Gelcarin 812 15.1 Gellan Gum 40025-35

The results are shown above. As seen from the table Gellan Gum 400 andGelcarin 379 are by far the most efficient gelling agents, followed byGelcarin 812, HPMC 100 000 and Carboxy Methyl Cellulose-Na. EudragitL100-55 and Gua Gum 400 were less suitable gelling agents.

Example 11 Plasticizers to Enforce Physical Properties of the ShellConstruction I

Pharmaceutical composition were produced as described in Methods by themeans of large scale injection moulding with the purpose ofinvestigating the physical properties of the shell compositioncomprising PLA with different plasticizer and thereby enforcing physicaldeterrence. Physical deterrence was tested by subjecting thepharmaceutical composition for example tablets to milling in a Kruppscoffee grinder. The method applied is described in the protocol ontampering methods.

Matrix composition % w/w: Morphine Sulphate pentahydrate 36.0 PoloXamer188 12.2 PEO 300.000 16.0 PEO 200.000 22.7 Mannitol 3.0 BHT 0.1 HPMC100.000 5 Carrageenan 379 5

The applied plasticizers and the content are stated below. The shellcomposition consists of PLA and one or more plasticizers.

Batch no. of PLA PEG 20 000 PEO 200 000 PEO 300 000 PEO 600 000 shellmaterial (% w/w) (% w/w) (% w/w) (% w/w) (% w/w) 1049-090A 86 141049-090B 86 14 1049-090C 86 7 7 1049-090D 86 5 9 1049-090E 80 201049-090F 93 7 1049-090G 86 14 1049-090H 86 14

It was assessed whether or not the matrix composition could be removedfrom the shell. The results are shown below:

Coffee mill Krups - Test 1 Coffee mill Krups - 30 sec Batch No 1 tablet5 tablets 1 tablet 5 tablets Shell 2, wall 5 sec, 9 sec, shellEverything in Everything in small pieces thickness 1.4-1.8 mm)/ shellcrushed small pieces 1049-090 A crushed Shell 2, wall 3 sec, 11 sec,shell Shell to powder, Shell to powder, matrix small thickness 1.4-1.8mm)/ shell crushed matrix small and large pieces 1049-090 A crushedpieces Shell 2, wall 3 sec, 7 sec, shell didn't Shell and matrix 1 wholetablet, one tablet thickness 1.4-1.8 mm)/ shell came of in small piecesmissing half a shell, one tablet 1049-090 B crushed without shell, 2tablets in small and large pieces Shell 802/ 8 sec, 15 sec, two wholeEverything in Large pieces of shell, matrix in 1049-090 B shell cametablets, three small pieces small pieces of tablets in pieces Shell 802/15 sec, 15 sec, four whole Large pieces of Large pieces of shell, matrixin 1049-090 B shell came tablets, one tablet shell, matrix in smallpieces of in pieces small pieces Shell 2, wall 4 sec, 7 sec, three wholeEverything in Not tested thickness 1.4-1.8 mm)/ shell came tablets andtwo small pieces 1049-090 C of without shell Shell 2, wall 15 sec, 12sec, three whole Small and large Large pieces, lid on mill thickness1.4-1.8 mm)/ half a shell tablets but the mill pieces broken 1049-090 Ccame of broke down

Example 12

Naltrexone % w/w Matrix composition (placebo) PEO 200.000 43.7% PEO300.000 31.0% Poloxamer 188 12.2% Mannitol  3.0% HPMC 100.000  5.0%Carragenan 379  5.0% BHT  0.1% Shell composition Polylactid acid  100%Total tablet weight was approximately 925 mg

Polylactid acid was injection moulded in a Haake Minijet (Haake MiniJetII, Thermo Electron, Karlsruhe, Germany) as described in Methods. Aninner core filled with approximately 25 mg Naltrexone hydrochloride wasprepared and closed in both ends with the above mentioned shellcomposition. The inner core has a size of 8 mm×4.26 mm×2.49 mm. Theinner core was placed in the cavity of a larger shell 2 (H: 20 mm; L: 6mm; B: 6 mm) with the same shell composition and the large shell wasfilled with placebo matrix composition as described in Methods.

Dissolution tests of naltrexone were performed in accordance to USP 30,NF 25, (711). Apparatus 2 (paddle method). The dissolution mediumconsisted of phosphate buffer solution pH 6.8. The volume of thedissolution medium was 500 ml and the rotation speed of the paddles was50 rpm throughout the dissolution rum. The temperature was 37° C.Samples were withdrawn at suitable time intervals and analysed forcontent of active drug substance by means of HPLC UV detection. Intacttablets n=2 and tablets milled in a Coffee Grinder, Krups GVX242 (n=2)were analyse in dissolution.

The amount of naltrexone was determined by a modified USP method. Thetechnique was reverse phase chromatography, using a Supelco AscentisExpress C18 2.7 μm 4.6*100 mm column. The mobile phase consisted of 1.08g sodium 1-octanesulphonate, 23.8 g sodium acetate, 1 ml triethylamine,450 ml methanol and approximately 550 ml water. The HPLC settings wereas follows: lsocratic, column temperature 30° C. flow 0.6 ml/min,detection HPLC-UV at 280 nm, injection volume 20 μl with a 6 minutes runtime.

During the milling, described above, some naltrexone was spilled whichexplains the amount found to be less than the 25 mg (i.e. 100%) that wasfilled in the small inner core, see the results below.

Sample 0.2 hours 0.5 hours 0.8 hours 1.5 hours 20 hours 30 hours 1Intact ND ND ND ND ND ND 2 Intact ND ND ND ND ND ND 1 Ground 34.1% 36.3%36.6% 37.4% 39.0% 34.9% 2 Ground 31.5% 34.2% 34.7% 34.9% 37.1% 35.9% ND:not detectable

The invention claimed is:
 1. An abuse resistant pharmaceuticalcomposition, the pharmaceutical composition comprising a shell resistantto physical tampering and a matrix composition, wherein the matrixcomposition is at least partly contained within the shell and comprisesan active drug substance, wherein the shell comprises an outer shellwall having an inner surface and an outer surface, the outer surfacebeing a double curved surface, wherein the shell extends from a firstend to a second end, the shell having a length in a range of from 4 mmto 20 mm, wherein the outer shell wall has a first opening at the firstend and a second opening at the second end, the first opening and thesecond opening having an area in a range of from about 1 mm² to about100 mm², and wherein the outer shell wall is of varying thickness andhas a maximum thickness in a range of from 1.0 mm to about 10 mm, theouter shell wall being impermeable to water.
 2. The pharmaceuticalcomposition according to claim 1, wherein the shell comprises one ormore reinforcement elements extending from the inner surface of theouter shell wall.
 3. The pharmaceutical composition according to claim2, wherein the one or more reinforcement elements comprises a firstreinforcement wall.
 4. The pharmaceutical composition according to claim3, wherein the first reinforcement wall is a plane wall.
 5. Thepharmaceutical composition according to claim 3, wherein the firstreinforcement wall is perpendicular to a first axis from the first endto the second end.
 6. The pharmaceutical composition according to claim3, wherein the first reinforcement wall is parallel to a first axisextending from the first end to the second end.
 7. The pharmaceuticalcomposition according to claim 3, wherein the first reinforcement wallhas a thickness in a range of from 0.2 mm to 2 mm.
 8. The pharmaceuticalcomposition according to claim 3, wherein the first reinforcement wallhas one or more openings.
 9. The pharmaceutical composition according toclaim 2, wherein the one or more reinforcement elements comprises asecond reinforcement wall.
 10. The pharmaceutical composition accordingto claim 9, wherein the second reinforcement wall is a plane wall. 11.The pharmaceutical composition according to claim 9, wherein the secondreinforcement wall is perpendicular to a first axis extending from thefirst end to the second end.
 12. The pharmaceutical compositionaccording to claim 9, wherein the second reinforcement wall is parallelto a first axis extending from the first end to the second end.
 13. Thepharmaceutical composition according to claim 9, wherein the secondreinforcement wall has a thickness in a range of from 0.2 mm to 2 mm.14. The pharmaceutical composition according to claim 9, wherein thefirst reinforcement wall and the second reinforcement wall are parallel.15. The pharmaceutical composition according to claim 14, wherein thefirst reinforcement wall and the second reinforcement wall extend in thesame plane.
 16. The pharmaceutical composition according to claim 9,wherein the first reinforcement wall intersects the second reinforcementwall forming an angle between the first reinforcement wall and thesecond reinforcement wall.
 17. The pharmaceutical composition accordingto claim 1, wherein the shell defines a cavity extending from the firstend to the second end and the matrix composition is at least partlycontained within the cavity.
 18. The pharmaceutical compositionaccording to claim 1, wherein the shell defines a plurality of separatedcavities extending from the first end to the second end and the matrixcomposition is at least partly contained within at least one of theplurality of separated cavities.
 19. The pharmaceutical compositionaccording to claim 18, wherein one or more of the cavities has acircular cross section perpendicular to a first axis extending from thefirst end to the second end.
 20. The pharmaceutical compositionaccording to claim 18, wherein one or more of the cavities has anelliptical cross section perpendicular to a first axis extending fromthe first end to the second end.
 21. The pharmaceutical compositionaccording to claim 1, wherein the outer surface of the shell has anelliptical cross section perpendicular to a first axis extending fromthe first end to the second end.
 22. The pharmaceutical compositionaccording to claim 1, wherein the outer surface of the shell forms anarc from the first end to the second end in a cross section along afirst axis extending from the first end to the second end.
 23. Thepharmaceutical composition according to claim 1, wherein the shellcomprises polylactic acid, and wherein the concentration of thepolylactic acid in the shell is at least 50% w/w.
 24. The pharmaceuticalcomposition according to claim 1, wherein the shell comprises one ormore polymers selected from the group consisting of ethyl cellulosegrade 20, ethyl cellulose grade 100, cornpack 200, polycaprolactone, PEO7000000, and polyhydroxybuturate.
 25. The pharmaceutical compositionaccording to claim 1, wherein the shell comprises one or moreplasticizers selected from the group consisting of cetostearyl alcohol,castor oil, dibutyl sebacate, polyethylene oxide, and poloxamer.
 26. Thepharmaceutical composition according to claim 1, wherein the shellcomprises a single polymer and the concentration of the polymer is in arange of from 5% to 100% w/w.
 27. A pharmaceutical composition accordingto claim 1, wherein the shell comprises a mixture of polymers and thetotal concentration of polymers included in the shell is in a range offrom 70% to 100% w/w.
 28. The pharmaceutical composition according toclaim 1, wherein the length of the outer shell wall is 16 mm.
 29. Thepharmaceutical composition according to claim 1, wherein the active drugsubstance comprises an analgesic selected from the group consisting ofopioids, natural opium alkaloids, semi-synthetic opium alkaloids,morphine, opium, hydromorphone, nicomorphine, oxycodone, dihydrocodeine,diamorphine, papavereturn, codeine, phenylpiperidine derivatives,ketobemidone, pethidine, fentanyl, diphenylpropylamine derivatives,dextromoramide, piritramide, dextropropoxyphene, bezitramide, methadone,benzomorphan derivatives, pentazocine, phenazocine, oripavinederivatives, buprenorphine, morphinan derivatives, butorphanol,nalbuphine, tilidine, tramadol, dezocine, salicylic acid andderivatives, acetylsalicylic acid, aloxiprin, Choline salicylate, sodiumsalicylate, salicylamide, salsalate, ethenzamide, morpholine salicylate,dipyrocetyl, benorilate, diflunisal, potassium salicylate, guacetisal,carbasalate calcium, imidazole salicylate, pyrazolones, phenazone,metamizole sodium, aminophenazone, propyphenazone, nifenazone, anilides,paracetamol, phenacetin, bucetin, propacetamol, rimazolium, glafenine,floctafenine, viminol, nefopam, flupirtine, and ziconotide.
 30. Thepharmaceutical composition according to claim 1, wherein the active drugsubstance comprises one or more opioids selected from the groupconsisting of buprenorphine, codeine, dextromoramide, dihydrocodeine,fentanyl, hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine,oxycodone, oxymorphone, and tramadol, including pharmaceuticallyacceptable salts, molecular complexes, solvates, anhydrates, isomers,enantiomers, racemic mixtures, and mixtures thereof.
 31. Thepharmaceutical composition according to claim 30, wherein the one ormore opioids are selected from the group consisting of hydrocodone,oxycodone, and morphine, including pharmaceutically acceptable salts,molecular complexes, solvates, anhydrates, isomers, enantiomers, racemicmixtures, and mixtures thereof.
 32. The pharmaceutical compositionaccording to claim 31, wherein the shell constitutes at least 40% v/v ofthe pharmaceutical composition.
 33. The pharmaceutical compositionaccording to claim 31, wherein the pharmaceutical composition isformulated and configured for oral administration.
 34. Thepharmaceutical composition according to claim 31, wherein the matrixcomposition comprises a polyethylene oxide polymer.
 35. Thepharmaceutical composition according to claim 34, wherein the matrixcomposition further comprises a block copolymer.
 36. The pharmaceuticalcomposition according to claim 31, wherein the matrix compositioncomprises one or more gelling agents.
 37. The pharmaceutical compositionaccording to claim 31, wherein the matrix composition comprises anantagonist or aversive agent.
 38. The pharmaceutical compositionaccording to claim 37, wherein the matrix composition comprises an innercore enclosing the antagonist or aversive agent.
 39. The pharmaceuticalcomposition according to claim 37, wherein the matrix compositioncomprises coated particles containing the antagonist or aversive agent.40. A pharmaceutical composition according to any one of claims 34 and35, wherein the polyethylene oxide polymer is selected from apolyethylene oxide having a molecular weight selected from a rangefalling within the group consisting of from 20,000 to 700,000 daltons,from 20,000 to 600,000 daltons, from 35,000 to 700,000 daltons, from35,000 to 500,000 daltons, from 35,000 to 400,000 daltons, from 35,000to 300,000 daltons, and from 50,000 to 300,000 daltons.
 41. Apharmaceutical composition according to any one of claims 34 and 35,wherein the polyethylene oxide polymer is selected from a polyethyleneoxide having a molecular weight selected from a range falling within thegroup consisting of at least 35,000 daltons, at least 50,000 daltons, atleast 75,000 daltons, at least 100,000 daltons, at least 150,000daltons, at least 200,000 daltons, at least 250,000 daltons, at least300,000 daltons, and at least 400,000 daltons.